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The overall aim of this research project was to develop surfactant dry powder formulations 
and devices for efficient delivery of aerosol formulations to infants using the excipient enhanced 
growth (EEG) approach. Use of novel formulations and inline delivery devices would allow for 
more efficient treatment of infants suffering from neonatal respiratory distress syndrome and 
bronchiolitis.  
A dry powder aerosol formulation has been developed using the commercial product, 
Survanta® (beractant) and EEG technology to produce micrometer-sized hygroscopic particles. 
Spray drying and formulation parameters were initially determined with 
dipalmitoylphosphatidylcholine (DPPC, the dominant phospholipid in pulmonary surfactant), 
which produced primary particles 1 µm in size with a mass median aerodynamic diameter of 1-2 
µm.  
 Investigation of dry powder dispersion enhancers and alcohol concentration on the effect 
of powder aerosol characteristics were performed with the Survanta-EEG formulation. The 
optimal formulation consisted of Survanta®, mannitol and sodium chloride as hygroscopic 
excipients, and leucine as the dry powder dispersion enhancer, prepared in 20% v/v ethanol/water. 
The powders produced primary particles of 1 µm with >50% of the particles less than 1 µm. The 
presence of surfactant proteins and surface activity were demonstrated with the Survanta-EEG 
formulation following processing. 
A novel containment unit dry powder inhaler (DPI) was designed for delivery of the 
surfactant-EEG formulation using a low volume of dispersion air. Studies explored optimization 
of air entrainment pathway, inlet hole pattern, delivery tube internal diameter and length. With 3-
10 mg fill masses of spray dried surfactant powder, the DPI enabled delivery of >2 mg using one 
3-mL actuation of dispersion air. Overall, it was possible to deliver >85% of the loaded fill mass 
using three actuations. 
Nebulized aerosol formulations are characterized with low delivered doses. Using a novel 
mixer-heater delivery system, the highest estimated percent lung dose achieved during realistic in 
vitro testing of a Survanta-EEG formulation aerosolized with a commercial mesh nebulizer was 
when nebulization was synchronized with inhalation of the breathing profile. Design changes to 
the mixer-heater system eliminated the need for synchronization, achieving an estimated percent 
lung dose of 31% of the nominal, an improvement compared with existing systems that achieve 
approximately <2% lung dose. 
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CHAPTER 1 
1 BACKGROUND AND INTRODUCTION……… 
1.1 Anatomy and physiology of the respiratory tract 
Anatomically, the respiratory tract can be classified into two broad divisions, the upper and 
lower airways. The upper airways consist of the extrathoracic regions from the nasal cavity and 
mouth to the larynx, one function of which is to warm and humidify the inhaled ambient air. The 
lower airways include the trachea, bronchi, bronchioles and the alveoli, which can be functionally 
divided into the conducting (trachea, bronchi, bronchioles) and respiratory (alveoli) regions 
(Figure 1.1) [1-3]. The main function of the respiratory system is gas exchange – to take in oxygen 
and remove waste carbon dioxide – which is done by (i) exchanging gases between the external 
environment and the alveolar space through breathing, and (ii) exchanging gases between the 
alveolar space and the blood by diffusion [4]. The conducting airways are a conduit for the 
transport of gases to and from the external environment to the respiratory regions where gas 
exchange occurs. From the trachea, the airways repeatedly bifurcate creating a series of airway 
generations that terminate in the alveolar sacs, each of which contain a collection of alveoli. The 
diameters of the airways decrease with increasing generations as the surface area of the airways 
increase [4].  
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Figure 1.1 Schematic of the conducting and respiratory regions of the human respiratory tract, 
adapted from [3]. 
1.1.1 Respiratory tract epithelium and airway surface fluid 
The different regions of the respiratory tract are lined with two main cell types, secretory 
and ciliated epithelial cells, which change in concert with its physiological function (Figure 1.2). 
In the conducting airways, the secretory cells are goblet cells; they, along with submucosal glands, 
produce and secrete mucus. Airway mucus, which consists mainly of water and mucins (high 
molecular weight glycoproteins), has multiple important functions which include protection of the 
epithelium from dehydration, promoting saturation of inhaled air, and trapping inhaled foreign 
particles [4, 5]. The mucus layer is separated from the epithelium by an aqueous sol layer, also 
referred to as periciliary fluid. The low viscosity sol layer surrounds the cilia of the columnar 
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epithelium allowing it to beat and propel the mucus layer with trapped particles to the pharynx 
where it is swallowed or expectorated. This movement of mucus from the lower respiratory tract 
to the pharynx is driven by air flow and mucociliary clearance [6]. The two layers are separated 
by a thin layer of surfactant, which promotes spreading of the mucus and allows for efficient 
transfer of energy from the beating cilia, therefore influencing the effectiveness of mucociliary 
clearance [7].  
 
 
Figure 1.2 Cell types of the respiratory epithelium, adapted from [4]. 
The goblet cells and mucous glands are not present in the respiratory tract beyond the 
terminal bronchioles, therefore no mucus is produced in the peripheral airways [4]. The secretory 
cells in the transition region from the conducting airways to the respiratory region are club cells 
(Clara cells in Figure 1.2). The ciliated epithelial cells observed in this region are cuboidal in shape 
with shortened cilia compared to the columnar epithelial cells of the conducting airways.  
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The alveolar epithelium consists of type I and type II pneumocytes (Figure 1.2). Simple 
squamous type I cells cover over 90% of the alveoli and are responsible for gas-exchange with 
blood in the pulmonary capillaries [8, 9]. The type II cells are cuboidal cells that secrete collagen 
and elastin, creating a fluid extracellular matrix (aqueous alveolar hypophase) that supports the 
structure of the alveoli and allows for dissolution of gases for passive diffusion with capillaries 
[8]. The type II cells are also responsible for the production and secretion of pulmonary surfactant, 
a complex mixture of lipids and proteins, vital for proper lung function [2]. The presence of 
pulmonary surfactant extends into the bronchioles where it prevents cohesion of the bronchiolar 
walls and decreases the surface tension of the airway mucus lining [5, 7]. 
1.2 Pulmonary surfactant  
Pulmonary surfactant consists roughly of 90% lipids and 10% proteins, with a disaturated 
phospholipid, dipalmitoylphosphatidylcholine (DPPC) as the dominant lipid present (30-70% of 
the total lipid concentration) [10-12]. Its primary role is to facilitate breathing by forming a surface-
active layer at the respiratory interface.  
1.2.1 Surface tension and surfactant function 
The presence of the alveolar hypophase at the airway surface of the alveoli results in high 
surface tension due to an imbalance of forces – the cohesive forces between the fluid molecules 
are stronger than the interactive forces between the air and fluid molecules – causing an inward 
force into the bulk of the fluid [13]. Surface tension is related to the work needed to counter this 
inward force and expand the surface of the fluid. The work of breathing is mainly having to inflate 
the alveoli against the high surface tension at the air-liquid interface across the large surface area 
of the lungs, 3-5 m2 at birth which increases to 70-150 m2 in adults [14]. The required energy is 
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reduced by the presence of pulmonary surfactant. Pulmonary surfactant (PS) creates a surface-
active layer that lowers and varies the surface tension as a function of alveolar size during breathing 
[13]. By doing so, PS reduces the work of breathing while stabilizing alveoli from collapse or over 
distention.  
For proper pulmonary function, the surfactant present in the lungs must be rigid enough to 
resist collapse during exhalation, yet fluid enough to allow for rapid adsorption during inhalation 
to spread and cover the alveolar surface [10]. DPPC, the dominant lipid in PS, is the primary 
component responsible for resisting high surface pressures during exhalation due to its high 
transition temperature that maintains the chemical rigidity of the saturated acyl chains (Figure 1.3), 
which allow for tight packing at normal physiological temperature [15].  
 
 
Figure 1.3 Chemical structure of dipalmitoylphosphatidylcholine (DPPC, 16:0/16:0 PC). 
Phospholipids have the unique thermal characteristic of a phase transition at temperatures 
lower than their final melting point. Known as the glass-transition temperature (Tg; or solid-gel to 
liquid-crystalline temperature), Tg is the temperature at which the lipid bilayer loses its ordered 
packing while increasing fluidity (Figure 1.4). The Tg of phospholipids is dependent on: (i) the 
polar headgroup, (ii) the acyl chain length, (iii) the degree of hydrocarbon chain saturation, and 
(iv) the nature and ionic strength of the suspension medium [16]. Generally, Tg is lowered by 
hydrophobic acyl chains polar headgroup
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decreased chain length, unsaturation of the acyl chains and presence of branched chains and bulky 
headgroups. 
 
 
Figure 1.4 Schematic representation of solid-gel to liquid-crystalline phase transition of a DPPC 
bilayer, adapted from [17]. 
The relatively long, saturated acyl chains of DPPC results in a high transition temperature 
relative to other phospholipids, 41 °C [15, 17]. At normal physiological temperature of 37 °C, 
DPPC exists in the solid-gel phase making it chemically rigid enough to withstand the pressure of 
compression from exhalation, but results in its slow adsorption and re-spreading when 
compression is relieved [18, 19]. The presence of unsaturated phospholipids, neutral lipids, and 
protein components in pulmonary surfactant help to fluidize the interfacial layer during 
compression and expansion cycles of the alveoli during breathing.  
1.2.2 Adsorption and self-assembly 
The amphiphilic nature of surfactants – polar headgroup and hydrophobic tails (acyl 
chains) – allow them to adsorb at interfaces and self-assemble in solution. At the alveolar air-liquid 
interface, the polar head group of the phospholipid molecules are submerged in the liquid phase 
solid-gel 
phase
liquid-crystalline 
phase
polar headgroup
hydrophobic tails
Tg
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with the hydrophobic chains protruding out into the air phase. Within the airway surface fluid, the 
phospholipids self-assemble into mixed-lipid bilayers.  
The classic model to explain the stability of lung surfactant is the “squeeze-out” model in 
which it is hypothesized that the less stable fluid components (non-DPPC) are gradually removed 
from the interfacial monolayer into the subphase during film compression, resulting in a DPPC 
monolayer at the interface [11, 12]. When compression is relieved, the fluid components return to 
the interface from the subphase. Dynamic compression-expansion cycling studies indicate that 
phospholipid uptake into the interface occurs too quickly to be explained by de novo adsorption 
of phospholipid vesicles from the subphase [20]. It has been proposed that at least part of the PS 
film is thicker than a single monolayer; in places, the surface monolayer plus one or more lipid 
bilayers are closely and functionally associated with the interfacial monolayer, which forms the 
surface-associated “surfactant reservoir” [11, 20].  
The non-DPPC components of endogenous surfactant include phosphatidylglycerol 
(POPG), phosphatidylethanolamine, phosphatidylinositol, some neutral lipids (mainly 
cholesterol), and four surfactant specific proteins: SP-A, SP-B, SP-C, and SP-D [21, 22].  
1.2.3 Surfactant proteins 
Surfactant proteins A and D (SP-A and SP-D) are large hydrophilic glycoproteins (26-38 
and 43 kDa, respectively [15]) that are involved in pulmonary host defense with the primary role 
of binding to inhaled particles and pathogens to enhance phagocytic clearance [23]. SP-A is 
essential for the formation of tubular myelin (loosely packed surfactant in the alveolar hypophase) 
and regulates phospholipid insertion into the monolayer [24]. SP-A does not have a large effect on 
surfactant adsorption alone, but is capable of further enhancing adsorption in the presence of SP-
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B and calcium [15, 25]. The smaller hydrophobic surfactant proteins, SP-B and SP-C, are 
necessary for regulating the surface tension in the lungs by independently promoting rapid 
adsorption of phospholipids from the subphase to the interface [10, 15]. SP-B, an 8.7 kDa protein 
with 79-amino acid residues, exists as a disulfide linked homodimer with a molecular weight of 
17.4 kDa [26]. SP-B plays a role in formation of tubular myelin and influences the molecular 
ordering of the phospholipid layer as well as SP-C processing [24]. Absence of SP-B results in 
lethal respiratory distress, whereas SP-C deficiency is associated with chronic interstitial lung 
disease [10]. SP-C is the most hydrophobic and smallest of the surfactant proteins with 34-amino 
acid residues at 4.0 kDa [26].  
1.3 Surfactant therapy 
The basic concept of surfactant therapy involves the delivery of exogenous surfactant to 
replace or supplement endogenous surfactant that is deficient or has become dysfunctional [13]. 
The treatment is intended only as an immediate course of action as the lungs are presumed to 
eventually establish or recover the ability to produce their own surfactant and maintain normal 
pulmonary function. Surfactant therapy has been shown to be highly effective in the treatment of 
immaturity-related respiratory distress in preterm infants [27]. Surfactant therapy in infants results 
in mucus that is more hydrated and better transported by mucociliary clearance compared to mucus 
in untreated infants, suggesting that surfactant therapy may also be useful in other lung diseases 
with airway mucus obstruction, such as severe bronchiolitis [6, 28, 29]. The success of the therapy 
mainly depends on the surfactant composition and efficient and uniform delivery to the targeted 
regions of the lungs. 
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1.3.1 Animal-derived exogenous surfactants 
Natural surfactant preparations commercially available in the United States include 
beractant (minced bovine lung extract) [30], calfactant (bovine lung lavage extract) [31], and 
poractant alfa (minced porcine lung extract) [32]. Trembath et al. [33] found no significant 
differences in outcomes of air leak syndromes, death and bronchopulmonary dysplasia among the 
three formulations. Similarly, a Cochrane review concluded that there were no differences in 
clinical outcome for the two bovine-derived preparations, but concluded that it is unclear if a 
difference exists from the porcine-derived preparation as there have been a lack of dose-equivalent 
comparison groups with appropriate sample size [33, 34].  
The surfactant formulations are obtained by animal lung lavage or by mincing animal lung 
tissue, which is then purified by lipid extraction removing hydrophilic components, including the 
surfactant proteins A and D. The purified extract retains surfactant proteins B and C, neutral lipids, 
and phospholipids [34, 35]. Table 1.1 compares the phospholipid and protein concentrations in the 
three formulations. After purification, beractant (Survanta®, Abbott Laboratories, Columbus, OH) 
supplements its formulation with the addition of DPPC, palmitic acid, and tripalmitin [30]. 
Calfactant (Infasurf®, Forest Pharmaceutical, St Louis, MO) has higher concentrations of SP-B 
presumably due to the differing processes involved in preparing extracts from lung lavage 
compared to minced lung processes [35]. Following extraction, poractant (Curosurf®, Chiesi 
Farmaceutici, Prima, Italy) undergoes additional purification to remove neutral lipids [35].  
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Table 1.1 Commercially available in the US animal-derived surfactant phospholipid and protein 
concentration comparison, from [35]. 
Formulation Extract origin 
Phospholipid 
concentration, 
mg/mL 
Phospholipid 
dose, mg/kg 
SP-B, 
µg/µmol 
SP-C, 
µg/µmol 
Beractant 
(Survanta®) 
minced bovine 
lung 25 100 0-1.3 1-20 
Calfactant 
(Infasurf®) 
bovine lung 
lavage 35 105 5.4 8.1 
Poractant 
(Curosurf®) 
minced porcine 
lung 76 200, then 100 2-3.7 5-11.6 
 
1.4 Neonatal respiratory distress syndrome (RDS) 
About 15 million babies are born prematurely each year – more than one in ten of all births 
per year worldwide [36]. Respiratory distress syndrome (RDS) results from the insufficient 
production of surfactant in the lungs of preterm infants, most prevalent in infants born <32 weeks 
gestational age [13]. The pulmonary surfactant system is one of the last systems to develop before 
birth as it matures between 29-32 weeks of gestation [9]. Type II pneumocytes, the specialized 
cells that produce pulmonary surfactant, differentiate and begin to produce surfactant between 24-
34 weeks of gestation [7, 9, 37]. Although small quantities of surfactant can be detected at 24 
weeks of gestation, it is not found in physiologically relevant amounts until after 30 weeks [7, 9]. 
Premature birth, consequently, can result in surfactant deficiency due to the immature development 
of the lungs. The deficiency can lead to reduced pulmonary compliance, increased surface tension 
and risk of alveoli collapse at end-expiration resulting in a reduction of surface area for gas 
exchange and consequently respiratory distress [38].  
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1.4.1 Treatment 
Exogenous surfactant replacement therapy for immaturity-related respiratory distress has 
been shown to be effective in reducing mortality and morbidity of infants since it was introduced 
in the 1980s leading to its use being approved in the early 1990s [39, 40]. Current respiratory care 
practice guidelines describe two treatment strategies for immaturity-related respiratory distress: (i) 
prophylactic, in which high risk infants receive surfactant at the time of birth or shortly after; and 
(ii) rescue, in which surfactant is administered to mechanically ventilated infants with confirmed 
respiratory distress [41]. There are drawbacks to both strategies. The prophylactic therapy strategy 
increases the number of treated infants, exposing more infants to the potential risks of intubation, 
mechanical ventilation and surfactant administration; while the rescue strategy has the potential to 
delay surfactant administration allowing lung inflammation and fluid influx to impair gas 
exchange [41].  
Amid findings from recent random controlled trials, the Committee on Fetus and Newborn 
of the American Academy of Pediatrics has made recommendations for alternative methods over 
the current guidelines [42]. The Committee recommends to provide nasal continuous positive 
airway pressure to infants immediately after birth with subsequent selective surfactant 
administration by intubation to those with persistent severe respiratory distress; and if respiratory 
support with a ventilator is likely needed, then early administration of surfactant followed by rapid 
extubation is suggested rather than prolonged ventilation.  
1.4.2 Issues with surfactant therapy for RDS 
While the treatment is straightforward and effective, delivery of a liquid bolus is associated 
with non-uniform distribution of surfactant within the airways and requires a high dosage regimen. 
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Current treatments instruct for surfactant administration to be delivered in partial doses with the 
infant oriented in different positions, which is done in an effort to achieve a uniform dose by 
relying on gravity to coat the airspaces of the lungs [30]. The optimal dose and volume of 
exogenous surfactant is uncertain, however recommended doses are based on the size of the 
surfactant pool in healthy term infants, estimated to be 100 mg/kg, even though only 3 mg/kg of 
surfactant phospholipids are needed to coat the inside airspaces with a monolayer [25]. 
Additionally, the invasive endotracheal intubation procedure is often unsuccessful, nearly 40%, 
and typically requires >30 seconds to perform [43]. Dosing concerns include plugging the 
endotracheal tube and single lung deposition. In addition, liquid bolus delivery results in the 
increased risk of hypoxemia, bradycardia, hypertension, increased intracranial pressure, and 
increased pulmonary vascular resistance [44]. 
1.5 Bronchiolitis 
Increased mucus production is observed in bronchiolitis, which results in acute 
inflammation and obstruction of the bronchioles [45]. Signs and symptoms usually start with 
rhinitis and cough, possibly progressing to tachypnea, wheezing, rales, use of accessory muscles 
and/or nasal flaring. It is an infection of small airways in the lungs and one of the most common 
causes of respiratory failure in infants and children less than two years of age. It is a major cause 
of hospitalization in infants as moderate and severe infections lead to intensive care and 
mechanical ventilation. Approximately 2-3% of all children in the United States (57,000-172,000) 
less than 12 months of age are hospitalized with bronchiolitis annually; approximately 8% of 
which are admitted into intensive care for severe illness [46].  
The most common cause of bronchiolitis is respiratory syncytial virus (RSV), but can also 
be caused by rhinovirus, or the influenza virus [46]. RSV first infects the epithelial cells in the 
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upper respiratory tract and are thought to spread to the lower respiratory tract by direct cell-to-cell 
spreading and by aspiration of nasopharyngeal secretions [47]. The pathogen triggers lymphocyte 
infiltration to the airway walls and tissues resulting in edema and narrowing of air passages [48]. 
The bronchioles are further narrowed by accumulated cellular debris and increased mucus 
production leading to respiratory distress, wheezing and tachypnea [45, 48].  
1.5.1 Treatment  
A guideline released by the American Academy of Pediatrics provides an evidence-based 
approach to the diagnosis, management and prevention of bronchiolitis [49]. The guideline states 
that albuterol, epinephrine, and corticosteroids should not be administered; and nebulized 
hypertonic saline should not be administered unless the infant is hospitalized. Treatment is focused 
on supportive care, which involves intravenous hydration – intravenous or nasogastric fluids may 
be used for children who cannot maintain hydration orally – and discretional use of supplemental 
oxygen [49, 50]. Overall, there is no treatment that shortens the course of bronchiolitis or hastens 
the resolution of symptoms [46]. An antiviral treatment for RSV is currently approved, however, 
its use is recommended only for patients with severe, potentially life-threatening infections since 
the antiviral (ribavirin) has shown variable efficacy results in clinical trials and exposes health care 
workers to potential toxic effects [51].  
A method of treatment being explored to support breathing in afflicted infants is the use of 
blended, heated, humidified air and oxygen, through a high-flow nasal cannula interface. The 
delivery of heated, humidified gas reduces complications of decreased airway function resulting 
from increased mucous viscosity and reduced cilia beat frequency; it also has a role in the 
maintenance of body temperature in infants [52]. A Cochrane review concluded that there is 
insufficient evidence to determine the effectiveness of high-flow nasal cannula therapy for treating 
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infants with bronchiolitis, but that there is some indication that HFNC therapy is feasible and well 
tolerated [53]. 
1.6 Non-invasive ventilation in infants 
Non-invasive ventilation (NIV) refers to respiratory support that delivers a constant or 
variable pressure without tracheal intubation, used both as a method of weaning following a period 
of mechanical ventilation and as a primary mode of respiratory support [54]. Forms of NIV that 
deliver a constant airway pressure include continuous positive airway pressure (CPAP) and high-
flow nasal cannula (HFNC) therapy, while variable pressure NIV modes include nasal intermittent 
positive airway pressure (NIPPV), ventilation bilevel positive airway pressure (BiPAP), and high-
frequency ventilation (HFV) [55]. 
1.6.1 Constant airway pressure ventilation 
1.6.1.1 Continuous positive airway pressure (CPAP) 
CPAP delivers a continuous distending pressure, greater than atmospheric pressure, to the 
proximal airway, which splints the upper airway, assists in expansion of the lungs and prevents 
alveolar collapse [56]. CPAP systems are able to maintain a positive end expiratory pressure 
(PEEP), usually set between 5 and 10 cm H2O [57], but tidal ventilation is completely dependent 
on the respiratory muscles of the infant [58]. CPAP systems include: (i) a gas source to provide 
continuous delivery of warm humidified air and/or oxygen; (ii) a pressure generator to create a 
positive pressure in the circuit; and (iii) an interface that connects the system tubing to the patient.  
Pressure generator devices for CPAP systems can be constant or variable flow devices. The 
pressure in constant flow devices are generated by adjusting the exhalation orifice (ventilator 
PEEP) or by altering the length of the expiratory limb of the respiratory circuit that is submerged 
  
 
15 
under a known depth of water (bubble CPAP). Variable flow devices have an integrated nasal 
interface and generate CPAP pressure by varying the flow in response to the infant’s respiratory 
efforts [55, 56]. Common CPAP interfaces include binasal prongs (short, wide tubes that extend 
~1 cm into the nostrils, also called nasal cannulas) and nasal masks; less common interfaces 
include single nasopharyngeal prongs and face masks.  
1.6.1.2 High-flow nasal cannula (HFNC) therapy 
High-flow nasal cannulas are small, thin, tapered binasal tubes that sit just inside each 
nostril without occluding them [59]. HFNC therapy delivers heated and humidified air or 
air/oxygen blends at gas flows typically in the range of  1 to 8 L/min for infants [60]. In contrast 
to CPAP units, HFNC therapy circuits do not routinely measure the positive distending pressure. 
Important features of HFNC have been identified, such as (i) washout of nasopharyngeal dead-
space [61]; (ii) more comfortable for infants due to the smaller nasal prongs compared to those for 
CPAP [62] and (iii) a preferred treatment to administer by nurses due to ease of use [60].  
1.6.2 Variable airway pressure ventilation 
The different types of variable ventilation include nasal intermittent positive airway 
pressure ventilation (NIPPV), bilevel positive airway pressure (BiPAP), and high-frequency 
ventilation (HFV). NIPPV provides nasal CPAP with intermittent pressure increases applied at the 
nose [63]. BiPAP cycles between two levels of CPAP, a higher pressure during inhalation and 
lower pressure during exhalation, which can be triggered by the infant’s breathing efforts in a 
synchronized mode or preset in a non-synchronized mode [55]. HFV uses pressure oscillations to 
cause small displacements of ventilation gases, considerably smaller than tidal volumes, which 
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allows for higher PEEP values with lower inspiratory pressures to minimize barotrauma, in an 
effort to reduce ventilator-associated morbidity [64].  
1.6.3 NIV in infants with respiratory distress 
The use of nasal CPAP in preterm infants has been shown as an effective and safe 
alternative to mechanical ventilation [65], requiring fewer days of ventilation [66, 67] and 
decreased incidence of air leaks with reduction in the need for subsequent mechanical ventilation 
[68]. A Cochrane review concluded that HFNC therapy has shown similar rates of efficacy 
compared to other forms of non-invasive respiratory support (CPAP, NIPPV) in preterm infants 
for preventing treatment failure, chronic lung disease and death, with its main use as post-
extubation support [69]. Although CPAP and HFNC therapy systems offer a non-invasive means 
of treatment over mechanical ventilation, they are not without adverse effects; the nasal prongs 
used in CPAP are associated with trauma to the nasal septum and deformity on healing of the nares 
[70], and concern with the lack of knowledge of the actual level of PEEP with HFNC therapy, 
which may lead to significant lung overexpansion [71]. 
1.7 Pulmonary drug delivery 
Aerosolized drugs for the treatment of pulmonary diseases, such as RDS and bronchiolitis, 
is an attractive route of administration since it could provide (i) targeted delivery to the peripheral 
lungs, resulting in lower dose requirements and consequently lower incidence of systemic side 
effects, and (ii) flexibility in delivery as administration can utilize non-invasive ventilation 
techniques [1]. Although attractive, there are challenges with delivering drugs to the lungs, 
especially if the target site is the alveoli. The complex branching and narrowing diameter of the 
airways (trachea diameter of 1.8 cm to alveolar ducts of 450 µm [72]) requires inhaled particles to 
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travel a tortuous path in order to reach the alveoli (Figure 1.1). Consequently, drug delivery by 
inhalation requires aerosolization of the drug formulation to an appropriate small size for 
deposition to the targeted peripheral regions of the lungs [73].  
Deposition of aerosols in the airways occurs by one of three mechanisms: (i) inertial 
impaction (larger particles, >5 µm, that cannot follow the change in direction which occurs in the 
upper respiratory tract), (ii) gravitational sedimentation (intermediate particles, 1-5 µm, which tend 
to settle in the central and peripheral regions), or (iii) Brownian diffusion (very small particles, <1 
µm, that deposit as a result of random collisions that occur primarily in the alveolar region), thus 
particles too large tend to impact in the mouth-throat region and particles too small tend to be 
exhaled [74]. The desired size of inhaled particles can be controlled by drug formulation and device 
design optimization. 
1.7.1 Excipient enhanced growth 
An approach to deal with the challenges of efficient aerosol generation and delivery to the 
peripheral regions of the lungs is the dynamic particle size strategy of excipient enhanced growth 
(EEG) developed by Hindle and Longest [75]. The EEG method is an approach in which the 
particle or droplet size of an aerosol is increased after inhalation due to the addition of hygroscopic 
excipients (i.e. mannitol and/or sodium chloride). The combination submicrometer (or sufficiently 
small sized) particles, containing drug, a hygroscopic excipient, and a dispersion enhancing agent 
(for powder formulations), are inhaled and aerosol growth occurs due to the inherent humidity of 
the lungs. Since submicrometer-sized aerosols do not have enough inertia to deposit efficiently in 
the lungs, the use of a hygroscopic excipient allows the initial small sized aerosols to grow when 
exposed to the natural relative humidity in the lungs, which results in sufficient size increase to 
  
 
18 
enable deposition. The EEG method has been shown to demonstrate high dispersion efficiency 
and low mouth-throat deposition when developed both as a spray-dried powder (with mannitol as 
the hygroscopic excipient and leucine as a dispersion enhancer) [76] and as a liquid formulation 
(with mannitol or sodium chloride as the hygroscopic excipient) [77]. 
1.7.2 Aerosol delivery devices 
Aerosol delivery devices are based on one of three main platforms: pressurized metered-
dose inhalers (pMDIs), dry powder inhalers (DPIs) and nebulizers. The most common inhalers are 
the pMDIs, which contain liquid propellant-drug formulations and are designed to deliver a precise 
amount of aerosol when actuated. The drawback with pMDIs are that they require coordination 
between device actuation and patient inhalation for maximum delivery. The use of spacers and 
valved holding chambers have been introduced to mitigate this issue, but lung deposition is still 
often poor even when technique is good [72].   
There are two types of DPIs, passive and active. Passive DPIs rely on the patient inhalation 
to aerosolize the powder, which eliminates the need for coordination as in the pMDIs, but the force 
needed to disperse and deliver the powder may not always be achieved. Active or power-assisted 
DPIs, on the other hand, have an alternative energy source to deaggregate the powders for 
inhalation. DPIs do not contain propellants and lung deposition is often higher and less variable 
than pMDIs [72].   
The third platform, nebulizers, convert liquid formulations and suspensions into aerosols 
for inhalation. Nebulizers do not require a precise inhalation technique as normal tidal breathing 
is often adequate. There are three types of nebulizers: jet, ultrasonic, and vibrating mesh. There 
are advantages and disadvantages to each type. With jet nebulizers, they are less expensive 
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compared to the ultrasonic and vibrating mesh nebulizers, but require a compressed gas source and 
are inefficient with higher residual volumes (0.8-1.2 mL) and result in an increase in solute 
concentration due to evaporative effects [78].  Ultrasonic nebulizers are capable of nebulizing large 
volumes of liquid in a shorter delivery time than jet nebulizers, but usually have similar residual 
volumes to jet nebulizers and generate heat, which possibly cause complex molecules to 
breakdown. In addition, ultrasonic nebulizers are not suitable for suspensions. The vibrating mesh 
nebulizers generate aerosol by using electricity to vibrate a mesh plate to produce droplet sizes 
partially determined by the diameter of the apertures. The mesh nebulizers have lower residual 
volumes (0.1-0.3 mL) and shorter delivery times than the jet nebulizer and are able to deliver 
highly uniform and respirable droplets, but are more expensive and cleaning can be difficult [78].  
1.7.3 Aerosol therapy in infants 
There are additional challenges with delivering aerosolized drugs to infants.  The smaller 
airways in infants result in higher aerosol deposition in the upper and central airways as compared 
to adults, consequently delivering a lower dose to the peripheral regions of the lungs [28, 78, 79] 
Also, the breathing pattern of infants are rapid and shallow (30-60 breaths per minute; tidal volume 
of 10-60 mL [81]) compared to that of larger children and adults (12-15 breaths per minute; tidal 
volume of 500 mL), resulting in short residence-time for aerosols to deposit in the airways, which 
further contributes to the predominantly central rather than peripheral drug deposition in the lungs. 
Another challenge with delivering aerosols to infants arises from their characteristic nasal 
breathing [82]. Aerosols delivered through the nasal route must navigate the narrow passages of 
the nasal cavity, which has high filtration efficiency resulting in reduced drug available for 
pulmonary deposition [1, 72]. For efficient delivery of inhaled drugs via the nasal route, a particle 
or droplet size of < 2 µm is desired to efficiently bypass the upper respiratory tract [1, 73]. 
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1.8 Aerosolized surfactants 
With increasing emphasis towards non-invasive methods of treatment, the delivery of 
aerosolized surfactant during NIV has been studied as a promising surfactant therapy method. 
Studies of dry powder surfactant aerosols with animal models have shown improved outcomes 
with doses as low as 2-3 mg phospholipids/kg [83] and with more uniform distribution within the 
lung [84] compared to instilled methods. However, delivery of nebulized liquid surfactant has been 
met with mixed results in clinical studies [85-87]. Berggren et al. [85] found that delivery of 
surfactant aerosol generated with a jet nebulizer and delivered during nasal CPAP over 3 hours 
resulted in no beneficial effects compared to the control group that did not receive surfactant, 
which, as the authors stated, probably reflects low lung deposition attributed to administration 
techniques.  
1.8.1 Dry powder surfactants  
Dry powder aerosols are an attractive means of improving the dose delivery of surfactant 
to the lungs; with no dilution effects of having to be suspended in liquid, so a high concentration 
aerosol can be delivered. Dry powder formulations have higher stability and are less susceptible 
to environmental factors. Studies have explored the delivery of dry powder surfactants prepared 
by micronization [88], spray drying [89] and drying inline from a nebulizer [90] into animal models 
using novel delivery devices. The novel devices described in the studies required an external gas 
line for aerosol delivery [88] or included bulky components [89, 90], which would be difficult to 
incorporate into a NIV circuit. 
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1.8.1.1 Dry powder production 
For dry powders to be effectively delivered to the lungs, the particles must be in the 
respirable range, <5 µm in diameter. Common particle formation techniques include milling, spray 
drying, spray freeze drying, and supercritical fluid crystallization. Milling, or micronization to 
produce powders in the respirable range, involves crystallization, which results in polydispersed 
particles >10 µm in size [91], followed by one of several milling techniques (fluid-energy mills, 
such as the jet mill; high-peripheral-speed mills, such as the pin-mill; and the ball mill, [92]). 
Micronization of crystalline particles results in powders with high surface charge that are more 
surface-active leading to cohesive powders that are prone to aggregation and therefore have poor 
dispersibility [93].  
Preparation of dry powders using the bottom-up method of spray drying is a popular 
approach as it is a simple, fast, and scalable method that produces particles of uniform size and 
shape with diameters in the respirable range [91]. The spray drying process consists of three 
fundamental steps in which a feed solution or suspension is (i) atomized to produce liquid droplets 
that are (ii) dried by exposure to heated drying gas resulting in dried particles, which is then (iii) 
separated from the drying gas and collected [94]. A nozzle atomizes the feed stock into droplets 
creating particles with increased surface area. In the drying chamber, the solvent (a mixture of 
water and organic solvents) is evaporated from the droplets by hot drying gas producing particles 
with low moisture content. Droplet drying can be controlled by the inlet temperature, the drying 
gas flow rate, the feed stock flow rate, and the solvents used in the feed stock. The dried particles 
are then separated from the drying gas by either a cyclone and collected in a collection vessel, as 
in the Büchi Mini Spray Dryer B-290, or using an electrostatic particle collector, as with the Büchi 
Nano Spray Dryer B-90 and B-90 HP.  
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The particle size of the powder is largely influenced by the solids concentration of the feed 
stock and also by the size of the droplets produced from atomization as shown in Equation 1.1 
[95]. The geometric diameter of the dry particle is governed by mass balance: 
 -./012345 = 	 789: -;0<.451           Equation 1.1 
When a total solute concentration in the feedstock of C is atomized into droplets of diameter ddroplet, the geometric diameter of the spray dried particle dparticle is produced with density r. 
Traditional spray dryers employ atomizers with a nozzle tip. The desire to produce smaller 
particles has led to advancements in spray drying technology in which atomization occurs via a 
vibrating mesh system (Büchi Nano Spray Dryer B-90 and B-90 HP). A comparison of the spray 
nozzle/meshes of the traditional Büchi Mini Spray Dryer B-290 with the newer Nano Spray Dryers 
is shown in Table 1.2.  
 
Table 1.2 Nozzle, droplet and particle size comparison of the traditional Mini Spray Dryer B-290 
with the Nano Spray Dryer B-90 and B-90 HP, from [94, 96]. 
 Mini B-290 Nano B-90 Nano B-90 HP 
Atomizer size 
0.7, 1.4, 2.0 mm 
(nozzle diameter) 
4.0, 5.5, 7.0 µm  
(spray mesh hole size) 
small, medium, 
large 
Water droplet 
size range 5-30 µm (0.7 mm tip) 
3-8 µm (4.0 µm spray mesh), 
4-12 µm (5.5 µm spray mesh), 
5-15 µm (7.0 µm spray mesh) 3-15 µm 
Dried particle 
size range 2-25 µm 0.3-5 µm 0.2-5µm 
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With the traditional spray dryer, the larger mean droplet size range was due to the larger spray 
nozzle diameters, resulting in spray dried particles of a broader size range. The newer vibrating 
mesh spray dryers make it possible to produce particles in the submicrometer range with a 
narrower size distribution compared to that of the traditional spray dryer, which has been shown 
to have low collection efficiency for fine particles less than 2 µm [97].  
Spray freeze drying is a two-step process: (i) atomization of the feedstock into a freezing 
medium, commonly liquid nitrogen, that produces frozen droplets of the sprayed feedstock, then 
(ii) lyophilization to remove the ice via sublimation, leaving behind a powder [91]. Spray freeze 
drying is performed at sub-ambient temperatures, therefore has the advantage of preserving the 
integrity of thermolabile therapeutics but is less utilized compared to spray drying due to its higher 
complexity and more tedious scale-up and higher costs [93]. 
A supercritical fluid (SCF) is a compressed gas or liquid above its critical pressure and 
temperature that exists as a single phase with liquid-like density and gas-like transport properties. 
SCFs exhibit pressure-tunable solubility enabling them to be used for recrystallization processes 
[92]. The most common SCF used is supercritical CO2 due to its low critical temperature (31.1 °C) 
and pressure (73.9 bar). Supercritical CO2 is used as a solvent in rapid expansion of supercritical 
solutions (RESS) in which drug containing SCF is passed through a nozzle allowing for 
precipitation of the drug through rapid expansion of CO2 in the vessel [91]. This method is limited 
by the poor solubility of most active pharmaceutical ingredients (APIs) in supercritical CO2. The 
use of supercritical CO2 as an anti-solvent has been developed to overcome this limitation by 
dissolving drug in a solvent miscible with CO2, but the use of SCFs in particle manufacturing still 
has the challenge of predictive control of particle size [91, 93].   
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1.8.1.2 Spray drying of surfactants 
The relatively high phospholipid Tg of DPPC is regarded as being at a low temperature in 
terms of dry powder formulation via spray drying. Therefore, phospholipids are difficult to 
formulate as dry powders due to their Tg values and amorphous nature, which lead to powders that 
are cohesive and difficult to deaggregate and aerosolize [98]. The transition temperature 
determines the chemical and physical stability of the amorphous solid and becomes a critical factor 
when it is approached or exceeded by the product during processing (e.g. drying temperature for 
spray drying and storage temperature) [99]. For spray drying, a Tg value lower than the outlet air 
temperature of the dryer causes the components to remain in a more cohesive form, even though 
they are dried to a low moisture content; while a storage temperature close to the Tg of the 
formulation increases the possibility of the amorphous powder to transition to the more stable 
crystalline state. The addition of materials with higher transition temperatures would raise the Tg 
of the system and allow for more flexibility during processing and storage [99]. 
The inclusion of sodium chloride in the formulation of a spray dried surfactant-EEG 
powder would serve two functions: (i) to act as a hygroscopic excipient, and (ii) to raise the Tg of 
the formulation allowing for particle formation. Sodium chloride exists as a crystalline solid, so 
its presence in the feed dispersion for spray drying would raise the Tg of the system. The other 
component materials need to be accounted for to determine the Tg of the system, which would 
include mannitol (Tg of 6 °C), leucine (dispersion enhancer with Tg of 122 °C) or trileucine 
(alternative dispersion enhancer with Tg of 110 °C) plus the other components of the commercial 
formulation (the other major lipid component in Survanta® aside from DPPC is POPG, with a 
transition temperature of -2 °C [100]).  
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The low aqueous solubility of components in the commercial surfactant formulation results 
in the production of a dispersion for spray drying in an aqueous media. The homogeneity of the 
feed dispersion is important to ensure uniformly sprayed particles. A method to prepare 
homogenous dispersions involves the use of sonication. Sonication can be introduced to the liquid 
suspension either by immersing an ultrasonic probe in the suspension (direct sonication) or by 
introducing a vessel with the suspension into a bath sonicator (indirect sonication). Direct 
sonication yields higher energy output into the suspension requiring less sonication time, but has 
the side effect of introducing impurities into the suspension as titanium metal erodes from the 
probe tip [101]. 
1.8.2 Nebulized surfactants 
With nebulized surfactant, studies in animal models have shown that approximately 4 to 
11% of the administered dose was recovered from the lungs [84, 102]. In infants, deposition of 
<1% of nominal dose [103, 104] has been observed. The main challenge with nebulized surfactants 
is efficient delivery to the targeted regions of the lungs, which suggests the need for development 
of improved drug formulations and delivery techniques for more effective treatment. 
For bronchiolitis, where surfactant therapy does not need to be administered in the quick 
manner that RDS necessitates, the use of nebulizers to deliver surfactant aerosols containing 
mannitol would provide supplemental treatment. Mannitol has been shown to have little effect on 
the surface activity of a dilute Survanta suspension (0.75 mg/mL phospholipids) at different 
concentrations of mannitol (0.1, 0.5 and 1.0 mg/mL) when measured at 37 °C [105]. The 
combination of surfactant and mannitol would help facilitate mucociliary clearance since 
surfactant decreases the adhesion of mucus to the airway epithelium [7], and mannitol, with 
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hygroscopic properties at > 75% relative humidity [106], has been shown to increase mucociliary 
clearance [107]. 
1.9 Surfactant-EEG formulation characterization 
Preparation of surfactant-EEG formulations for aerosolization utilizes methods of 
sonication and nebulization, which may raise concerns of possible adverse effects on the 
components and surfactant function of the commercial suspensions; specifically, the role of 
surfactant in reducing the surface tension at the air-liquid interface.  
1.9.1 Phospholipid detection  
DPPC has two 16-carbon chains with a phosphate group and a quaternary amine (Figure 
1.3). The nitrogen is positively charged and the oxygen of the phosphate is negatively charged 
resulting in a zwitterionic headgroup with a molecular weight of 734.04 Da (exact mass of DPPC 
is 733.56 Da) when the oxygen of the phosphate group is not protonated. A challenge with DPPC 
analysis arises when performing quantitative detection of the phospholipid following separation 
by high performance liquid chromatography (HPLC). DPPC lacks UV chromophores and 
fluorophores, which eliminates the option of employing commonly utilized UV absorption- and 
fluorescence-based detectors without first performing derivatization reactions. A common method 
of detection employed is the use of mass spectrometry.   
Mass spectrometry (MS) is a method that separates ions based on their mass-to-charge 
ratios (m/z). Typical instruments include an ion source, a mass analyzer, and a detector. The ion 
source induces either a loss or gain of a charge from a neutral species, which are then 
electrostatically directed into a mass analyzer where they are separated by their m/z and then 
measured and detected. The result is a mass spectrum.  
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Common ion source methods include electron ionization (EI), chemical ionization (CI), 
matrix-assisted laser desorption ionization (MALDI) and electrospray ionization (ESI). Of all the 
source types, EI results in the highest fragmentation (hardest ionization) and is most widely used 
with gas chromatography (GC) MS. CI is a softer ionization technique that uses a reagent gas (such 
as methane or ammonia) for ionization. CI is performed in both closed sources (under vacuum) 
and in atmospheric pressure (APCI). APCI is typically coupled to HPLC systems and does not 
generate multiply charged ions. It is commonly used to analyze smaller, thermally stable 
compounds as it operates at higher temperatures.  
The most common ionization methods used for biochemical analyses are MALDI and ESI. 
Both techniques can operate in positive and negative modes. MALDI results in higher analyte 
fragmentation when compared to ESI and is not attached to a separation instrument as described 
with the previous methods. MALDI samples are first dissolved in a volatile solvent and mixed 
with a matrix prior to application onto a sample plate, which is then inserted into the MS under 
high vacuum. MALDI primarily produces singly charged species. ESI is the softest of the 
ionization methods. It can be coupled to a separation instrument, but direct infusion with a syringe 
pump is possible for simple matrix samples. The analyte containing eluent is introduced into the 
source via a capillary, at low flow rates (1 µL/min to 1 mL/min), that is surrounded by drying gas 
(usually nitrogen), which helps to aerosolize the solvent. A high voltage is applied to the tip of the 
capillary, producing an aerosol of highly charged droplets. Sample ionization occurs at 
atmospheric pressure.  
There are two types of mass analyzers: scanning and pulsed. Scanning mass analyzers, 
such as the single and triple quadrupoles, detect ions successively along a time scale, while pulsed 
mass analyzers (e.g. time-of-flight, orbitrap) detect ions simultaneously. For triple quadrupole MS, 
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ions are sampled through a series of orifices into the first quadrupole where filtering occurs based 
on the m/z. Mass separated by ions pass into the hexapole collision cell that either undergo collision 
induced decomposition (CID) or pass unhindered to the second quadrupole. The fragmented ions 
are mass analyzed by the second quadrupole and the transmitted ions detected by a conversion 
dynode, phosphor and photomultiplier detector system. Triple quadrupole is low resolution given 
that they cannot fully distinguish a change in the m/z of less than 0.5 in a mass spectrum. Time-of-
flight (TOF) analyzers, used to detect ionization from MALDI sources, measure arrival times of 
ions to the detector assuming that the same kinetic energy is applied to all the ions which are 
allowed to travel the same fixed distance. 
1.9.2 Surface activity 
Static surface tension is the surface tension value in thermodynamic equilibrium 
independent of time, whereas the dynamic surface tension (or interfacial tension) is the surface 
tension at a particular surface (or interface) age. For fluids containing surface-active materials, this 
value can differ from the equilibrium surface tension value. A newly formed interface of a 
surfactant solution has a surface tension close to that of the solvent, however, over time, the surface 
tension will decay to the equilibrium value and this period of time ranges from milliseconds to 
days depending on the surfactant type and concentration [108].  
Methods commonly used to determine surface activity include the Langmuir-Wilhelmy 
balance, the pulsating bubble surfactometer, captive bubble surfactometer and constrained sessile 
drop. There are advantages and disadvantages to each method. The Langmuir-Wilhelmy balance 
is used to study surface rheology properties of surfactant monolayers and phospholipid phase 
behaviors. The method can be combined with microscopic and spectroscopic techniques [109], but 
its environment is difficult to control and is not capable of studying adsorbed films. The pulsating 
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bubble surfactometer provides a quick comparison of surface activity and is able to simulate 
breathing, but the surface tension at low values tend to be inaccurate. The method of the captive 
bubble surfactometer allows for simulation of the alveolar environment and is capable of studying 
both adsorbed and spread films, although it has a limitation on the maximum surfactant 
concentration used when studying adsorption. The instruments used in captive bubble 
measurements are often difficult to operate and clean. The constrained sessile drop method uses a 
precisely-controlled environment and requires low sample volumes (in µL range). The method is 
also capable of studying both adsorbed and spread films and does not have a limitation on the 
surfactant concentration.   
1.9.3 Surfactant protein analysis 
Of the four surfactant proteins known to be present in endogenous surfactant (SP-A, SP-B, 
SP-C, SP-D), only the hydrophobic proteins, SP-B and SP-C, are present in the commercial 
formulations processed for human use. The vital role that proteins play in the proper function of 
pulmonary surfactant deems it necessary to determine that their presence and activity following 
the processes endured during formulation preparation (i.e. sonication, spray drying) are 
maintained. During processing, the proteins are subject to various stresses (e.g. sheer, thermal, 
dehydration) that can lead to high inter-particle interactions and physicochemical degradation that 
can affect the primary, secondary and tertiary structures of the proteins, possibly resulting in partial 
or complete loss of biological activity. Physical degradation results from denaturation and non-
covalent aggregation, while chemical degradation results from covalent aggregation, oxidation, 
deamidation, and/or glycation [110].  
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The challenge with analysis of surfactant proteins is the difficulty in separation of its low 
content from the other components in the formulation, especially due to the hydrophobic nature of 
both the proteins and lipids. Protein separation and purification can be performed by exploiting 
differences in solubility, size, charge, and binding affinity; the most common methods of which 
are precipitation and analytical separation.  
1.9.3.1 Protein purification by precipitation 
Protein precipitation can be induced by causing changes in the solvent properties to 
manipulate the electrostatic forces between proteins. Some common reagents used for precipitation 
of proteins are ammonium sulfate, hexane/isopropanol, methanol/chloroform, acetone, and 
trichloroacetic acid.  
Ammonium sulfate uses the mechanism of salting-out based on preferential solvation; 
water molecules are titrated away from hydration layer around the protein to the hydration layer 
around the ions that make up the salt. This causes increased hydrophobic interaction between 
protein and water due to increased surface tension, and in response, the protein decreases its 
surface area to minimize contact with the solvent [111]. Salts high in the Hofmeister series are 
most efficient at protein precipitation since they form large, stable hydration layers. The use of 
ammonium sulfate is preferred for salting-out due to its high solubility and that both NH4+ and 
SO42- are at the high ends of their respective Hofmeister series [112]. Disadvantages with salting-
out are that contaminants often precipitate with the protein, requiring further purification steps and 
there exists a high concentration of salt at the end of precipitation, which may lead to analytical 
issues if the salt is not removed [112]. 
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Hexane is nonpolar, and when combined with a polar solvent such as isopropanol, the 
mixture is able to interact with and extract phospholipids and triglycerides that have both nonpolar 
and polar regions. The use of a hexane/isopropanol mixture has been shown successful in the 
determination of hydrophobic proteins and allowed for simultaneous extraction and determination 
of lipids using very small volumes of samples (5-50 µL) [113]. However, use of 
hexane/isopropanol to extract lipids is not selective as the method was shown to have < 80% 
protein recoveries [113] and has been shown to also extract a high proportion of proteins when the 
hexane-to-isopropanol ratio was increased [114]. 
Methanol/chloroform extraction involves partitioning of components into the binary 
mixture. Methanol disrupts the hydrogen bonding or electrostatic forces between cell-membrane 
lipids (i.e. phospholipids, glycoproteins and cholesterol) and proteins. When chloroform is added 
(nonpolar), the two-phase system forms and enables extraction of neutral lipids (i.e. triglycerides) 
[115].  
Acetone causes precipitation of proteins by lowering the dielectric constant of the aqueous 
solution containing protein (dielectric constant of acetone at 20 °C is 21.3, while that of water is 
80.0 [116]). Organic solvents with small dielectric constants discourage the dispersion of protein 
molecules in the media, reducing their solubility. Therefore, adding a water-soluble solvent such 
as acetone to an aqueous solution of protein induces precipitation by lowering the effective 
dielectric constant of the media.  
Trichloroacetic acid (TCA) induces protein precipitation by disrupting hydration layers and 
decreasing the pH, partially denaturing proteins, exposing more of the hydrophobic surface to the 
solvent [117, 118]. TCA is a relatively weak acid and therefore does not hydrolyze the peptide 
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bonds of proteins. Drawbacks of TCA precipitation include protein denaturing, which limits the 
use of this method if protein activity is to be retained. 
1.9.3.2 Protein purification by analytical separation 
Analytical purification methods can utilize protein properties for separation: (i) ion-
exchange chromatography by isoelectric point, (ii) reverse-phase chromatography by 
polarity/hydrophobicity, and (iii) size-exclusion chromatography by size or molecular weight. 
Successful protein separation from a majority of the phospholipids (> 96%) has been 
reported [119]. The method separates proteins by gel-exclusion with a Sephadex LH-60 column 
using chloroform/methanol and requires a large amount of starting material (which is identical to 
the commercial Curosurf formulation), 300-500 mg, in which pooled fractions from several 
preparations are needed for a second separation on a longer Sephadex LH-60 column to obtain the 
separated proteins.  
1.9.3.3 Protein detection 
Pellets collected from protein precipitation must be solubilized in appropriate buffers 
before they can be analyzed further. Detergents (surfactants or a mixture of surfactants) are 
frequently used to enhance solubilization and stabilize proteins as well as deaggregate membrane-
bound protein complexes [120, 121]. However, detergents interfere with mass spectrometry as 
they are preferentially ionized and are typically present in high concentrations, which can obscure 
the detection or suppress ionization of the protein. Loo et al. [121] observed poor-to-no protein 
signal at 1.0% surfactant concentration with better results obtained at lower surfactant 
concentrations in ESI-MS.  
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The detection and quantitation of the hydrophobic surfactant proteins in bronchoalveolar 
lavage fluid (without preprocessing of samples) has been performed using enzyme-linked 
immunosorbent assay (ELISA) [122].  The assay uses a sandwich enzyme technique in which an 
antibody specific for the individual proteins was precoated onto a microplate. Protein in the 
standards and samples are bound by the antibody and any unbound substances are removed. A 
biotin-conjugated antibody specific for the protein was added, then washed and followed by 
addition of an advin conjugated Horseradish Peroxidase (HRP). Once this was washed, a substrate 
was added and color developed in proportion to the amount of the protein bound in the initial step. 
Color development was stopped after and the intensities were measured. Disadvantages with 
ELISA include: (i) the cumbersome washing procedures, (ii) the lengthy incubation times and (iii) 
the high cost of each kit.  
1.9.4 Dispersion stability 
Spray drying of large batches of dispersion vehicle can be a long process performed over 
a number of hours. The zeta potential can be used as an indication of dispersion stability. Particles 
in suspension can form aggregates, which may settle out due to gravity (flocculate). According to 
DVLO theory, the stability of particles in a suspension is dependent on its total potential energy 
function, which is a balance of three factors: (i) the potential energy due to the solvent (minor 
contribution), (ii) the attractive (van der Waals) forces, and (iii) repulsive (electrical double layer) 
forces. The attractive and repulsive forces (dotted lines in Figure 1.5) are summed to obtain the 
net energy (solid line). 
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Figure 1.5 Schematic of free energy with particle separation according to DVLO theory [123]. 
The theory proposes that particles initially separated cannot approach each other due to the 
repulsive force, but if particles are forced with sufficient energy to overcome the repulsion (net 
energy peak), then the attractive force will pull them together. Particles with sufficiently high 
repulsion, high zeta potential values (further from zero, positive or negative) will resist flocculation 
resulting in a stable system. The zeta potential provides a good index of the magnitude of 
interaction between particles and can be used as a measure of dispersion stability.  
The generally accepted dividing line between stable and unstable suspensions is +/-30 mV, 
so particles with zeta potential values more positive than +30 mV or more negative than -30 mV 
are considered stable [123]. The surface charge is dependent on the nature of the particle and its 
surrounding medium, on the acidic or basic strengths of the surface groups (resulting in negatively 
or positively charged surfaces, respectively), and on the pH of the solution. 
  
 
35 
Sirsi et al. [124] determined the zeta potential (z) of Survanta® at different pH values 
(Figure 1.6), which revealed that the commercial suspension is highly negatively charged over the 
pH range of 4 to 12, with an isoelectric point at approximately pH 3. 
 
 
Figure 1.6 Zeta potential of Survanta (1 mg/mL phospholipids) as a function of pH [124]. 
1.10 Objectives 
This research focuses on the reformulation of commercial surfactants using the EEG 
approach for aerosolized delivery coupled to administration with novel devices to achieve 
improved delivery to the infant lungs. The delivery of a dry powder surfactant during nasal CPAP 
will allow for rapid surfactant delivery to the lungs of infants at risk or suffering from RDS. In 
addition, the use of a nebulized surfactant-EEG formulation to be delivered as supplemental 
treatment during HFNC therapy for bronchiolitis would help to facilitate mucociliary clearance.  
  
 
36 
CHAPTER 2 
2 HYPOTHESIS AND SPECIFIC AIMS……… 
The overall aim of this research project was to develop surfactant dry powder formulations 
and devices for efficient delivery of aerosol formulations to infants using the excipient enhanced 
growth (EEG) approach. The development of novel formulations used in combination with novel 
inline delivery devices would allow for more efficient treatment of infants suffering from neonatal 
respiratory distress syndrome (RDS) and viral bronchiolitis. The research goals were achieved by 
addressing the following hypotheses and specific aims: 
 
Hypothesis 1: The excipient enhanced growth (EEG) approach can be applied to 
dipalmitoylphosphatidylcholine (DPPC) to produce spray dried powders. 
 
Specific aim 1-1: Develop methods to reproducibly produce micrometer sized spray dried DPPC-
EEG powders suitable for inhalation. 
Specific aim 1-2: Investigate the influence of spray drying and formulation variables on the 
primary particle size, aerosol performance, and surface tension activity of a range of spray dried 
DPPC-EEG powders. 
 
 
 
  
 
37 
Hypothesis 2: Optimization of the spray drying and formulation variables will improve 
dispersibility of EEG powders prepared with commercial replacement surfactants. 
 
Specific aim 2-1: Produce EEG formulations with a commercially available exogenous surfactant 
using dry powder dispersion enhancers of different aqueous solubility in spray vehicles with 
different ethanol concentrations. 
Specific aim 2-2: Investigate the influence of the dispersion enhancer on the feed dispersions, 
powder characteristics, and particle size distributions at different dispersion pressures.   
Specific aim 2-3: Determine the influence of dispersion feed composition on the aerosol 
performance of spray dried powders using a novel dry powder inhaler. 
Specific aim 2-4: Evaluate the presence of the surfactant proteins (SP-B and SP-C) following 
formulation processing and spray drying. 
 
Hypothesis 3: Optimization of the design of a novel low dispersion air volume dose-
containment unit dry powder inhaler will improve the delivery and dispersion of spray dried 
surfactant-EEG powders. 
 
Specific aim 3-1: Investigate the influence of a series of design modifications to the low dispersion 
air volume dose-containment unit dry powder inhaler on the emitted mass and particle size of 
EEG-surfactant powders. 
Specific aim 3-2: Determine the influence of fill mass on the emitted mass and particle size of 
surfactant-EEG powders with the dose-containment unit dry powder inhaler.  
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Hypothesis 4: Methods to reduce nebulized droplet size and synchronized aerosol delivery 
can be employed to improve the delivery of aerosols to a realistic infant model during in vitro 
testing of surfactant excipient enhanced growth formulations. 
 
Specific aim 4-1: Perform experiments under steady state inhalation conditions with a novel low-
volume mixer-heater device designed to deliver a micrometer sized aerosol and compare aerosol 
deposition and delivery efficiency with the standard of care methods using a nebulized albuterol 
sulfate formulation.  
Specific aim 4-2: Using realistic in vitro test methods, determine the optimal breath 
synchronization and nebulization duration settings to achieve the maximum estimated lung dose 
using a novel low-volume mixer-heater device. 
Specific aim 4-3: Determine the aerosol performance of surfactant-EEG formulations with the 
modified very low-volume mixer-heater device with the optimized breath synchronization 
conditions. 
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CHAPTER 3 
3 ASSESSMENT OF THE EFFECT OF SPRAY DRYING PROCESS PARAMETERS 
AND FORMULATION FACTORS ON POWDER CHARACTERISTICS AND 
AEROSOL PERFORMANCE OF DPPC-EEG POWDERS 
3.1 Introduction 
The use of aerosolized surfactant has been explored as a potential delivery method to treat 
respiratory distress syndrome (RDS) as it can be administered by non-invasive means and has 
possible superiority over liquid instillation [10, 85-87]. Nebulization to generate surfactant 
aerosols for non-invasive administration has been studied extensively; however, administration 
challenges such as poor delivery efficiency to the alveolar region of the lungs, long delivery times, 
and insufficient evidence of efficacy have limited the use of surfactant as an aerosol therapy [10, 
89]. The development of a dry powder surfactant formulation, using the excipient enhanced growth 
(EEG) application, administered via novel delivery devices and ventilation components, designed 
for minimal depositional losses, is hypothesized to provide a high lung delivery combination that 
will overcome the challenges of aerosolized surfactant therapy.  
The delivery of dry powder surfactants has advantages over liquid formulations, such as 
the ability to deliver larger doses since there is no need for dilution of the surfactant suspension to 
enable nebulization, and delivery can be performed over a much shorter time frame. Dry powder 
surfactant preparations that have been investigated for the treatment of RDS include synthetic 
mixtures of DPPC with phosphatidylglycerol [125, 126], micronized powder formulations 
consisting of recombinant SP-C–based surfactant protein [88], and spray dried recombinant SP-C 
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surfactant protein [89]. Preparations of dry powder surfactants that utilize its low surface tension 
characteristics for applications as a drug delivery-carrier have also been attempted [127]. These 
formulations have all been synthetic in nature and a dry powder formulation prepared from 
naturally derived surfactant has yet to be studied.  
Commercially available naturally derived replacement surfactant formulations in the 
United States include Curosurf® (poractant), Infasurf® (calfactant), and Survanta® (beractant). The 
formulations differ in the composition of proteins and lipids, but are similar in that 
dipalmitoylphosphatidylcholine (DPPC) is present as the dominant lipid component [30-32]. 
Given the high cost of each single-use vial of drug, which ranges from $400-800 per vial, 
development studies to reliably produce a dry powder surfactant formulation were carried out with 
the main lipid component, DPPC. 
Spray drying of DPPC has been explored for a number of applications including drug 
encapsulation [128] for protein stabilization [129], as a permeation enhancer to increase protein 
bioavailability [130], and as an excipient to produce low density powders [131]. In this study, 
DPPC was used as a model drug in spray drying experiments to minimize development costs with 
the intention of applying the developed methods to commercial surfactant formulations. 
The aim of this study was to develop methods to reliably produce DPPC-EEG powders and 
use the developed methods to investigate the influence of spray drying process parameters and 
formulation factors on the mass median aerodynamic diameter (MMAD), fine particle fraction less 
than 1 µm and less than 5 µm of DPPC-EEG dry powder aerosol formulations using a full factorial 
design of experiments. The formulation factors included the percent solids concentration, the 
percentage of hygroscopic excipients, and the percent ethanol concentration in the feed dispersion. 
The process parameters studied were spray mesh size and inlet drying temperature. The levels 
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selected for the factors studied were based on the limits of the operating parameters as determined 
in preliminary studies. The developed methods were then applied to commercial surfactant 
formulations to produce dry powder formulations for the treatment of neonatal RDS. 
3.2 Materials and methods 
3.2.1 Materials 
DPPC was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). L-leucine was 
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Pearlitol® PF-mannitol was 
donated from Roquette Pharma (Lestrem, France). Sodium chloride and all other reagents were 
purchased from Fisher Scientific Co. (Hanover Park, IL). Size 3 hydroxypropyl methylcellulose 
(HPMC) capsules were donated from Capsugel (Morristown, NJ) and Qualicaps, Inc. (Whitsett, 
NC). Molycote® 316 silicone spray was purchased from Dow Corning Corporation (Midland, MI). 
Curosurf® (poractant), Infasurf® (calfactant), and Survanta® (beractant) intratracheal suspensions 
was purchased from Cardinal Health, Inc. (Greensboro, NC) and stored at 2-8 °C.  
3.2.2 Development of methods to produce DPPC-EEG feed dispersions for spray drying 
Preliminary experiments were performed to assess the feasibility of adapting methods 
developed using water soluble albuterol sulfate as the active ingredient in EEG powders [76] to 
produce EEG spray dried formulations with DPPC which has a low water solubility (< 5 µg/mL).  
Experiments explored formulation combinations of varying concentrations of DPPC, mannitol, 
sodium chloride and trehalose; leucine was included in all formulations at a concentration of 20% 
w/w. Feed dispersions for spray drying were prepared in 20% v/v ethanol in water, in which DPPC 
was dissolved in ethanol and the excipients in water, then combined. The nominal composition of 
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the initial eleven feed dispersions and spray dried powders are listed as Formulations P1-P11 in 
Table 3.3. The percentage of solids concentration for these studies was 0.125% w/v. 
3.2.2.1 Spray dried powder formation 
Feed dispersions were spray dried using the Büchi Nano Spray Dryer B-90 (Büchi 
Labortechnik AG, Flawil, Switzerland) in the open-loop configuration. Parameters used for spray 
drying were based on methods for albuterol sulfate EEG preparation: size 4 µm spray mesh, inlet 
drying temperature of 70 °C (outlet temperature ranged from 38 to 41 °C), drying airflow of 120 
L/min, and liquid feed rate of 100%. Powders were collected from the electrostatic particle 
collector into a tared vial. Powders were stored in a desiccator in a refrigerator (2-8 °C) when not 
in use. The percent powder yield was calculated from the mass of powder collected as a percentage 
of the mass of solids weighed in the feed dispersion using Equation 3.1. 
 
=>?-@A	BC@D-,% =	 .<G;50	H/II	3<445315;,			HJ3<K3	I<42;I	2K	;2I.50I2<K,				LMLN 	∗	P<4QH5	<R	;2I.50I2<K	I.0/S	;025;,			HT 	× 	100             
                        Equation 3.1 
3.2.2.2 Aerodynamic particle size characterization in ambient conditions  
The aerosolization properties of the spray dried powders were determined following 
conventional cascade impaction methods using the Next Generation Impactor (NGI, MSP Co., 
Shoreline, MN) and an Aerolizer® dry powder inhaler (Novartis Pharmaceuticals, Basel, 
Switzerland). Approximately 1 to 2 mg of powder was filled into size 3 HPMC capsules and placed 
into the dry powder inhaler. The NGI collection cups and pre-separator were coated with 
Molycote® 316 silicone release spray (Dow Corning, Midland, MI) to minimize particle bounce. 
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The NGI was fitted with the pre-separator and positioned in an upright position to permit the use 
of the Aerolizer® in its horizontal orientation held in place with a mouthpiece adapter made from 
RTV (room temperature vulcanizing) silicone mold rubber (Micro-mark Ten-to-One, Berkeley 
Heights, NJ). Powder was released into the NGI at 80 L/min for 3 s. The flow rate was selected 
based on previous studies performed with albuterol sulfate EEG powder and the Aerolizer® [76].  
Powder was extracted from the pre-separator, collection cups and filter using 100% 
methanol. DPPC was quantitatively analyzed using an LC-MS method to determine the emitted 
dose, the MMAD and particle fraction less than 1 µm and less than 5 µm at ambient temperature.  
 
XYCZZ@-	->[@,% = 	H/II	<R	;0QJ	5H2115;	R0<H	2K\/450,			HJK<H2K/4	;0QJ	;<I5,			HJ 	× 	100                  Equation 3.2 
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MMAD values were directly calculated as the size associated with a cumulative count of 50% 
based on mass percentages calculated relative to the impactor dose. 
3.2.2.3 Liquid chromatography-mass spectrometry for DPPC 
DPPC detection was performed with positive electrospray ionization mass spectrometry. 
Quantification was performed following a liquid chromatography-mass spectrometry (LC-MS) 
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method adapted from Li et al. [132]. The system consisted of a tandem quadrupole mass 
spectrometer, Waters Micromass Quattro micro™, linked to an Alliance 2695 Separations Module 
with MassLynx software v4.1 (Waters Corporation, Milford, MA). A Waters Atlantis hydrophilic 
interaction liquid chromatography (HILIC) silica column (1.0 mm x 50 mm, 5 µm) was used for 
the separation. The isocratic mobile phase, which consisted of 85% acetonitrile and 15% 5 mM 
ammonium formate in water with 0.1% formic acid, was eluted at a flow rate of 0.5 mL/min. A 
volume of 2 µL was injected for each sample. The mass spectrometer was used in positive 
electrospray ionization mode with the following settings: capillary, 4 kV; cone, 35 V; source 
temperature, 120 °C; desolvation temperature, 300 °C; desolvation gas flow, 420 L/h; cone gas 
flow, 35 L/h. The mass spectrometer was operated in selected ion monitoring (SIM) mode for m/z 
734.6 (exact mass of DPPC is 733.56 Da).  
For powder content analysis, approximately 1.3 mg of spray dried powder were dissolved 
in 100 mL of methanol by sonication for 30 s. Percent DPPC content was calculated by measuring 
the amount of drug in the spray dried powder by LC-MS and using Equation 3.5. 
 
e==m	^>`Z@`Z,% =	 /II/S5;	/H<QK1	<R	noo8	2K	I.0/S	;025;	.<G;50,			HJH/II	<R	I.0/S	;025;	.<G;50	2K	I/H.45,			HJ 	× 	100   Equation 3.5 
3.2.2.4 Thermogravimetric analysis  
Thermogravimetric analysis (TGA) was performed on samples using the Pyris 1 TGA 
(PerkinElmer, Covina, CA) with TAC 7/DX Thermal Analysis Controller. Weight loss was 
determined from 1 to 2 mg samples of powder that were heated from 25 °C to 100 °C at a rate of 
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10 °C/min and then held at 100 °C for 45 minutes while under a nitrogen purge at 40 mL/min. The 
percent weight loss % following the isothermal hold corresponds to loss of water of hydration. 
3.2.3 Development of methods for surface tension sample preparation and measurement  
The aim of this task was to develop a sample preparation method for surface tension 
measurements to study the dynamic adsorption behavior of DPPC following spray drying. Surface 
tension measurements were necessary to ensure that the spray dried powders maintained their 
surface tension reduction properties with the understanding that DPPC would be chemically stable 
following processing, but possible conformational changes due to interactions with excipients in 
the formulation may affect its surface activity. A bubble pressure tensiometer (BP2, Krüss, 
Hamburg, Germany) was used to determine the dynamic surface tension of a liquid by measuring 
the maximum internal pressure of a gas bubble formed in a liquid from a capillary of known 
diameter. Using the Young-Laplace equation (Equation 3.6), the dynamic surface tension, g, can 
be determined from the maximum pressure. 
 
p = iq (=H/s − =u)A3                                  Equation 3.6 
Where Pmax is the maximum bubble pressure, P0 is the hydrostatic pressure in the capillary of 
known inner radius, rc. Surface tension measurements of the DPPC dispersions were performed 
with the tensiometer connected to a recirculating water bath (Lauda-Brinkmann M3, Delran, NJ) 
that allowed for temperature-controlled measurements. Measurement settings were as follows: 
start at surface age of 0.5 to 10 s, stop at surface age of 50 s, stop quickscan at 5 s, linear acquisition, 
and 30 values were collected for each measurement.  
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A reference tensiogram for the surface activity of the commercial Survanta® formulation 
at 37 °C with a phospholipid concentration of 0.75 mg/mL is shown in Figure 3.1 [133]. At the 
young surface age of 0.01 s, the surface tension was approximately 70 mN/m, similar to that of 
saline [105], the solvent for the commercial surfactant formulation. At a surface age of 30 s, the 
dynamic surface tension was determined to be 45 mN/m; the extrapolated equilibrium surface 
tension was determined to be 37 mN/m [133]. 
 
 
Figure 3.1 Dynamic tensiogram for the commercial Survanta formulation (0.75 mg/mL 
phospholipids) at 37 °C [133]. 
Dispersion preparation methods were explored using heat and sonication. Indirect 
sonication was performed with a bath sonicator (Bransonic® 5510R-MT, Branson Ultrasonics, 
Danbury, CT) and direct sonication was employed with a probe sonicator (Q700 with 1/8” microtip 
probe part no. 4418, Qsonica; Newtown, CT). The effect of sample preparation method, 
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measurement temperature and DPPC concentration on the dynamic surface tension of DPPC spray 
dried powders were studied. 
3.2.4 Full factorial design of experiment (DOE) to assess selected formulation factors and 
spray drying parameters  
The preliminary experiments described above were performed to develop processing and 
analytical methods and to identify the main factors that influence DPPC-EEG feed dispersions and 
spray dried powder performance. Factors and levels that were studied are shown in Table 3.1. 
Weight of solids and solvent volumes were dependent on the solids concentration, the ratio of the 
hygroscopic excipients and the ethanol concentration in the spray vehicle (Table 3.2). The nominal 
composition of sixteen feed dispersions and spray dried powders are listed as Formulations 1-16 
in Table 3.9. 
 
Table 3.1 Factors and levels for full factorial DOE assessment of DPPC-EEG formulation 
optimization. 
Factors Levels 
Solids in feed dispersion, % w/v 0.125 0.250 
Ratio of mannitol-to-sodium chloride 3:1 15:1 
Ethanol in feed dispersion, % v/v 0 5 
Spray mesh size, µm 4 7 
Inlet drying temperature, °C 70 80 
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Table 3.2 Weight and volume amounts used for the formulation factors studied. 
Weights Mannitol-to-sodium chloride 3:1 15:1 
 Mannitol, mg 60 75 
 Sodium chloride, mg 20 5 
  
Volumes 
solids, % w/v 0.125  0.250 
ethanol, % v/v 0 5  0 5 
 Water, mL 160 152  80 76 
 Ethanol, mL 0 8  0 4 
*Total solids weight of 200 mg; DPPC and leucine kept constant at 80 and 40 mg, respectively 
 
 
Initial experiments with the spray mesh size of 7 µm resulted in consistently low yields 
(mean ± standard deviation yields of 1.33 ± 1.37%) and therefore removed as a study factor. A full 
factorial DOE approach was used to test the remaining four factors. Sixteen spray dried powders 
were studied with the aim of studying the effects of the different parameters on emitted dose, 
MMAD and particle fraction less than 1 µm and less than 5 µm. 
3.2.4.1 Particle size determination 
The primary particle size of each formulation was determined by laser diffraction using the 
Sympatec HELOS (submicron R1 lens with 20 mm focal length) with RODOS/M disperser and 
ASPIROS sample feeder (Sympatec GmbH, Clausthal-Zellerfeld, Germany). Sample vials were 
filled with 3 to 4 mg of powder, capped and placed into the ASPIROS sample feeder set to 60 
mm/sec. The RODOS/M used compressed air set to 3.0 bar to disperse the powders. The minimum 
optical concentration (Copt) was set to 2.1%. Data were collected over a measurement duration of 
10 s. All measurements were performed in triplicate. Volume-based size distributions were 
calculated by WINDOX software using the Fraunhofer theory: the particle size below which 10%, 
50% and 90% of the spray lies (Dv10, Dv50, and Dv90, respectively). The span of the particle size 
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distribution (PSD), indication of the width of the distribution, was calculated following Equation 
3.7. The percentage of particles having a diameter less than 1 µm and 5 µm (Dv<1 µm and Dv<5 
µm, respectively) was obtained from the Sympatec software. 
 
dz]` = 	nP{u|nPiunPku                                                                                                        Equation 3.7 
3.2.5 Statistical analysis 
Data analysis was performed using JMP® Pro software version 12.0 (SAS Institute Inc., 
Cary, NC). For DOE analysis, response was based on the powder characteristics, the powder 
aerosol performance and surface activity. The influence of each factor and two factor interactions 
on the response was performed using full factorial analysis of variance (ANOVA). For responses 
with no significant interactions, the effects of the main factors were assessed individually by 
Student’s t-test. The Pearson correlation coefficient was determined to quantify the strength of 
linear relationships. A flat line (weakest correlation) would be indicated by a Pearson correlation 
equal to 0 while the strongest correlation occurs when the coefficient is equal to the absolute value 
of 1. The significance (p-value) indicates whether the correlation is different from a flat line. One-
way ANOVA followed by Dunnett’s method was used to determine the significant differences of 
powder characteristics of EEG formulations produced with commercial surfactant compared to the 
optimal DPPC-EEG formulation. P values less than 0.05 were considered as statistically 
significant.  
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3.3 Results and discussion 
3.3.1 Development of methods to produce DPPC-EEG feed dispersions for spray drying 
Previous EEG formulations have been prepared with relatively high aqueous solubility 
drugs (albuterol sulfate, terbutaline sulfate, azithromycin, tobramycin) and excipients. In contrast, 
DPPC is nearly insoluble in water. Feed dispersions in these initial experiments were prepared by 
dissolving the water-soluble excipients in the aqueous phase (80% v/v of the feed dispersion) and 
the DPPC in ethanol (20% v/v of the feed dispersion). These were then combined to produce the 
feed dispersion for spray drying. It should be noted that a coarse dispersion of DPPC was produced 
by precipitation of DPPC when the two phases were combined.  
3.3.1.1 Preliminary studies on the effect of formulation excipients on powder yield  
For the eleven feed dispersions prepared, leucine was kept at a concentration of 20% w/w 
while varying the concentrations of DPPC and mannitol. The percent solids concentration was 
0.125% w/v. Low powder yields were observed, preliminary formulations P1-P3 in Table 3.3, 
which led to exploration of other excipients. The use of trehalose, a non-reducing sugar similar to 
mannitol in that it does not undergo Maillard reaction, did not improve powder yield (preliminary 
formulation P4, Table 3.3). Sodium chloride, however, was found to more than triple the percent 
powder yield when included as the hygroscopic excipient when compared to formulations with 
mannitol or trehalose (preliminary formulation P5 vs preliminary formulation P1 or P4, Table 3.3). 
The addition of sodium chloride to the formulation increased the transition temperature of the 
system enabling particle formation. Sodium chloride is highly hygroscopic, therefore not an ideal 
excipient for aerosol powder formulation as it may cause high particle agglomeration. Since 
mannitol is known to be hygroscopic at higher RH conditions, ~80% RH at 25 °C [106, 134], 
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varying compositions of mannitol and sodium chloride were explored as excipients for DPPC-
EEG formulations (preliminary formulations P6-P11, Table 3.3).  
The estimated moisture content in the spray dried powders was determined by measuring 
the total weight loss by heating. The powders were found to have low estimated moisture contents 
of < 4% w/w (Table 3.3). The highest powder yields were achieved with formulations containing 
2.5-40% w/w sodium chloride, and therefore, explored further.  
 
Table 3.3 Effect of formulation excipients on spray dried powder yield and DPPC content of 
DPPC-EEG powders. 
Formulation 
Formulation components, % w/w* Powder 
yield,  
% w/w 
Water 
content, 
% w/w  
DPPC 
content, 
% w/w# DPPC Mannitol Trehalose NaCl 
P1 40 40 0 0 18 . . 
P2 60 20 0 0 5 . . 
P3 20 60 0 0 16 . . 
P4 40 0 40 0 18 . . 
P5 40 0 0 40 63 2.4 30.1 (2.6) 
P6 40 20 0 20 46 2.2 31.3 (1.6) 
P7 40 30 0 10 62 2.6 29.5 (0.7) 
P8 40 35 0 5.0 59 3.8 35.2 (3.6) 
P9 40 37.5 0 2.5 63 2.4 30.8 (2.2) 
P10 40 39.0 0 1.0 38 2.6 32.8 (0.4) 
P11 40 39.5 0 0.5 32 2.3 26.9 (1.4) 
*Leucine included in all formulations at a concentration of 20% w/w 
#Values are mean (SD), n=3 
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3.3.1.2 Preliminary studies on the effect of mannitol-to-sodium chloride ratio on aerosol 
performance 
The aerosol performance of the formulations with the highest powder yields (preliminary 
formulations P6-P9) were determined using the NGI and Aerolizer® DPI (Table 3.4). Formulations 
P6 and P7, with mannitol-to-sodium chloride ratios of 1:1 and 3:1, respectively, were observed to 
have more than 50% of the impactor dose deposited on stage 1 of the impactor, therefore MMAD 
values could not be determined and the aerosol performance was reflective of a poorly dispersed 
formulation. Formulation P9 was found to have the best aerosol performance with the smallest 
MMAD of 2.3 µm and highest particle fractions less than 1 µm and 5 µm of 22.8% and 60.3%, 
respectively. Formulation P9 was shown to have the best deaggregation corresponding to the 
lowest amount of sodium chloride (mannitol-to-sodium chloride ratio of 15:1); decreasing the 
mass of sodium chloride in the DPPC-EEG formulations appeared to reduce particle 
agglomeration and improve aerosol dispersion performance. 
 
Table 3.4 Aerosol performance with the Aerolizer® of DPPC-EEG spray dried formulations using 
mannitol, sodium chloride and leucine as excipients. 
Formulation 
Excipients, % w/w* 
Mannitol-to-NaCl 
MMAD, 
µm 
Particle fraction, % 
Mannitol NaCl <1 µm <5 µm 
P6 20 20 1:1 n/a 6.9 19.7 
P7 30 10 3:1 n/a 7.8 27.2 
P8 35 5 7:1 5.2 10.6 29.9 
P9 37.5 2.5 15:1 2.3 22.8 60.3 
*DPPC and leucine included at concentrations of 40% w/w and 20% w/w, respectively.  
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3.3.1.3 Preliminary studies on the effect of feed dispersion preparation method on DPPC 
content 
The main challenge with spray drying feed dispersions containing the poorly soluble 
hydrophobic DPPC with hydrophilic excipients in a mainly aqueous vehicle (80/20% v/v 
water/ethanol) was ensuring the production of powders with DPPC content that was close to the 
nominal or expected content of DPPC in the spray dried powder. The nominal concentration of 
DPPC in the preliminary formulations was 40% w/w. Analysis of the DPPC content in a series of 
spray dried powder samples revealed that DPPC was present at concentrations of between 26.9-
35.2% w/w (Table 3.3), which was between 62-87% of the expected DPPC concentration. During 
spray drying, excessive foaming was observed and the presence of solids remaining at the end of 
the spray drying process was observed, suggesting that the feed dispersion was not homogeneous 
over the duration of the spray drying process (5-8 hours), which likely caused the lower than 
expected DPPC content.  
The use of direct sonication was explored to prepare a homogenous and stable feed 
dispersion for spray drying following a method adapted from Gugliotti et al. [17]. Dispersions 
were prepared with the understanding that above its transition temperature of 41 °C, DPPC forms 
fluid liposomes (multilamellar), which when sonicated, tend to form stable vesicles (unilamellar) 
with an aqueous core [17, 135], which may or may not contain the hydrophilic excipients. The 
Qsonica model Q700 (Qsonica, Newtown, CT) with standard probe (12.7 mm tip diameter, part 
no. 4219) was used to disperse DPPC in water. The temperature was maintained below 60 °C using 
a water jacketed vessel attached to a recirculating water bath (Fisher Scientific model 9505, 
Waltham, MA) set to 45 °C. Sonication was performed at an amplitude of 35 for 15 minutes. After 
sonication, the dispersions were centrifuged (Beckman Coulter Avanti J-E centrifuge with JS-5.3 
rotor, Pasadena, CA) at 6100×g for 20 minutes at 40 °C to remove titanium particles left behind 
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from the probe. Ethanol was added to the dispersion prior to spray drying. The maximum amount 
of ethanol that could be added without noticeable foaming was 5% v/v. Feed dispersions 
containing the excipient composition of preliminary formulation P9 were prepared in 
water/ethanol mixtures of 95/5 and 100/0% v/v, then spray dried as described above. The feed 
dispersions were assayed for DPPC content after sonication and at the end of spray drying. The 
DPPC content was also determined in the spray dried powders and compared to the nominal DPPC 
content (Table 3.5). 
The expected DPPC content in the feed dispersion was maintained through feed dispersion 
preparation and powder formation when probe sonication was employed, indicating that a uniform 
feed dispersion was spray dried and that it was close to the nominal value. In both water and 
water/ethanol spray vehicles, the DPPC content remained > 90% of the nominal (Table 3.5). Assay 
of the spray dried powder determined DPPC contents of 37 and 40% w/w (92 and 99% of the 
nominal) for powders prepared in water/ethanol and 100% water, respectively. Both spray vehicles 
were explored further in the full factorial DOE. 
 
Table 3.5 DPPC content of feed dispersions (nominal concentration = 20% w/w) prepared by 
probe sonication and resultant spray dried powder (nominal concentration = 40% w/w). Values are 
mean (SD), n=3. 
 Dispersion feed vehicle (water/ethanol), % v/v 
 95/5 100/0 
 
DPPC,  
% w/w 
DPPC,  
% nominal 
DPPC,  
% w/w 
DPPC,  
% nominal 
Feed dispersion     
After sonication 18.8 (1.6) 92.1 (7.7) 18.9 (0.6) 93.6 (3.0) 
End of spray drying 20.3 (4.1) 99.6 (20.1) 18.8 (1.1) 96.5 (6.9) 
     
Spray dried powder 37.4 (2.4) 92.3 (2.0) 39.8 (5.0) 99.4 (12.5) 
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3.3.2 Development of methods for surface tension measurements of DPPC-EEG powders 
3.3.2.1 Effect of sample preparation and measurement temperature on DPPC surface 
activity measurements 
The surface activity of DPPC-EEG powders was assessed to determine if the surfactant 
activity was maintained after spray drying. Following a sample preparation method adapted from 
Wen and Franses [136] (method 1), unprocessed DPPC (1.2 mg/mL) was dispersed in normal 
saline (154 mM sodium chloride) and heated for 30 min in a 55-60 °C water bath, then bath 
sonicated for 2 hours at 55 °C. The dynamic surface tension was measured at room temperature 
and found to have a final surface temperature of 72 mN/m at a surface age of 50 s, which was 
similar to that of 154 mM NaCl measured under the same conditions (Figure 3.2). Increasing the 
study temperature had no effect on the initial surface tension compared to their respective 
temperature vehicle controls. At room temperature and 37 °C, there was no surface activity 
observed in the final surface tension measurements with a surface age of 50 s compared to the 
respective temperature controls or the initial surface tension measurement. However, there was a 
small reduction in the final surface tension measurement with a surface age of 50 s for the study 
performed at 50 °C. At the elevated temperature of 50 °C, the final surface tension was 65 mN/m 
(Figure 3.2). The increased activity observed is due to the increased fluidity of DPPC lipid layers 
at temperatures above its transition temperature, which allow DPPC particles to migrate to the 
newly formed air-liquid interfaces at an increased rate. Future analysis would be performed at 50 
°C. It was hypothesized that at the lower temperatures the absence of any effect was due to 
insufficient time for the DPPC to orient at the newly created surface.   
Surface tension measurements of unprocessed DPPC in water was also studied. Following 
the same procedure described above, DPPC was prepared in water instead of normal saline and 
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analyzed. At 37 °C, the sample in water was found to reach a final surface temperature of 69 
mN/m, similar to the surface tension observed for the sample prepared in normal saline, indicating 
that the presence of sodium chloride in the sample had no effect on the surface tension activity of 
DPPC.  
Surface tension values using method 1 for DPPC were higher than reported in the literature 
for equivalent concentrations (dispersions of 1.3 mg/mL DPPC in 154 mM NaCl resulting in 
surface tensions as low as 34 mN/m at 37 °C [136]). A second method for preparing lipid 
dispersions was studied. Method 2 was adapted from Kim and Franses [135]. Unprocessed DPPC 
(1.0 mg/mL) in water was heated for 30 minutes at 55-60 °C, stirred with a magnetic stir bar for 1 
hour at 55-60 °C, then bath sonicated until clear (~7 hours) to decrease the size of the liposomes 
as much as possible. Determination of the sample surface tension after 6 hours of sonication at a 
measurement temperature of 50 °C revealed a final surface tension value of 62 mN/m. Further 
sonication yielded further reductions in the surface tension, with 17.5 hours of sonication resulting 
in a final surface tension value of 43 mN/m (Table 3.6). The increased sonication times produced 
a corresponding increase in surface activity as indicated by higher surface tension reduction rates 
(0.10, 0.15, and 0.47 mN/m/s for the 6, 12.5 and 17.5 h sonication times, respectively). It is 
believed that the increased sonication times produced increasingly smaller liposomes and vesicles 
that were able to adsorb more extensively and faster at the surface. 
The sample preparation time of method 2 was not conducive to efficient analysis of repeat 
samples, therefore a third preparation method was studied. Direct sonication methods for sample 
preparation as described by Gugliotti et al. [17] were followed. Unprocessed DPPC (1.0 mg/mL) 
was dispersed in 1 mM NaCl using a microtip probe sonicator. The use of a 1 mM NaCl vehicle 
was assumed to have no effect on the surface tension activity of DPPC as the NaCl concentration 
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was within the range previously studied – 0 (water) and 154 mM NaCl – both of which were shown 
not to influence the surface tension measurements. The sample was held in place in a water jacket 
vessel connected to a recirculating water bath set to 41 °C. Sonication was performed at an 
amplitude of 35 for 15 minutes with the temperature monitored (Fisher Scientific Traceable 
Double Thermometer with Type K thermocouple, Waltham, MA) to ensure it remained below 60 
°C. At a measurement temperature of 50 °C, the final surface tension of the sample was 43 mN/m, 
similar to that observed for the 17.5 h sample prepared by method 2. The two samples were also 
observed to have similar surface tension reduction rates of 0.46 mN/m/s and 0.47 mN/m/s for 
method 3 and method 2, respectively. With direct sonication, the total energy released from the 
probe was transferred to the sample; whereas with bath sonication, the energy is diluted by the 
water it must travel through to reach the sample vessel. A plot of the surface tension measurements 
for the three methods studied is shown in Figure 3.3. Surface tension measurements would be 
performed using samples prepared by probe sonication following method 3 in future studies. 
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Table 3.6 Comparison of surface activity of unprocessed DPPC following different preparation methods. 
Preparation 
method 
Sonication 
method 
DPPC 
concentration, 
mg/mL Solvent 
Sonication 
time,  
h 
Measurement 
temperature,  
°C 
Surface 
age,  
s 
Final 
surface 
tension, 
mN/m 
Surface 
tension 
reduction 
rate,  
mN/m/s* 
Wen et al. [136] bath 1.2 154 mM NaCl 2.0 RT 50.2 72.4 0 
(method 1)     37 52.4 70.7 0 
     50 133.0 64.7 0.03 
   water 2.0 37 50.1 69.3 0.02 
Kim et al. [135] bath 1.0 water 6.0 50 56.0 62.1 0.10 
(method 2)    12.5 50 52.0 60.9 0.15 
    17.5 50 50.6 43.3 0.47 
Gugliotti et al. [17] 
(method 3) probe 1.0 1 mM NaCl 0.25 50 55.7 43.0 0.46 
*Negative values indicated as zero 
RT=room temperature 
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Figure 3.2 Effect of sample temperature on surface activity of 1.2 mg/mL dispersion of 
unprocessed DPPC in 154 mM NaCl vehicle performed using method 1. The surface activity of 
154 mM NaCl solution is also shown for comparison. Markers represent individual values. 
RT=room temperature. 
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Figure 3.3 Effect of sample preparation method effect on surface activity measurement of DPPC 
(1.0-1.2 mg/mL) dispersed in NaCl aqueous vehicle at 50 °C. Method 1: heat and bath sonication 
at elevated temperature; method 2: heat, stirring and bath sonication at elevated temperature; 
method 3: probe sonication at elevated temperature. The surface activity of water is also shown 
for comparison. Markers represent individual values. 
3.3.2.2 Effect of DPPC concentration on DPPC surface activity measurements 
The effect of DPPC concentration in the samples for surface tension measurements was 
studied. Unprocessed DPPC was prepared for surface tension measurements in concentrations 
varying from 0.5 to 1.5 mg/mL. Measurements were performed at 50 °C using method 3 as 
described previously. A significant negative correlation was observed where higher concentrations 
of DPPC resulted in lower final surface tension values (r = -0.9195, p<.0001; Pearson correlation) 
with the following relationship,  
 
Final surface tension, mN/m = 90.25 – 40.89*DPPC concentration, mg/mL             Equation 3.8 
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and a coefficient of determination of R2 = 0.8455. The scatterplot correlation is shown in Figure 
3.4. The higher the concentration of DPPC, the more surface-active particles there are available to 
reach the air-liquid interface to lower the surface tension; however, at DPPC concentrations above 
its critical micelle concentration, the surface activity will plateau as the interface becomes 
saturated. This correlation can be used to determine the DPPC concentration required to reach a 
desired surface tension within the range of concentrations studied. 
To minimize the amount of powder necessary to prepare samples for surface tension 
measurements, a target concentration of 0.86 mg/mL of DPPC was selected for future 
measurements as it was the intermediate surface tension value of the concentrations studied, 55 
mN/m, and a provided a measurable reduction in surface tension. 
 
 
Figure 3.4 Correlation of final surface tension values with DPPC concentration for samples 
measured at 50 °C using method 3. Markers represent individual values. 
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3.3.2.3 Surface tension measurements with preliminary spray dried DPPC-EEG powders  
The method developed for determining the surface tension of DPPC powders was applied 
to DPPC-EEG preliminary formulation P9. Powders were dispersed in 1 mM NaCl using the 
microtip probe sonicator at an amplitude of 35 for 15 minutes. The concentration of DPPC in the 
sample was 0.86 mg/mL. Surface tension measurements were performed at 50 °C. The mean ± SD 
final surface tension value for preliminary formulation P9 was 56.6 ± 4.0 mN/m, not significantly 
different from the expected final surface tension value of 55.1 mN/m calculated from Equation 
3.8.  
Samples were compared to unprocessed DPPC powders analyzed using the same methods, 
Table 3.7. There were no significant differences observed in the surface age, final surface tension 
values and surface tension reduction rates for preliminary formulation P9 powders when compared 
to unprocessed DPPC, indicating that the surfactant activity of DPPC was not significantly affected 
by formulation excipients following spray drying. A comparison of unprocessed DPPC and 
preliminary formulation P9 surface tensiograms is shown in Figure 3.5. 
 
Table 3.7 Comparison of surfactant activity for unprocessed DPPC and spray dried formulation 
P9 at a nominal DPPC concentration of 0.86 mg/mL dispersed in 1 mM NaCl measured at 50 °C 
using method 3. Values are mean (SD), n=3. 
Powder sample 
Surface age, 
s 
Final surface tension,  
mN/m 
 Surface tension 
reduction rate, 
mN/m/s 
Unprocessed DPPC 51.0 (0.4) 52.7 (3.0) 0.31 (0.06) 
Formulation P9 54.6 (3.8) 56.6 (4.0) 0.35 (0.07) 
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Figure 3.5 Surface tension activity comparison of unprocessed DPPC and spray dried formulation 
P9 with a nominal DPPC concentration of 0.86 mg/mL measured at 50 °C using method 3. The 
surface activity of water is also shown for comparison. Markers represent individual values. 
3.3.2.4 Effect of powder age on DPPC surface activity measurements 
A fresh batch of preliminary formulation P9 powder was prepared to determine the effect 
of powder age on surface tension activity. Measurements of surface activity of this powder batch 
was performed using the developed methods as described in the previous section and measured at 
intervals over 14 days. Powders were stored in the refrigerator (2-8 °C) between measurements. 
Surface tension measurement results are shown in Table 3.8. The measured surface tension was 
observed to be lowest when the powders were measured immediately after spray drying on day 0 
and the measured surface activity of the powders was observed to decrease with increasing powder 
age. The highest surface activity, as indicated by the surface tension reduction rate, was observed 
with the freshly prepared powders, 0.49 mN/m/s. The surface activity decreased with increasing 
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powder age, which appeared to level off between 7 and 14 days after the powder was prepared. 
The largest change from the surface activity of freshly prepared powder was observed 7 days after 
powders were prepared, indicating that surface tension measurements should be performed within 
the first few days after powder preparation. The decrease in surface tension is not a concern for 
reasons other than performing accurate comparisons between DPPC-EEG formulations since these 
initial studies are focused on developing methods to be applied for EEG formulations with 
commercial surfactant. 
 
Table 3.8 Surfactant activity characteristics of preliminary formulation P9 when stored at 2-8 °C 
for 14 days. Values are mean (SD), n=3. 
Powder age, 
days 
Surface age, 
s 
Final surface 
tension,  
mN/m 
 Surface tension 
reduction rate, 
mN/m/s 
Surface tension 
difference from day 0, 
 mN/m 
0 53.2 (2.7) 24.4 (0.5) 0.49 (0.03) n/a 
1 55.6 (5.0) 28.1 (2.5) 0.44 (0.09) 3.7 
7 53.6 (2.5) 44.8 (1.8) 0.31 (0.02) 20.4 
14 61.4 (2.1) 43.3 (3.4) 0.31 (0.04) 18.9 
 
 
 
3.3.3 Full factorial design of experiment (DOE) to assess select formulation factors and 
spray drying parameters 
The effects of four factors on the aerosol characteristics of spray dried DPPC-EEG 
formulations were investigated. The studied factors included percent solids in the feed dispersion, 
the ratio of mannitol-to-sodium chloride, percentage ethanol in the feed dispersion and the inlet 
drying temperature of the spray dryer. Each factor was studied at two levels and the preliminary 
studies described above were used to guide the factor selections.  
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Preliminary studies were performed with a percent solids concentration in the feed 
dispersion of 0.125% w/v. The formulation with the best aerosol performance had the highest ratio 
of mannitol-to-sodium chloride (15:1) and resulted in micrometer sized primary particles with an 
aerosol MMAD of 2.3 µm. The use of probe sonication to prepare uniform feed dispersions was 
employed since spray drying of feed dispersions prepared without sonication resulted in low DPPC 
content in the spray dried powders. The percent ethanol in the aqueous feed dispersion was reduced 
from 20% v/v to 0-5% v/v to minimize the amount of visible foaming.  
A full factorial DOE was performed to determine if the factors affect each other with 
changing levels. The effect of the main factors and two-way interactions on the powder 
characteristics, the powder aerosol performance and surface activity were considered in the 
analysis. If no significance was determined with the interactions of the factors, then effects of the 
main factors were assessed individually. 
3.3.3.1 Effect of formulation factors and spray drying parameters on powder yield and 
DPPC content of DPPC-EEG formulations 
The powder characteristics (powder yield, moisture content and DPPC content) for the 
sixteen spray dried powders with the studied factors and levels are shown in Table 3.9. The powder 
yield ranged from 47-71%. ANOVA with main factors and their interactions did not identify any 
significant effects on powder yield. When examined separately, a significant effect of ethanol 
concentration was observed on powder yield where the higher concentration of ethanol resulted in 
higher powder yields (0% ethanol: 56 ± 5% yield, 5% ethanol: 64 ± 6% yield, p=0.0149; Student’s 
t-test). Higher ethanol concentrations in the feed dispersion promote more efficient drying of the 
droplets exiting the nozzle of the spray dryer since it has a lower boiling point compared to that of 
water (78 °C vs 100 °C). There were no significant differences observed with percent solids in the 
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feed dispersion, the ratio of mannitol-to-sodium chloride and the inlet drying temperature on the 
percent yield when the effects were examined separately.  
The DPPC content in the powders were observed to range from 35 to 44% (88-109% of 
the nominal value of 40% w/w) for the different powder formulations. No significant interactions 
were revealed with ANOVA. When examined separately, the percent solids concentration was 
observed to have a significant effect on the DPPC content where the higher solids content of 
0.250% w/v resulted in higher DPPC content (0.125% w/v solids: 38 ± 2% DPPC, 0.250% w/v 
solids: 40 ± 2% DPPC, p=0.0076; Student’s t-test). There were no significant differences observed 
with the other main factors when they were examined separately. 
The spray dried powders were observed to have low moisture content, < 3% w/w; no 
significant effects were observed with the main factors on the moisture content of the spray dried 
powders.
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Table 3.9 Effect of formulation factors and spray drying parameters on the powder characteristics of spray dried DPPC-EEG powders. 
Expt 
Run 
order 
Solids in feed 
dispersion,  
% w/v Mannitol-to-NaCl 
Ethanol in feed 
dispersion,  
% v/v 
Inlet drying 
temperature, 
°C 
Powder 
yield,  
% w/w 
Water 
content (SD), 
% w/w 
DPPC 
content (SD), 
% w/w 
1 1 0.125 3:1 0 70 57.0 1.0 41.4 (0.3) 
2 16 0.125 3:1 0 80 58.1 1.0 (0.5) 38.0 (2.5) 
3 13 0.125 3:1 5 70 62.0 1.1 (0.6) 35.9 (1.2) 
4 14 0.125 3:1 5 80 63.9 1.6 (1.0) 36.9 (2.0) 
5 11 0.250 3:1 0 70 63.0 2.1 (1.2) 39.0 (0.4) 
6 8 0.250 3:1 0 80 55.8 1.9 38.3 (0.5) 
7 10 0.250 3:1 5 70 71.3 0.7 (0.1) 38.4 (1.3) 
8 3 0.250 3:1 5 80 62.3 0.9 42.4 (0.9) 
9 5 0.125 15:1 0 70 54.1 1.4 38.3 (3.0) 
10 12 0.125 15:1 0 80 61.3 1.5 (1.3) 36.9 (1.6) 
11 2 0.125 15:1 5 70 55.2 0.8 35.8 (7.4) 
12 9 0.125 15:1 5 80 57.3 1.8 (0.1) 35.1 (0.5) 
13 6 0.250 15:1 0 70 46.6 0.8 38.7 (1.5) 
14 4 0.250 15:1 0 80 53.9 0.6 43.0 (0.5) 
15 15 0.250 15:1 5 70 68.7 1.5 (0.7) 43.5 (1.1) 
16 7 0.250 15:1 5 80 69.0 1.5 40.6 (0.7) 
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3.3.3.2 Effect of formulation factors and spray drying parameters on the primary particle 
size distribution of DPPC-EEG formulations 
The primary particle size values, particle fractions and span for the sixteen spray dried 
powders determined using the Sympatec HELOS with RODOS/M disperser are shown in Table 
3.10. Overall, the powders were observed to be approximately one micrometer in size with small 
span values of < 2. The particle fraction less than 1 µm and 5 µm was > 33% and > 97%, 
respectively. 
Analysis of the main factors and their two-way interactions on primary particle size, the 
particle fraction less than 1 µm and 5 µm and the span revealed no significant effects with their 
interactions. A summary of the mean values for primary particle size for the sixteen spray dried 
powder lots are shown in Table 3.11 by study factor. When examined separately, the percent solids 
content was found to have a significant effect on the primary particle size with the lower 
concentration of solids producing smaller primary particles (p=0.0003; Student’s t-test). No other 
significant effects were observed on the primary particle size. 
The particle fraction less than 1 µm for the sixteen formulations were shown to be 
significantly affected by the percent solids concentration with the lower solids concentration 
resulting in a higher fraction of particles less than 1 µm (p=0.0001; Student’s t-test). No other 
significant effects were observed on the fractions of particles less than 1 µm. Analysis of the 
fraction of particles less than 5 µm and the span revealed there were no significant effects of main 
factors when examined separately. 
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Table 3.10 Primary particle size measurements and aerosol properties of spray dried DPPC-EEG powders for each experiment varying 
formulation factors and spray drying parameters. Values are mean (SD), n=3. 
 Primary particle  Aerosol properties 
Expt 
Dv50,  
µm 
Particle fraction, % 
Span 
 Emitted 
dose,  
% 
MMAD,  
µm 
Particle fraction, % 
GSD <1 µm <5 µm  <1 µm <5 µm 
1 0.99 (0.01) 50.8 (0.5) 100 (0.0) 1.5 (0.0)  62.9 (8.1) 1.44 (0.04) 20.9 (2.0) 77.5 (3.8) 1.8 (0.0) 
2 1.06 (0.01) 46.3 (0.2) 98.8 (0.2) 1.5 (0.0)  73.1 (1.8) 1.70 (0.06) 8.8 (1.7) 50.2 (3.6) 1.9 (0.1) 
3 1.03 (0.02) 47.9 (1.4) 99.7 (0.4) 1.5 (0.0)  68.2 (2.0) 1.61 (0.02) 12.2 (0.2) 60.4 (0.4) 1.8 (0.0) 
4 1.07 (0.01) 45.1 (0.1) 98.2 (0.2) 1.6 (0.0)  70.6 (0.4) 1.75 (0.04) 8.6 (0.7) 54.1 (3.8) 1.9 (0.1) 
5 1.31 (0.03) 33.9 (0.9) 97.1 (0.7) 1.8 (0.1)  67.7 (1.8) 2.08 (0.03) 4.0 (0.3) 49.0 (2.2) 1.9 (0.0) 
6 1.13 (0.01) 42.2 (0.2) 99.4 (0.4) 1.6 (0.0)  65.2 (2.5) 1.73 (0.01) 10.9 (0.7) 68.1 (2.9) 1.8 (0.0) 
7 1.12 (0.01) 42.2 (0.7) 99.8 (0.2) 1.5 (0.0)  62.3 (4.2) 1.58 (0.03) 15.4 (0.9) 76.0 (2.3) 1.7 (0.0) 
8 1.14 (0.01) 41.6 (0.6) 99.9 (0.0) 1.6 (0.0)  66.2 (3.8) 1.60 (0.02) 16.7 (0.4) 82.7 (0.7) 1.3 (0.1) 
9 0.94 (0.01) 55.3 (0.6) 100 (0.0) 1.5 (0.0)  59.1 (0.8) 1.50 (0.02) 18.7 (1.2) 74.2 (2.8) 1.8 (0.0) 
10 1.01 (0.01) 49.1 (0.9) 100 (0.0) 1.5 (0.0)  68.1 (1.1) 1.62 (0.03) 12.4 (0.7) 69.5 (4.5) 1.7 (0.1) 
11 0.96 (0.01) 52.7 (0.2) 100 (0.0) 1.5 (0.0)  51.0 (3.2) 1.42 (0.00) 21.7 (0.7) 76.0 (2.0) 1.5 (0.1) 
12 1.01 (0.01) 49.6 (0.5) 99.9 (0.1) 1.4 (0.0)  69.3 (0.9) 1.52 (0.01) 14.8 (0.8) 63.3 (2.4) 1.8 (0.0) 
13 1.09 (0.01) 44.3 (0.6) 99.9 (0.0) 1.6 (0.0)  54.2 (4.3) 1.66 (0.04) 14.9 (2.0) 79.9 (6.8) 1.7 (0.0) 
14 1.12 (0.01) 42.8 (0.4) 99.9 (0.0) 1.7 (0.0)  56.4 (5.1) 1.69 (0.03) 13.1 (1.7) 76.1 (5.2) 1.7 (0.1) 
15 1.15 (0.01) 40.8 (0.4) 99.5 (0.5) 1.6 (0.0)  73.3 (4.0) 1.81 (0.02) 7.8 (0.2) 57.1 (2.0) 1.8 (0.0) 
16 1.12 (0.01) 42.3 (0.2) 99.9 (0.1) 1.6 (0.0)  59.6 (1.6) 1.67 (0.01) 13.0 (0.4) 77.1 (2.9) 1.7 (0.0) 
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Table 3.11 Summary of primary particle size of spray dried DPPC-EEG powders by study factor. 
Values are mean (SD), n=8. 
Study factor (level) 
Dv50,  
µm 
Particle fraction, % 
Span <1 µm <5 µm 
Solids (0.125% w/v) 1.01 (0.05) 49.6 (3.3) 99.6 (0.7) 1.5 (0.1) 
Solids (0.250% w/v) 1.15 (0.07)* 41.3 (3.1)* 99.4 (1.0) 1.6 (0.1) 
Mannitol-to-NaCl (3:1) 1.11 (0.10) 43.8 (5.1) 99.1 (1.0) 1.6 (0.1) 
Mannitol-to-NaCl (15:1) 1.05 (0.08) 47.1 (5.3) 99.9 (0.2) 1.5 (0.1) 
Ethanol (0% v/v) 1.08 (0.11) 45.6 (6.5) 99.4 (1.0) 1.6 (0.1) 
Ethanol (5% v/v) 1.08 (0.07) 45.3 (4.4) 99.6 (0.6) 1.5 (0.1) 
Inlet temperature (70 °C) 1.07 (0.12) 46.0 (7.1) 99.5 (1.0) 1.6 (0.1) 
Inlet temperature (80 °C) 1.08 (0.05) 44.9 (3.2) 99.5 (0.7) 1.6 (0.1) 
*Significant difference from 0.125% w/v solids; Student’s t-test, p<0.05 
 
 
 
 
3.3.3.3 Effect on aerosol performance 
The aerosol performance of the spray dried powders was determined using the NGI and an 
Aerolizer DPI operating a flow rate of 80 L/min. Overall, the powders demonstrated moderate 
aerosolization properties with the Aerolizer with emitted doses of 51-73% of the loaded mass. The 
MMAD of the powders were 1-2 µm in size with small span values of < 2. The fine particle fraction 
less than 1 µm and 5 µm were greater than 7% and 49% of the emitted dose, respectively. Aerosol 
performance data for each experiment are shown in Table 3.10. 
Analysis of the main factors and their two-way interactions on the MMAD, the aerosol 
particle fraction less than 1 µm and 5 µm and the GSD revealed no significant effects with their 
interactions. A summary of the mean values of the aerosol properties for the sixteen spray dried 
powder lots are shown in Table 3.12 by study factor. The percent solids content was found to have 
a significant effect on the MMAD with the lower concentration of solids producing smaller 
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MMAD values (p=0.0424; Student’s t-test). No other significant effects were observed on the 
MMAD. Analysis of the fraction of particles less than 1 µm and less than 5 µm and the GSD 
revealed there were no significant effects of main factors when examined separately. 
 
Table 3.12 Summary of aerosol properties of spray dried DPPC-EEG powders by study factor. 
Values are mean (SD), n=8. 
Study factor (level) 
MMAD,  
µm 
Particle fraction, % 
GSD <1 µm <5 µm 
Solids (0.125% w/v) 1.57 (0.12) 14.6 (5.5) 65.7 (10.3) 1.8 (0.1) 
Solids (0.250% w/v) 1.73 (0.16)* 12.0 (4.3) 70.8 (11.9) 1.7 (0.2) 
Mannitol-to-NaCl (3:1) 1.69 (0.19) 12.2 (5.3) 64.8 (13.2) 1.8 (0.2) 
Mannitol-to-NaCl (15:1) 1.61 (0.12) 14.6 (4.2) 71.7 (7.8) 1.7 (0.1) 
Ethanol (0% v/v) 1.68 (0.19) 12.8 (5.6) 68.1 (12.0) 1.8 (0.1) 
Ethanol (5% v/v) 1.62 (0.12) 13.8 (4.5) 68.3 (10.8) 1.7 (0.2) 
Inlet temperature (70 °C) 1.64 (0.22) 14.5 (6.2) 68.8 (11.5) 1.8 (0.1) 
Inlet temperature (80 °C) 1.66 (0.08) 12.1 (3.1) 68.6 (11.3) 1.7 (0.2) 
*Significant difference from 0.125% w/v solids; Student’s t-test, p<0.05 
 
 
 
 
The plot in Figure 3.6 shows the primary particle Dv50 values ordered in increasing size 
on the primary y-axis with combined study factors on the x-axis. The corresponding aerosol 
MMAD values are plotted on the secondary y-axis. A significant positive correlation was observed 
between MMAD values and Dv50 values, where higher Dv50 values resulted in larger MMAD 
values (r = 0.8766, p<.0001; Pearson correlation) with the following relationship,   
 
MMAD, µm = -0.003289 + 1.532*Dv50, µm                                                            Equation 3.9 
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and a coefficient of determination of R2 = 0.7685. The scatterplot is shown in Figure 3.7. The 
strong correlation between MMAD and Dv50 reveals the good dispersion efficiency of the 
powders. In terms of particle size, the powder formulations, relative to each other, performed 
similarly with the Aerolizer DPI at a pressure drop of 4 kPa as with the RODOS dispersion unit 
operating at a dispersion pressure 75x that of the DPI. The correlation could be used to estimate 
the aerodynamic size of spray dried DPPC-EEG powders, which would minimize having to 
perform time-consuming cascade impaction experiments.  
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Figure 3.6 Combined study factors ordered by increasing primary particle size (primary y-axis) with corresponding MMAD values on 
the secondary y-axis. Markers represent the mean, error bars represent the SD, n=3. 
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Figure 3.7 Correlation of MMAD with Dv50 values for DPPC-EEG powders. Markers represent 
mean values, n=3. 
3.3.3.4 Effect of formulation factors and spray drying parameters on the surface tension of 
DPPC-EEG formulations 
The surface tension of the spray dried DPPC-EEG powders was determined using the Krüss 
Bubble Pressure Tensiometer - BP2 on samples prepared by probe sonication (method 3). Samples 
were prepared with a nominal DPPC concentration of 0.86 mg/mL. The surface tension values 
determined for the different powder formulations are shown in Table 3.13. The final surface 
tension values ranged from 34 to 64 mN/m, comparable to the surface tension of unprocessed 
DPPC of 53 mN/m. The calculated surface tension reduction rates were 0.11 to 0.62 mN/m/s, 
indicating that the powders demonstrated retention of surface activity functionality.  
Analysis of the main factors and their two-way interactions on the final surface tension 
values and surface tension reduction rates showed no significant effects with their interactions. 
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Examining each of the factors separately revealed that the ratio of mannitol-to-sodium chloride 
was observed to significantly affect the final surface tension values of the spray dried powders. 
The mannitol-to-sodium chloride ratio of 3:1 resulted in significantly lower final surface tension 
values, 43.4 ± 7.2 mN/m, compared to the mannitol-to-sodium chloride ratio of 15:1, 52.7 ± 9.8 
mN/m (p=0.477; Student’s t-test). The mannitol-to-sodium chloride ratio was also observed to 
have a significant effect on the surface tension reduction rates with the mannitol-to-sodium 
chloride ratio of 3:1 resulting in higher reduction rates (0.45 ± 0.13 mN/m/s) than that of the 
mannitol-to-sodium chloride ratio of 15:1, 0.28 ± 0.17 mN/m/s (p=0.0427; Student’s t-test). 
Sodium chloride is known to reduce the electrokinetic repulsion between surfactant molecules 
allowing them to pack closer together, promoting adsorption of surfactants to the interface and 
thereby reducing the surface tension [137]. The higher amount of sodium chloride in the 
formulations with a mannitol-to-sodium chloride ratio of 3:1 compared to a ratio of 15:1 had a 
greater influence on surfactant adsorption leading to the observed outcome of lower final surface 
tension values and higher surface tension reduction rates with the mannitol-to-sodium chloride 
ratio of 3:1. Analysis of the other main factors (percent solids in the feed dispersion, percent of 
ethanol in the feed dispersion and the inlet drying temperature) revealed no significant effects on 
the final surface tension values and the surface tension reduction rates.
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Table 3.13 Effect of formulation factors and spray drying parameters on the surface tension for 
spray dried DPPC-EEG powder with DPPC concentration of 0.86 mg/mL dispersed in 1 mM NaCl 
at 50 °C. Values are mean (SD), n=3. 
Experiment 
Surface age,  
s 
Final surface tension,  
mN/m 
Surface tension 
reduction rate,  
mN/m/s 
1 54.9 (1.8) 42.0 (2.4) 0.49 (0.06) 
2 55.4 (3.2) 44.1 (1.1) 0.42 (0.06) 
3 51.5 (1.8) 37.3 (0.84) 0.62 (0.03) 
4 58.1 (5.2) 36.3 (2.9) 0.53 (0.04) 
5 56.2 (6.8) 51.1 (1.8) 0.33 (0.03) 
6 55.8 (3.6) 48.8 (4.4) 0.33 (0.10) 
7 60.5 (13.2) 53.4 (2.0) 0.27 (0.03) 
8 59.7 (7.6) 34.2 (2.0) 0.57 (0.07) 
9 54.5 (1.0) 61.8 (3.7) 0.12 (0.08) 
10 52.9 (0.2) 43.7 (1.7) 0.45 (0.02) 
11 54.7 (2.5) 35.3 (3.1) 0.57 (0.07) 
12 56.1 (2.6) 63.7 (2.8) 0.11 (0.05) 
13 53.8 (2.9) 57.9 (5.3) 0.21 (0.11) 
14 53.6 (0.5) 47.1 (7.9) 0.39 (0.15) 
15 66.5 (3.8) 55.1 (0.57) 0.20 (0.02) 
16 58.3 (6.2) 57.4 (2.1) 0.17 (0.05) 
 
 
Only a few significant effects were observed, which may have resulted from narrow 
high/low values of the levels that were able to be investigated in these studies. The values were 
selected based on results from preliminary experiments and the limitation of the spray dryer. The 
high level for the percent solids concentration was selected by doubling the solids concentration 
that was studied in preliminary experiments, 0.125% w/v. The ratio of mannitol-to-sodium 
chloride was selected based on the best performing powders in preliminary experiments. The 
high/low levels for the percent ethanol concentration were selected to minimize foaming of the 
feed dispersion. The high level for the inlet temperature was selected as it resulted in outlet 
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temperatures at the transition temperature of DPPC (41 °C), which would have resulted in more 
cohesive powders if exceeded. These experiments did reveal that the main factors studied have no 
significant interactions and also the relatively wide range of operating conditions that can be 
employed in which DPPC-EEG powders can be prepared with similar properties and aerosol 
performance.  
Based on the significant effects observed with the main factors, the optimal DPPC-EEG 
formulation was determined to be formulation 3 with an MMAD of 1.6 µm, particle fraction <1 
µm of 12%, and particle fraction <5 µm of 60%. Formulation 3 was produced with the following 
parameters: 0.125% w/v solids in the feed dispersion, mannitol-to-sodium chloride ratio of 3:1, 
5% v/v ethanol in water in the feed dispersion and inlet drying temperature of 70 °C. The described 
parameters were used to prepare EEG formulations with commercial surfactant. 
3.3.4 Preliminary assessment of EEG formulations with commercial surfactants 
The parameters specified from the results of the full factorial DOE were applied to the 
preparation of EEG formulations with commercial surfactants Curosurf® (poractant), Infasurf® 
(calfactant), and Survanta® (beractant). All commercial formulations are supplied as suspensions 
in 0.9% w/v sodium chloride. 
3.3.4.1 Feed dispersion preparation and powder formation of commercial surfactant-EEG 
formulations 
Feed dispersions were prepared based on the solids concentration of the commercial 
formulations with the goal of including the highest mass of phospholipids in the formulation while 
maintaining a feed dispersion solids concentration of 0.125% w/v. The solids concentration in the 
commercial formulations were determined by drying. For each commercial formulation, a syringe 
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was used to accurately transfer 20 µL of the suspension to a TGA sample pan and then allowed to 
dry in the TGA, which was programmed for an isothermal hold at 50 °C, until a stable weight was 
reached. DPPC content was also determined using accurately measured aliquots of the commercial 
formulations that were dissolved in methanol and assayed for DPPC using LC-MS as described 
previously. Table 3.14 shows the formulation characteristics.  
Excipients (mannitol, sodium chloride, leucine) were dissolved in water followed by 
addition of the commercial surfactant at the volume specified in Table 3.14. The amount of sodium 
chloride in the commercial formulations were calculated and supplemental sodium chloride was 
added to reach the mannitol-to-sodium chloride ratio of 3:1. Ethanol was added to the dispersions, 
then probe sonicated and centrifuged as described above (method 3). Dispersions were spray dried 
using the size 4 µm spray mesh with an inlet temperature of 70 °C and feed rate of 100%.  
Powders were collected from the electrostatic particle collector and the powder yield for 
each formulation was determined using Equation 3.1. Estimated moisture content of the surfactant-
EEG powders was determined using the TGA and DPPC content was assessed using LC-MS. The 
three formulations had decent powder yields of 62-69% w/w and low moisture contents, < 3% 
w/w. The DPPC content for the formulations were determined to be 10-12% w/w, which was 77-
85% of the expected DPPC content based on assay results of each commercial formulation for 
DPPC.  
The commercial surfactant-EEG formulation contents are shown in Table 3.15. The 
mannitol-to-sodium chloride ratio and leucine content was kept constant at 3:1 and 20% w/w, 
respectively, for all formulations. The phospholipid content was estimated for each EEG 
formulation based on the label claim and the DPPC content determined from LC-MS assay (shown 
in Table 3.14). As prepared, the Curosurf-EEG and Infasurf-EEG formulations were able to 
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include a higher mass of phospholipids in the spray dried formulations compared to the Survanta-
EEG formulation. This is due to the higher concentration of phospholipids present in the 
commercial Curosurf® and Infasurf® suspensions compared to Survanta®. The protein content for 
each formulation was estimated based on the label claim, with all formulations having a protein 
content < 2% w/w. The remaining components consisted of neutral lipids, palmitic acid and 
tripalmitin, depending on the commercial formulation used. The percent content of the remaining 
components was determined by summing up the known and estimated component contents and 
subtracting from 100%.
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Table 3.14 Characteristics of EEG formulations prepared with commercial surfactant. Values are mean (SD), n=3. 
 Commercial formulation  Powder characteristics 
Formulation 
Solids 
concentration,  
mg/mL 
DPPC content,  
mg/mL 
Volume in feed 
dispersion,  
mL  
Powder yield,  
% w/w 
Water content,  
% w/w 
DPPC content,  
% w/w 
Curosurf-EEG 95 (4) 25.5 (1.7) 0.9  62 2.4 (0.9) 10.4 (0.3) 
Infasurf-EEG 43 (1) 13.7 (0.6) 2  63 2.2 (0.7) 11.5 (0.1) 
Survanta-EEG 40 (3) 11.9 (0.1) 2  69 1.8 (1.1) 10.7 (0.1) 
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Table 3.15 Commercial surfactant-EEG formulation contents.  
Formulation 
Mannitol, 
% w/w 
NaCl,  
% w/w Mannitol-to-NaCl 
Leucine, 
% w/w 
Estimated from label claim,  
% w/w 
other components 
in commercial 
formulation,  
% w/w 
Total PL 
content# 
Protein 
content 
Curosurf-EEG 29.9 9.8 3:1 20.0 30.3 0.47 9.5 
Infasurf-EEG 31.9 10.8 3:1 21.4 32.1 1.02 2.8 
Survanta-EEG 33.0 10.9 3:1 22.0 24.5 <1.09 8.5 
#Includes DPPC content 
PL=phospholipids 
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3.3.4.2 Evaluation of the primary particle size of commercial surfactant-EEG formulations 
The primary particle size of the commercial surfactant-EEG formulations was determined 
using the Sympatec HELOS and compared with that determined for the optimal DPPC-EEG 
powder formulation. Overall, the powders prepared with the commercial surfactant formulations 
were found to have larger mean Dv50 values, lower percent particle fractions <1 µm and <5 µm 
and larger span values compared to the DPPC-EEG powders (Table 3.16).  
One-way ANOVA revealed significant differences in the primary particle size, particle 
fractions less than 1 µm and 5 µm and the span values for the different commercial surfactant EEG 
formulations (p<.0001). Using Dunnett’s method for post-hoc analysis, the formulations prepared 
with Curosurf®, Infasurf® and Survanta® were determined to have significantly larger Dv50 values 
compared to the optimal DPPC-EEG formulation (p<.0001, p<.0001, and p=0.0349, respectively). 
The particle fraction less than 1 µm for the three commercial surfactant formulations were 
determined to be significantly lower compared to the DPPC-EEG formulation (p<.0001; Dunnett’s 
method). The particle fraction less than 5 µm was also determined to be significantly lower for the 
commercial surfactant formulations compared to the DPPC-EEG formulation (Curosurf®: 
p<.0001, Infasurf®: p=0.0006, Survanta®: p=0.0077; Dunnett’s method). The span values for the 
commercial surfactant formulations were all observed to be significantly larger compared to the 
span of the DPPC-EEG formulation (Curosurf®: p<.0001, Infasurf®: p=0.0022, Survanta®: 
p=0.0032; Dunnett’s method).  
The particle size distributions are plotted in Figure 3.8. There is a clear difference in the 
particle size distributions of the EEG formulations prepared with commercial surfactant compared 
to the DPPC-EEG formulation, indicating that the primary particle size of the spray dried 
commercial surfactant EEG powders or the aggregation properties are determined by formulation 
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factors rather than the spray drying conditions that were held constant. The differences observed 
between the commercial surfactant-EEG formulations can be attributed to the variable lipid-
protein compositions that make up the commercial suspensions. It was observed that Curosurf-
EEG showed the most deviation from DPPC-EEG powders as it was shifted the furthest right 
(increased particle size). The Curosurf-EEG powders also showed a bimodal profile, which was 
suggested by the larger observed span (Table 3.16). The Survanta-EEG formulation was found to 
be the most comparable to the DPPC-EEG formulation. 
Since the commercial surfactant-EEG formulations were observed to have larger Dv50 
values and lower particle fractions compared to the DPPC-EEG formulation, the commercial-EEG 
formulations were not expected to exhibit similar aerosol performance. Therefore, aerosol 
performance was only determined for the best and worst commercial-EEG formulations, Survanta-
EEG and Curosurf-EEG, respectively. 
 
Table 3.16 Comparison of primary particle size characteristics of DPPC-EEG formulation with 
commercial surfactant-EEG formulations. Values are mean (SD), n=3. 
Formulation‡ 
Dv50,  
µm 
Particle fraction, % 
Span <1 µm <5 µm 
DPPC-EEG, formulation 3 1.03 (0.02) 47.9 (1.4) 99.7 (0.4) 1.5 (0.0) 
Curosurf-EEG 1.82 (0.12)* 24.3 (1.7)* 87.1 (1.7)* 2.9 (0.2)* 
Infasurf-EEG 1.60 (0.00)* 26.5 (0.1)* 95.3 (1.0)* 2.0 (0.1)* 
Survanta-EEG 1.19 (0.01)* 39.3 (0.3)* 96.2 (0.5)* 1.9 (0.0)* 
‡Statistically significant effect of formulation; one-way ANOVA, p<0.05 
*Significant difference compared to DPPC-EEG formulation 3; Dunnett’s method, p<0.05 
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Figure 3.8 Particle size distribution comparisons for commercial surfactant-EEG powders with 
DPPC-EEG formulation 3 determined on the Sympatec HELOS with RODOS dispersion pressure 
of 3.0 bar. Markers represent the mean value, error bars represent the SD, n=3. 
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3.3.4.3 Aerosol performance of commercial surfactant-EEG formulations 
The aerosolization properties of Curosurf-EEG and Survanta-EEG powders were 
determined using the NGI and an Aerolizer DPI operating a flow rate of 80 L/min for 3 s. The 
aerosol characteristics are shown in Table 3.17 with the optimal DPPC-EEG formulation for 
comparison. Although the EEG formulations prepared with commercial surfactant showed good 
emptying, emitted dose values of greater than 80% of the nominal dose, the MMAD values were 
larger and the particle fractions were lower than those observed with the optimal DPPC-EEG 
formulation.  
One-way ANOVA revealed significant differences in the MMAD particle fractions less 
than 1 µm and 5 µm (p=0.0003, p<.0001, p<.0001, respectively). Dunnett’s method for post-hoc 
analysis determined that the Curosurf-EEG formulation resulted in a significantly larger MMAD 
compared to the DPPC-EEG formulation (p=0.0003). The MMAD for the Survanta-EEG 
formulation was not significantly different from the DPPC-EEG formulation. Both spray dried 
commercial surfactant formulations were observed to have significantly lower particle fractions 
less than 1 µm when compared to DPPC-EEG powders (Curosurf-EEG: p<.0001, Survanta-EEG: 
p=0.0003; Dunnett’s method). Similarly, the particle fractions less than 5 µm for Curosurf-EEG 
and Survanta-EEG powders were observed to be significantly lower when compared to DPPC-
EEG powders (p<.0001 and p=0.0030, respectively; Dunnett’s method). No differences were 
found in the GSD values for the three formulations. 
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Table 3.17 Comparison of aerosol performance of DPPC-EEG formulation with spray dried 
commercial surfactant-EEG powders. Values are mean (SD), n=3. 
Formulation‡ 
Emitted 
dose,  
% 
MMAD,  
µm 
Particle fraction, % 
GSD <1 µm <5 µm 
DPPC-EEG, formulation 3 68.2 (2.0) 1.61 (0.02) 12.2 (0.2) 60.4 (0.4) 1.8 (0.0) 
Curosurf-EEG 80.0 (13.0) 3.32 (0.43)* 0.5 (0.0)* 16.0 (0.6)* 1.9 (0.1) 
Survanta-EEG 81.4 (2.6) 1.91 (0.04) 7.0 (1.0)* 49.6 (4.2)* 2.0 (0.0) 
‡Statistically significant effect of formulation; one-way ANOVA, p<0.05 
*Significant difference compared to DPPC-EEG formulation 3; Dunnett’s method, p<0.05 
 
 
3.3.4.4 Surface tension of commercial surfactant-EEG formulations 
Surface tension measurements of Curosurf-EEG and Survanta-EEG powders were 
performed with a target phospholipid concentration of 1.5 mg/mL to obtain a measurable decrease 
in surface tension. Measurements were also performed on the original commercial suspension 
formulations for comparison. The surface activity data are shown in Table 3.18. The mean ± SD 
final surface tension of Curosurf-EEG powders was determined to be 31.4 ± 2.1 mN/m, which was 
determined to be significantly higher than the final surface tension of the commercial Curosurf® 
formulation of 23.2 ± 0.3 mN/m (p=0.0023; Student’s t-test). However, the surface tension 
reduction rates of the two formulations were not significantly different, an indication that the 
surfactant activity was retained following formulation processing.  
For Survanta-EEG powders and the Survanta® commercial formulation, the mean ± SD 
final surface tension values were 33.0 ± 1.5 mN/m and 29.9 ± 5.5 mN/m, respectively. The surface 
tension reduction rates were 0.73 ± 0.16 and 0.58 ± 0.07 mN/m/s for Survanta® and Survanta-EEG 
formulations, respectively. There were no significant differences observed between the Survanta 
formulations, which indicate that the surface tension reduction properties were retained following 
formulation processing. 
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Table 3.18 Comparison of surfactant activity for EEG formulations prepared with commercial 
surfactant with nominal DPPC content of 1.5 mg/mL measured at 50 °C using method 3. Values 
are mean (SD), n=3. 
Formulation 
Surface age, 
s 
Final surface tension,  
mN/m 
 Surface tension 
reduction rate, 
mN/m/s 
Curosurf® 61.7 (6.5) 23.2 (0.3) 0.63 (0.10) 
Curosurf-EEG 57.2 (6.1) 31.4 (2.1)* 0.57 (0.07) 
Survanta® 59.0 (13.1) 29.9 (5.5) 0.73 (0.16) 
Survanta-EEG 65.6 (1.3) 33.0 (1.5) 0.58 (0.07) 
*Significant difference compared to Curosurf®; Student’s t-test, p<0.05 
 
 
Comparisons of the tensiograms for the EEG powder formulations with the commercial 
replacement suspension formulations are shown in Figure 3.9. The profiles for all formulations 
show a decrease in surface tension with increasing surface age. Curosurf® was observed to reach 
lower surface tension values at younger surface ages compared to Survanta®, which may be due 
to the higher concentration of lipids and proteins in Curosurf®; at a concentration of 1.5 mg/mL 
DPPC, an estimated 3.8 mg of phospholipids were present in the Curosurf® sample compared to 
2.8 mg of phospholipids in Survanta® sample based on the label claim. The shape of the Survanta® 
surface tension profile was observed to be similar to that found in literature (Figure 3.1), which 
had an estimated surface tension reduction rate of 0.83 mN/m/s.  
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Figure 3.9. Surface tension activity comparison of commercial replacement surfactant 
formulations with EEG powder formulations of Curosurf® (top) and Survanta® (bottom) with 
nominal DPPC content of 1.5 mg/mL measured at 50 °C using method 3. Markers represent 
individual values. 
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The surface tension values determined for the different formulations were in agreement 
with the predictions made from Equation 3.8 (predicted surface tension of 28.5 mN/m with 1.5 
mg/mL DPPC), based upon the changes expected for DPPC alone in the spray dried formulation 
as the surface-active agent, despite the presence of other formulation lipids and proteins. However, 
the commercial surfactant EEG formulations were observed to have different tensiometer profiles 
than observed for the DPPC-EEG formulations (Figure 3.10). The surface tension activity in both 
commercial surfactant EEG formulations were observed to be higher (lower surface tension 
values) at younger surface ages than those observed with unprocessed DPPC, likely due to the 
presence of proteins and other lipids in the formulation of the commercial surfactants. An 
evaluation of the integrity of the surfactant proteins in the spray dried formulation was performed 
and is described in Chapter 7. 
 
 
Figure 3.10 Surface tension activity comparison of unprocessed DPPC (squares) with commercial 
surfactant EEG powder formulations of Curosurf (circles) and Survanta (diamonds) with nominal 
DPPC content of 1.5 mg/mL measured at 50 °C using method 3. The surface activity of water is 
also shown for comparison. Markers represent individual values. 
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3.4 Conclusions 
This study developed methods to reliably produce DPPC-EEG formulations (Specific aim 
1-1), which were used to investigate the effect of spray drying factors (percent solids concentration 
in the feed dispersion, ratio of hygroscopic excipients, percent of ethanol in the feed dispersion 
and inlet drying temperature of the spray dryer) on the powder characteristics, the aerosol 
performance and the surfactant activity (Specific aim 1-2). DPPC-EEG spray dried powders were 
observed to be most influenced by the percent solids concentration in the feed dispersion, where 
the lower solids concentration of 0.125% w/v resulted in a smaller primary particle size, a higher 
primary particle fraction less than 1 µm, and a smaller MMAD than powders produced with a 
solids concentration of 0.250% w/v. The optimal processing parameters to produce DPPC-EEG 
powders were determined as follows: a percent solids concentration of 0.125% w/v in the feed 
dispersion, a ratio of mannitol-to-sodium chloride of 3:1, a percent ethanol concentration of 5% 
v/v in the feed dispersion and an inlet drying temperature of 70 °C. 
The parameters determined for optimal DPPC-EEG powder production were employed for 
EEG formulations with commercial replacement surfactants. Overall, the commercial surfactant 
EEG formulations were found to have a larger primary particle size, lower primary particle fraction 
less than 1 µm and 5 µm, and larger span. Aerosol performance of the commercial surfactant-EEG 
formulations revealed poorer performance (larger MMAD, lower particle fractions less than 1 µm 
and 5 µm) compared to that of the DPPC-EEG formulation. The commercial surfactant-EEG 
formulations were, however, shown to maintain surfactant activity following feed dispersion 
preparation and spray drying (Specific aim 5-1). 
This study demonstrated that although optimal formulation factors and spray drying 
parameters were determined for production of EEG powders prepared with DPPC, the 
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predominant lipid component in commercial surfactants, the parameters when applied to produce 
EEG formulations with commercial surfactants did not produce powders with similar 
characteristics or aerosol performance across the range of commercial surfactant formulations 
evaluated. While the particle size of DPPC-EEG powders was observed to be largely influenced 
by the percent solids concentration in the feed dispersion, the particle size or dispersibility of the 
commercial surfactant-EEG formulations were determined by other formulation factors. The 
formulation factors and spray drying parameters determined for the production of DPPC-EEG 
powders provided only a basis for the development of EEG formulations with commercial 
surfactants, as the complex mixture of lipids and proteins of the replacement formulations require 
additional optimization. The Survanta-EEG formulation was observed to be most comparable to 
the DPPC-EEG formulation with respect to powder characteristics and aerosol performance, 
therefore further optimization with this formulation was studied as described in the following 
chapter. 
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CHAPTER 4 
4 DETERMINATION OF THE EFFECT OF DISPERSION ENHANCERS AND 
SPRAY VEHICLE ALCOHOL CONCENTRATION ON THE DISPERSIBILITY OF 
EEG POWDERS PREPARED WITH COMMERCIAL REPLACEMENT 
SURFACTANTS 
4.1 Introduction 
The previous chapter described methods developed for the reliable production of EEG 
powders with DPPC. The developed methods were applied to commercial surfactant formulations 
but were found to not perform as well as the DPPC-EEG powders; the commercial surfactant EEG 
formulations had larger MMAD values and higher fine particle fractions. EEG powders produced 
with the commercial surfactant formulation Survanta® were observed to perform most comparable 
to the DPPC-EEG powder and thus selected for further optimization. 
When developing a drug formulation for inhalation, a primary consideration is ensuring 
that the aerosol generated has particles in the 1 to 5 micrometer size range to ensure deposition in 
the small airways and alveoli of the lungs. Powder formulations produced by spray drying are 
capable of generating particles in this size range, but the small size of the particles results in 
increased cohesive forces leading to agglomeration of the powder that requires effective dispersion 
to a primary particle aerosol during drug delivery. The need to generate a well dispersed aerosol 
for effective drug delivery is the main obstacle with delivering dry powders for inhalation.  
Particle dispersion efficiency is affected by many factors, mainly, powder formulation and 
DPI design. These factors can be controlled to optimize powder dispersion for enhanced drug 
delivery to the lungs. For the powder formulation, the incorporation of excipients can be used to 
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improve the dispersion. Leucine and trileucine have been shown to reduce agglomeration of spray 
dried powders, therefore effectively enhancing dispersibility of the powder formulations [95, 138, 
139]. The surface-active nature and low solubility of leucine and trileucine in ethanol/water co-
solvent systems is hypothesized to produce corrugated shells that encapsulate the other 
components in the formulation [95]. The corrugated surface of the dried particles reduces the 
surface area available for particle-particle interaction and thus, reduces agglomeration.  
In this study, the aim was to develop and characterize dry powder pulmonary surfactant 
formulations that would be used for the treatment of neonatal RDS during non-invasive ventilation. 
The specific objectives included exploring the use of leucine or trileucine as the dry powder 
dispersion enhancer combined with the commercially available natural surfactant formulation, 
Survanta® intratracheal suspension, to produce spray dried powders using the EEG application, 
and evaluation of the aerosol performance of the EEG powders with a novel DPI. Survanta® 
intratracheal suspension is a natural bovine lung extract suspended in 0.9% sodium chloride with 
25 mg/mL of phospholipids – dipalmitoylphosphatidylcholine (DPPC) and 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphoglycerol (POPG) are the two main lipid components, making up 44-62% and 
13-45% of the total formulation, respectively [30, 100]. Mannitol was selected as the hygroscopic 
excipient in addition to the sodium chloride present in the commercial surfactant formulation. 
4.2 Materials and methods 
4.2.1 Materials 
Survanta® (beractant) intratracheal suspension was purchased from Cardinal Health, Inc. 
(Greensboro, NC) and stored at 2-8 °C. Pearlitol® PF-mannitol was donated from Roquette Pharma 
(Lestrem, France). L-leucine was purchased from Sigma Chemical Co. (St Louis, MO). Trileucine 
was purchased from Fisher Scientific Co. (Hanover Park, IL) and stored at -20 °C. 
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4.2.2 Feed dispersion preparation 
The previous chapter described the use of probe sonication to prepare DPPC-EEG 
dispersions for spray drying. Direct sonication of samples results in higher effective energy output 
into the suspension and consequently shorter preparation time, however this requires an additional 
processing step. During direct sonication titanium particles are detached from the probe tip and 
contaminate the feed dispersion. An additional centrifugation step following sonication was 
employed, however it did not adequately separate the titanium particles, therefore, dispersions with 
Survanta® were prepared via indirect sonication methods. 
Feed dispersions for spray drying were prepared by heated bath sonication (Fisher 
Scientific™ CPXH, Hanover Park, IL) with the aim of producing homogenous dispersions to 
ensure uniform spray dried particles. All formulations contained mannitol and sodium chloride in 
a 3:1 ratio with a dry powder dispersion enhancer (leucine or trileucine) at a concentration of 20% 
w/w. Approximately 27% w/w of phospholipids (including approximately 14% w/w DPPC) were 
included in each formulation based on the Survanta® label claim [30] as 0.014 mL of Survanta was 
added per mL of dispersion feed solution.  
Excipients (mannitol and leucine/trileucine) were accurately weighed and dissolved in the 
spray vehicle (5 or 20 % v/v ethanol in water) followed by addition of Survanta® resulting in a 
total solids concentration of 0.125% w/v. Feed dispersions were sonicated for a minimum of 40 
minutes. The water bath was set to 60 °C, which resulted in a feed dispersion temperature of 55-
58 °C. This elevated temperature was used to ensure that sonication was performed >10 °C above 
the transition temperature of Survanta® to disrupt the order of the lipid bilayers, ideally allowing 
for homogenous incorporation of the added excipients, then reorganization of the bilayers, which 
theoretically occurs when the temperature returns below the main transition temperature [17, 100]. 
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4.2.2.1 Stability of feed dispersions 
The zeta potentials of the feed dispersions were measured to assess its suspension stability. 
High absolute zeta potential values lead to repulsion between particles, which can prevent 
aggregation and is thus used as a measure of dispersion stability. The zeta potentials (z) of the feed 
dispersions were determined using dynamic light scattering (Zetasizer Nano S, Malvern 
Instruments, Ltd., Worcestershire, UK). The mean particle sizes (z-Ave) and estimates of the width 
of the distribution (polydispersity index, PdI) were also determined by dynamic light scattering.  
For zeta potential and sizing analysis, appropriate cuvettes were filled with approximately 
0.5-1.0 mL of the prepared feed dispersion. All measurements were performed at 25 °C with the 
helium-neon laser operating at 633 nm set for backscatter detection. The test material was set as 
phospholipids (refractive index: 1.450, absorption coefficient: 0.001) and the dispersant set as 
water (refractive index: 1.330, viscosity: 0.887 cP, dielectric constant: 78.5). Zeta potential values 
were calculated using the Smoluchowski approximation for samples in aqueous media. Intensity-
weighted mean particle sizes and polydispersity values were estimated from cumulants analysis. 
All measurements were performed in triplicate. 
4.2.3 Spray dried powder formation 
Powders were formed using the Nano Spray Dryer B-90 HP (Büchi Labortechnik AG, 
Flawil, Switzerland) using the open-loop configuration for aqueous applications. The HP model 
incorporates a modified spray head for use with redesigned atomizers for more efficient spray 
drying compared to the spray meshes in the previous design (Nano Spray Dryer B-90), which were 
used to prepare the DPPC-EEG formulations described in the previous chapter. More efficient 
spray drying was reported to be achieved with an increased spray mesh diameter and an increased 
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spray frequency; the previous design operated at a fixed frequency of around 60 kHz [140] whereas 
the HP model has a controllable range of 80-140 kHz [96]. The spray drying parameters are listed 
in Table 4.1. 
 
Table 4.1 Spray drying parameters to produce Survanta-EEG powders. 
Spray drying parameter Setting 
Inlet temperature 70 °C (outlet temperatures of 37-41 °C) 
Drying gas flow 120 L/min (chamber pressure of 40-42 mbar) 
Spray frequency 120 kHz 
Pump speed 3% 
Spray percentage 80% 
 
 
A characteristic feature to the Nano Spray Dryer allowed for bypass flow in the spray head. 
Any excess feed dispersion that was not atomized by the spray mesh could be collected in a 
separate vessel or recycled back into the original feed stock container. In general, recycling of the 
surfactant feed dispersions was avoided to ensure uniform dispersion feed concentrations were 
maintained throughout the spray drying process. Preliminary studies with the HP model spray 
dryer found that a pump speed of 3% and a spray setting of 80% were ideal to prevent excess 
dispersion feed being presented to the spray head and therefore minimized amount of feed 
dispersion that was bypassed without considerably extending the spray drying time. During spray 
drying, feed dispersions were continuously mixed using a stir bar and stir plate and kept cool with 
ice packs. Preparations were spray dried in small batches of feed dispersion with the reminder kept 
in a refrigerator (2-8 °C). The feed dispersion bypass volume and total spray drying time was 
recorded for each run. 
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Powders were collected from the electrostatic precipitator and stored in tared glass vials. 
Percent powder yield was calculated from the mass of powder collected using Equation 4.1. 
Powders were stored in a desiccator in the refrigerator when not in use. 
 
!"#$%&	()%*$,% = ./0123	4566	7/8827921,			4:7/;7	6/8<16	<;	1<6.236</;,			=>=?	∗	A/8B42	/C	1<6.236</;	6.35D	13<21,			4E 	× 	100         
             Equation 4.1 
4.2.4 Particle size characterization 
The primary particle size distribution of each formulation was determined by laser 
diffraction using the Sympatec HELOS with RODOS/M disperser and ASPIROS sample feeder 
as described in the previous chapter. Sample vials were filled with 3 to 4 mg of powder, capped 
and placed into the ASPIROS sample feeder set to 60 mm/sec. The RODOS/M used compressed 
air to disperse the powders which for these studies was set to either 1.0 and 4.5 bar. The minimum 
Copt was set to 2.1%. Data were collected over a measurement duration of 10 seconds. All 
measurements were performed in triplicate. Volume-based size distributions for each of the 
dispersion pressures (1.0 and 4.5 bar) were calculated by WINDOX software using the Fraunhofer 
theory. The particle size below which 10%, 50% and 90% of the powder distribution lies (Dv10, 
Dv50, and Dv90, respectively) was determined. The span of the PSD was calculated using 
Equation 4.2. The percent of particles having a diameter less than 1 µm and 5 µm (Dv<1 µm and 
Dv<5 µm, respectively) was obtained from the Sympatec software. 
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IJKL = 	MANOPMAQOMARO                                                                                                       Equation 4.2 
4.2.5 DPPC content analysis 
The DPPC concentration was determined by LC-MS as described in the previous chapter. 
For DPPC content analysis of feed dispersions, 250 µL of the dispersion was aliquoted into a 10 
mL volumetric flask and then Q.S. to volume with methanol. For the spray dried formulations, 
approximately 1.1 mg of spray dried powder was dissolved in 25 mL of methanol using sonication 
for 20 seconds. The percent DPPC content was calculated by assessing the amount of drug in the 
spray dried powder and using Equation 4.3. 
 S!!T	U"LV%LV,% =	 W665D21	54/B;9	/C	MXXY	<;	6.35D	13<21	./0123,			4:Z566	/C	6.35D	13<21	./0123	C/3	5665D	654.82,			4: 	× 	100   Equation 4.3 
4.2.6 Aerosol performance of leucine powder formulation  
4.2.6.1 Modified low-volume dry powder inhaler 
A DPI designed to use a low volume of air (10 mL) to deaggregate and deliver dry powder 
aerosol was developed at the VCU School of Engineering by Farkas et al. [141]. As described in 
the following chapter, the low air volume DPI (LV-DPI) was modified to operate for use with a 
smaller volume of air (3 mL) with the intention of using it for intratracheal administration of dry 
powder to small animal models and eventually for use in very low birth weight infants. The outlet 
of the modified LV-DPI used in this study attached directly to a 12.7 mm long, 14-gauge catheter 
which could be inserted through an incision in the trachea. The device consists of two parts: 1) an 
inlet body that contains three 0.60 mm holes with a commercial luer lock connection, and 2) an 
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outlet body, that contains a 0.89 mm hole extending to a 19 gauge extra-thin-walled capillary 
needle (internal diameter = 0.89 mm) with a length of 55 mm (extended to the end of the catheter) 
when measured from the outer o-ring of the device (Figure 4.1). The DPI was constructed using 
rapid prototyping (Object24 printer, Stratasys Ltd., Eden Prairie, MN) with a rigid opaque 
photopolymer, VeroWhitePlus (RGD835). When assembled, the interior volume (dose 
containment unit or powder chamber) of the device measures 0.21 mL. 
 
 
Figure 4.1 Axial cross-section view of the assembled modified containment unit DPI with 55 mm 
delivery tube length. Inlet body (    ) and outlet body (    ) portions differentiated by fill pattern.  
4.2.6.2 Malvern Spraytec® aerosol characterization 
The particle size distribution of the aerosol exiting the device was determined by laser 
diffraction using a Malvern Spraytec® (Malvern Instruments, Ltd., Worcestershire, UK). All 
measurements were performed using the 100 mm focal length lens, which has a Dv50 size range 
of 0.5-200 µm, with the following settings: 98% transmission (2% obscuration), media refractive 
index of 1.00 + 0.00i (air) and particulate refractive index of 1.50 + 0.50i (opaque). A background 
reading was taken prior to each measurement. Applying Mie scattering theory, the RTSizer 
software reported data as Dv50, the 50% cumulative volume undersize. The particle fraction data 
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was calculated from the Spraytec® size results based on the percent of particles having a diameter 
less than 1 µm and 5 µm.  
A representative time history profile plot of the transmission and Dv50 values of the 
aerosol plume captured by the Spraytec® is shown in Figure 4.2. The % transmission gives an 
indication of the density of the aerosol plume, with a lower transmission indicating a denser plume 
as less of the laser light source is able to reach the detector. The % transmission is measured every 
0.4 ms and is plotted as a function of time. Similarly, a particle size distribution measurement was 
also made every 0.4 ms and the measured median volume diameter at each time point was plotted 
and labelled as Dv50 in Figure 4.2. For data analysis the average Dv50 is calculated over the entire 
run. Figure 4.2 shows an approximately 500 ms spray duration.  
 
 
Figure 4.2 Representative time history plot for the aerosol plume of Survanta-EEG powder 
generated with the modified containment unit DPI using 3 mL volume of dispersion air as captured 
by the Malvern Spraytec®. 
4.2.6.3 Emitted mass determination 
The emitted mass for the modified containment unit DPI was determined by gravimetric 
analysis. Powder was first weighed to determine the initial powder fill mass and then manually 
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filled into the inlet body of the device. Once assembled, the device with powder was weighed to 
determine mass of loaded device. A 5 mL syringe was filled with room air to 3 mL and connected 
to the luer-lock inlet of the DPI. The device with syringe was mounted in a horizontal position to 
a fixed stand so that the tip of the device outlet was 5 cm from the middle of the laser beam. The 
powders were dispersed by manual compression of the syringe, which occurred in approximately 
0.12 ± 0.01 seconds, as determined using a Photron PCI R2 high-speed camera to capture images 
at 1000 frames per second with Photron FASTCAM Viewer software to analyze the images. This 
results in a short burst at an airflow rate of approximately 1.6 L/min. The syringe was then 
disconnected from the DPI and the device was reweighed to determine the mass of device after 
actuation. Measurements were repeated for up to three actuations. The percent of powder mass 
emitted was calculated from the initial mass loaded into the device using Equation 4.4. 
 [\)VV%$	\K]],% =	 (4566	/C	8/5121	12A<72	P	4566	/C	12A<72	5C923	579B59</;),			4:<;<9<58	./0123	C<88	4566,			4: 	× 	100   
                                                                       Equation 4.4 
4.2.7 Spray dried powder analysis 
4.2.7.1 Scanning electron microscopy 
The morphology of the powders was examined using a scanning electron microscope, SEM 
(Carl ZEISS EVO 50XVP, Carl Zeiss AG, Germany). Samples were prepared on SEM specimen 
mounts using double-sided tape and then coated with gold grain in a sputter coater (EMS550X, 
Electron Microscopy Sciences, Hatfield, PA). Samples were viewed under high vacuum mode and 
an accelerating voltage of 15 kV at magnifications of 19,000 to 21,000 with a specimen working 
distance of 9 mm. 
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4.2.7.2 Solid state powder characteristics 
Spray drying produces powders with low-moisture content, which was verified by TGA. 
TGA was performed using the Pyris 1 TGA with TAC 7/DX Thermal Analysis Controller as 
described in the previous chapter. Powder samples weighing 1 to 2 mg were heated from 25 °C to 
100 °C while under a nitrogen purge at 40 mL/min. The % moisture content was determined by 
the stable weight loss (%) following an isothermal hold at 100 °C. 
The main transition temperature of the spray dried powders was determined by differential 
scanning calorimetry (DSC) using the DSC 7 (PerkinElmer, Covina, CA) with a TAC 7/DX 
Thermal Analysis Controller. Sample masses of 1 to 2 mg of spray dried powder were filled into 
tared aluminum DSC pans and hermetically sealed. In addition, the commercial suspension was 
also dried in a sample pan in an oven set to 50 °C to obtain 1 to 2 mg of sample.  These samples 
were analyzed by heating from 25 °C to 100 °C at a rate of 5 °C/min with a 20 mL/min nitrogen 
purge gas. 
4.2.8 Statistical analysis 
Data analysis was performed using JMP® Pro software version 12.0 (SAS Institute Inc., 
Cary, NC). Student’s t-statistic or one-way analysis of variance (ANOVA) followed by Tukey’s 
HSD was performed to determine statistically significant differences in the data obtained. The 
Pearson correlation coefficient was determined to quantify the strength of linear relationships. P 
values less than 0.05 were considered as statistically significant. 
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4.3 Results and discussion 
4.3.1 Effect of bypass flow on feed dispersion DPPC content 
Preliminary experiments studied the effect of feed dispersion recycling on its DPPC 
content. Feed dispersions were prepared with Survanta®, mannitol and trileucine in a 5% v/v 
ethanol in water spray vehicle and sonicated for 40 minutes. The spray drying bypass dispersion 
was collected into a separate vessel following each pass across the spray head and assayed for 
DPPC (Figure 4.3).  HPLC analysis of the DPPC content of the Survanta formulation allowed an 
estimated DPPC content in the feed dispersion following the addition of Survanta to be made of 
0.16 mg/mL DPPC. Analysis and assay of the initial feed dispersion revealed that the mean ± SD 
measured DPPC content was 0.17 ± 0.01 mg/mL. From the initial concentration to the third bypass 
cycle, there is a gradual increase in the DPPC content in the feed dispersion with each pass across 
the spray head; the mean ± SD DPPC concentration after the third cycle was 0.20 ± 0.01 mg/mL. 
This gradual increase is likely due to the evaporation of the spray vehicle, concentrating the 
remaining solids. Due to the inability to control the relative proportions of feed dispersion that 
were bypassed and were sprayed, dispersions for spray drying were not recycled in order to ensure 
that a uniform feed dispersion was introduced to the spray head throughout the spray drying 
process.   
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Figure 4.3 DPPC content in replicate runs of recycled dispersions of Survanta-EEG formulations 
with trileucine in 5% v/v ethanol in water spray vehicle. Markers represent the mean value, error 
bars represent the SD, n=3. 
4.3.2 Effect of sonication time on feed dispersion and spray dried powder characteristics 
The effect of sonication time on feed dispersion characteristics and the particle size 
distribution of the spray dried powders were explored (Table 4.2). Feed dispersions with 
Survanta®, mannitol and trileucine in a 5% v/v ethanol in water spray vehicle were sonicated for 
40, 75 and 100 minutes. Feed dispersion characteristics were determined with the Malvern 
Zetasizer. The dispersions produced at the different sonication times were all shown to have zeta 
potential values more negative than -30 mV, the threshold value for stability, indicating stable 
dispersions.  Determination of the Pearson correlation coefficient found that there was a significant 
positive correlation of sonication time with the zeta potential of the feed dispersion (r = 0.8650, 
p=0.0026, R2 = 0.7481), where an increase in sonication time resulted in more stable dispersions.  
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Spray drying of the feed dispersions resulted in spray rates of 0.23-0.29 mL/min and 
powder yields of 65-69%. Assay of the DPPC content in the Survanta® formulation allowed the 
calculation of a theoretical DPPC concentration of 12.5 ± 1.4% w/w in the powder formulation. 
The experimental DPPC content in the spray dried powders was determined to be 12.2-13.8% w/w 
for the spray dried powders, 98-110% of the theoretical value. Sonication time was not found to 
have an effect on the primary particle size characteristics or DPPC content of the spray dried 
powders. Although the sonication time was found to have a significant correlation with the stability 
of the feed dispersion, this was not reflected in the content uniformity data of the spray dried 
powders; powders produced following 40 minutes of sonication were found to be less variable 
than powders produced following 100 minutes of sonication (Table 4.2). All powders were 
observed to have a mean volume diameter of about 1 µm with over 40% of the particles <1 µm. 
Future studies prepared feed dispersions with 40 minutes of sonication to minimize preparation 
time. 
4.3.3 Effect of spray atomizer size on particle size distribution 
The redesigned spray atomizers used in the Nano Spray Dryer B-90 HP were produced in 
three sizes: small, medium and large. The effect of the spray atomizer size on the particle size of 
surfactant powders was studied. Feed dispersions for spray drying were prepared with Survanta®, 
mannitol and trileucine in a 5% v/v ethanol in water spray vehicle. The powder yields ranged from 
64-70% w/w. As expected, the spray rate increased with increasing atomizer size – 0.26, 0.34 and 
0.44 mL/min for the small, medium and large spray atomizer sizes, respectively (Table 4.3). The 
primary particle size of each powder formulation was determined by laser diffraction using the 
Sympatec HELOS with RODOS dispersion pressure of 4.5 bar. The mean primary particle Dv50 
values and the fraction of particles <1 µm were not affected by the spray atomizer size; however, 
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the span and fraction of particles <5 µm were significantly affected by the spray atomizer size 
(p=0.0296 and p=0.0338, respectively; one-way ANOVA). The powders prepared with the large 
spray atomizer had a significantly smaller span (p=0.0248; Tukey’s HSD) and significantly higher 
fraction of particles <5 µm (p=0.0343; Tukey’s HSD) compared to the powders prepared with the 
small spray atomizer. 
The modified containment unit DPI (Figure 4.1) was used to determine the aerosol 
performance of the spray dried powders produced from the different spray atomizer sizes. A 
nominal fill mass of 5 mg of spray dried powder was used and the aerosol performance was 
determined using the Malvern Spraytec®. The mean aerosol Dv50 values, particle fraction <1 µm 
and particle fraction <5 µm were not found to be significantly affected by the spray atomizer size; 
however the powders produced with the medium size spray atomizer were observed to have the 
smallest aerosol Dv50 value (2.6 µm) with the highest particle fractions (28% <1 µm and 57% <5 
µm, Table 4.3). Thus, powder formulations were prepared using the size medium spray atomizer 
in future studies. 
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Table 4.2 Effect of sonication time on feed dispersion characteristics (Malvern Zetasizer) and primary particle size characteristics 
(Sympatec HELOS with RODOS dispersion pressure of 4.5 bar). Values are mean (SD), n≥3. 
Sonication time, 
min 
Feed dispersion  Spray dried powder 
z-Ave, 
nm PdI 
z, 
mV‡  
Primary 
particle Dv50, 
µm Span 
Particle fraction, % DPPC 
content, 
% w/w <1 µm <5 µm 
40 154 (3) 0.36 (0.04) -32 (1)  1.11 (0.06) 1.8 (0.3) 43.6 (2.5) 96.8 (2.8) 13.8 (0.1) 
75 118 (4) 0.38 (0.01) -35 (2)  1.07 (0.04) 1.5 (0.2) 45.7 (2.5) 99.1 (1.6) 12.2 (0.5) 
100 171 (4) 0.42 (0.04) -40 (3)  1.10 (0.06) 1.7 (0.3) 44.1 (2.6) 97.0 (2.6) 12.8 (1.0) 
z = zeta potential 
‡Significant correlation with sonication time; Pearson correlation, p<0.05 
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Table 4.3 Effect of spray atomizer size on particle size characteristics: primary particle size determined on the Sympatec HELOS with 
RODOS dispersion pressure of 4.5 bar, aerosol performance determined on Malvern Spraytec® with the modified containment unit DPI 
using 5 mg powder fill mass and 3 mL volume dispersion air. Values are mean (SD), n≥3. 
Spray 
atomizer 
size 
Spray rate, 
mL/min 
Primary particle size  Aerosol performance 
Primary 
particle Dv50, 
µm Span‡ 
Particle fraction, %  Aerosol 
Dv50, 
µm 
Particle fraction, % 
<1 µm <5 µm‡  <1 µm <5 µm 
small 0.26 1.11 (0.06) 2.1 (0.3) 43.9 (1.8) 95.3 (1.4)  3.1 (0.8) 25.4 (1.8) 57.1 (3.8) 
medium 0.34 1.07 (0.04) 1.9 (0.2) 41.9 (3.1) 96.6 (2.2)  2.6 (0.3) 27.9 (1.6) 57.1 (1.7) 
large 0.44 1.10 (0.06) 1.5 (0.2)* 41.8 (2.2) 99.4 (1.3)*  3.3 (0.6) 24.1 (2.2) 55.7 (3.2) 
‡Statistically significant effect of spray atomizer size; one-way ANOVA, p<0.05 
*Significant difference compared to small spray atomizer size, Tukey’s HSD, p<0.05 
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4.3.4 Selection of dispersion enhancer 
4.3.4.1 Effect of dispersion enhancer on feed dispersion characteristics 
Table 4.4 summarizes the spray drying feed dispersion characteristics determined by 
dynamic light scattering for the studied formulations. For the feed dispersions in 5% v/v ethanol 
in water, the presence of leucine resulted in significantly more stable dispersions (z = -40 mV, 
p=0.0365; Student’s t-test) than feed dispersions prepared with trileucine (z = -36 mV). Feed 
dispersions prepared with leucine were also observed to have a significantly smaller mean particle 
size (z-Ave = 125 nm, p<.0001; Student’s t-test) with higher polydispersity (PdI = 0.48, p=0.0250; 
Student’s t-test) than the feed dispersions containing trileucine.  
As with the 5% v/v ethanol in water feed dispersion, the polydispersity index was 
significantly higher for feed dispersions prepared with leucine than trileucine (0.60 vs 0.41) at the 
20% v/v ethanol concentration (p<.0001; Student’s t-test); however, there were no significant 
differences observed in the dispersion stability and mean particle size of the feed dispersions 
prepared in 20% v/v ethanol between the two dispersion enhancers. Dispersions prepared with a 
higher ethanol concentration were observed to have decreased dispersion stability (lower zeta 
potential values). This was expected since short-chain alcohols are known to disturb the natural 
microstructure of the lipid membrane by residing in the headgroup region resulting in the observed 
increase in disorder [142].
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Table 4.4 Effect of dispersion enhancer on the zeta potential (z), particle size (z-Ave), and 
polydispersity index (PdI) of the spray drying dispersion. Values are mean (SD), n≥3. 
Ethanol concentration,  
% v/v 
Dispersion 
enhancer 
z,  
mV 
z-Ave,  
nm PdI 
5 leucine -40 (1)* 125 (2)* 0.48 (0.06)* 
5 trileucine -36 (4) 162 (10) 0.39 (0.05) 
     
20 leucine -22 (1) 176 (15) 0.60 (0.05)# 
20 trileucine -21 (1) 188 (9) 0.41 (0.04) 
* Significant difference compared to trileucine at 5% v/v ethanol in water concentration; 
Student’s t-test, p<0.05 
# Significant difference compared to trileucine at 20% v/v ethanol in water concentration; 
Student’s t-test, p<0.05 
 
 
4.3.4.2 Effect of dispersion enhancer on primary particle size distribution 
The spray dried powders were determined to have powder yields ranging from 65 to 76 % 
w/w. The DPPC content of the spray dried powders were determined to range from 11 to 14 % 
w/w which represented values of 85 to 110% of the theoretical content assessed based on assay of 
DPPC content in the stock commercial surfactant, Survanta®.  
A summary of the mean particle size characteristics (Dv10, Dv50 and Dv90) of the spray 
dried Survanta-EEG powders are shown in Figure 4.4. Overall, the particle size of the powders 
was observed to be dependent on the air dispersion pressure (4.5 vs 1.0 bar) used during the 
primary particle analysis, with greater dispersion at the higher air dispersion pressure – the average 
primary particle Dv50 was approximately 0.3 µm smaller at 4.5 bar than 1.0 bar. Assuming that 
the results obtained at 4.5 bar represent the primary particle characteristics, the median particle 
diameter (Dv50) of the powders at this higher pressure are all approximately 1 µm. At the lower 
air dispersion pressure of 1.0 bar, powders prepared with leucine appeared to have less aggregates 
(low Dv90) at both ethanol concentrations compared to powders prepared with trileucine (gray 
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wavy fill pattern bar vs gray solid fill pattern bar in second cluster of data, Figure 4.4), although 
this was most pronounced at the 5% v/v ethanol in water concentration (gray solid fill bar vs gray 
diagonal fill pattern bar in the first cluster of data, Figure 4.4). This difference was not anticipated 
as trileucine has been shown to have improved dispersibility compared to leucine [143]. This 
unexpected observation may be explained by the presence of other surface-active components in 
the formulation (phospholipids in the commercial formulation) that compete for space at the air-
liquid interface of the droplets exiting the spray atomizer during the spray drying process. In this 
scenario, the surface of the dried particle may then be more enriched with phospholipids than the 
dispersion enhancer and the difference observed between the dispersion enhancers is not as 
expected and becomes difficult to predict. 
 
 
 
Figure 4.4 Primary particle size characteristics of spray dried Survanta-EEG powders determined 
on the Sympatec HELOS with RODOS dispersion pressures of 1.0 and 4.5 bar. Bars represent the 
mean value, error bars represent the SD, n≥3. 
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 The choice of dispersion enhancer was shown to have a significant effect on the primary 
particle size (Dv10, Dv50, and Dv90), the span, and the fraction of particles less than 1 µm and 5 
µm (Table 4.5). For the 5% v/v ethanol in water feed dispersions, powders prepared with leucine 
were observed to show a significantly lower median primary particle size (Dv50) compared to 
those prepared with trileucine (p=0.0005; Student’s t-test) when characterized using 4.5 bar air 
dispersion pressure. However, this difference in particle size was relatively small (~0.1 µm). 
Similarly, significant differences were also seen with other particle characterization parameters, 
Dv10 and Dv90 (p=0.0002 and p=0.0079, respectively; Student’s t-test). Leucine powders had a 
smaller span (1.4 vs 1.8, p=0.0159; Student’s t-test), a higher fraction of submicrometer particles 
(50 vs 44%, p=0.0003; Student’s t-test), and a higher fraction of particles <5 µm (100 vs 98%, 
p=0.0440; Student’s t-test) when compared to trileucine powders.  
Similarly, leucine powders prepared in 20% v/v ethanol in water were shown to produce 
significantly smaller particles (0.96 vs 1.07 µm, p<.0001; Student’s t-test), a smaller span (1.4 vs 
1.5, p=0.0022; Student’s t-test), and a higher submicrometer particle fraction (53 vs 46%, 
p=0.0001; Student’s t-test) than the powders prepared with trileucine when characterized at 4.5 
bar air dispersion pressure.  
Similar effects were observed when characterizing the spray dried powders at the air 
dispersion pressure of 1.0 bar (Table 4.6). At the 5% v/v ethanol in water concentration, powders 
produced with leucine were shown to have a significantly smaller median particle size compared 
to powders prepared with trileucine (1.26 vs 1.41 µm, p=0.0035; Student’s t-test). The leucine 
powders had a smaller span (1.57 vs 2.23, p=0.0005; Student’s t-test), a higher fraction of 
submicrometer particles (36.2 vs 31.8%, p=0.0041; Student’s t-test), and a higher fraction of 
particles <5 µm (99.7 vs 94.0%, p=0.0005; Student’s t-test) when compared to trileucine powders. 
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At the 20% v/v ethanol in water concentration, powders produced with leucine were shown to have 
a significantly smaller median particle size (1.25 vs 1.46 µm, p=0.0001; Student’s t-test) and a 
higher fraction of submicrometer particles (36.9 vs 30.5%, p=0.0001; Student’s t-test) compared 
to powders prepared with trileucine. There was no significant difference observed in the span 
values and the fraction of particles <5 µm of the leucine and trileucine powders at the 20% v/v 
ethanol in water concentration, 1.91 vs 1.98 and 96.7 vs 96.4%, respectively. 
Dispersibility of the powders were studied by comparing the Dv90 results at RODOS 
dispersion pressures of 1.0 bar vs 4.5 bar for each dispersion enhancer-ethanol concentration 
combination. For the leucine powders prepared at 5% v/v ethanol in water concentration (solid 
gray bars in first and third cluster of data, Figure 4.4), the leucine powders prepared at 20% v/v 
ethanol in water concentration (gray bars with wavy fill pattern in second and fourth cluster of 
data, Figure 4.4), and the trileucine powders prepared at 20% v/v ethanol concentration (solid gray 
bars in second and fourth cluster of data, Figure 4.4), the Dv90 values at 4.5 bar dispersion pressure 
were found to be significantly smaller than the Dv90 values at 1.0 bar dispersion pressure with a 
p-value of <.0001 using Student’s t-test. For trileucine powders prepared at 5% v/v ethanol in 
water concentration (gray bars with diagonal fill pattern in first and third cluster of data, Figure 
4.4), the Dv90 value at 4.5 bar dispersion pressure was also found to be significantly smaller than 
the Dv90 value at 1.0 bar dispersion pressure, however the p-value showed lower significance 
(p=0.0061; Student’s t-test), indicating that the trileucine powders prepared at 5% v/v ethanol in 
water concentration had poorer dispersion of aggregates compared to the other three dispersion 
enhancer-ethanol concentration powder combinations.
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Table 4.5 Effect of dispersion enhancer on the primary particle size characteristics, span and particle fractions of the spray dried powders 
determined using the Sympatec HELOS with RODOS dispersion pressure of 4.5 bar. Values are mean (SD), n=3. 
Ethanol 
concentration, 
% v/v 
Dispersion 
enhancer 
Primary particle, µm 
Span 
Particle fraction, % 
Dv10 Dv50 Dv90 <1 µm <5 µm 
5 leucine 0.51 (0.00) 1.00 (0.01) 1.95 (0.02) 1.44 (0.01) 50.0 (0.5) 100 (0.0) 
5 trileucine 0.53 (0.01)* 1.10 (0.05)* 2.49 (0.41)* 1.76 (0.28)* 43.8 (2.9)* 97.7 (2.5)* 
        
20 leucine 0.51 (0.01) 0.96 (0.03)^ 1.82 (0.06)^ 1.36 (0.03)^ 53.3 (2.5)^ 100 (0.0) 
20 trileucine 0.53 (0.00)# 1.07 (0.03)# 2.08 (0.06)# 1.45 (0.04)# 45.6 (1.9)# 100 (0.0) 
*Significant difference compared to leucine at 5% v/v ethanol in water concentration; Student’s t-test, p<0.05 
#Significant difference compared to leucine at 20% v/v ethanol in water concentration; Student’s t-test, p<0.05 
^Significant difference compared to leucine at 5% v/v ethanol in water concentration; Student’s t-test, p<0.05 
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Table 4.6 Effect of dispersion enhancer on the primary particle size characteristics, span and particle fractions of the spray dried powders 
determined using the Sympatec HELOS with RODOS dispersion pressure of 1.0 bar. Values are mean (SD), n=3. 
Ethanol 
concentration, 
% v/v 
Dispersion 
enhancer 
Primary particle, µm 
Span 
Particle fraction, % 
Dv10 Dv50 Dv90 <1 µm <5 µm 
5 leucine 0.56 (0.00) 1.26 (0.03) 2.53 (0.12) 1.57 (0.07) 36.2 (0.9) 99.7 (0.6) 
5 trileucine 0.59 (0.02)* 1.41 (0.08)* 3.74 (0.53)* 2.23 (0.24)* 31.8 (2.1)* 94.0 (2.1)* 
        
20 leucine 0.56 (0.01) 1.25 (0.05) 2.96 (0.17)^ 1.91 (0.07)^ 36.9 (1.9) 96.7 (1.1)^ 
20 trileucine 0.60 (0.01)# 1.46 (0.07)# 3.49 (0.12)# 1.98 (0.09) 30.5 (1.7)# 96.5 (1.0) 
*Significant difference compared to leucine at 5% v/v ethanol in water concentration; Student’s t-test, p<0.05 
#Significant difference compared to leucine at 20% v/v ethanol in water concentration; Student’s t-test, p<0.05 
^Significant difference compared to leucine at 5% v/v ethanol in water concentration; Student’s t-test, p<0.05 
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4.3.5 Evaluation of leucine formulation  
Further analysis was performed on the leucine powder formulation since the results at both 
dispersion pressures showed smaller PSDs, smaller spans, and higher submicrometer particles for 
leucine powders compared to trileucine powders. The aerosol performance of the leucine 
formulation prepared at both ethanol concentrations were evaluated using the modified 
containment unit DPI at a fill mass of 10 mg using 3 mL volumes of dispersion air. 
4.3.5.1 Effect of ethanol concentration in feed dispersion on the primary particle size 
distribution  
The ethanol concentration was shown to have a small, but significant effect on the primary 
particle size Dv50 and Dv90 values, the span, and the fraction of particles less than 1 µm (Table 
4.5). The leucine powders prepared in 20% v/v ethanol in water concentration were observed to 
have significantly smaller Dv50 and Dv90 values compared to leucine powders prepared in 5% 
v/v ethanol in water concentration (p=0.0044 and p=0.0006, respectively; Student’s t-test). The 
powders prepared in 20% v/v ethanol in water concentration were observed to have a smaller span 
(p=0.0007; Student’s t-test), and a higher fraction of submicrometer particles (p=0.0089; Student’s 
t-test) compared to leucine powders prepared at the 5% v/v ethanol in water concentration.  
At the lower RODOS dispersion pressure of 1.0 bar, the ethanol concentration was 
observed to have small, but significant effect on the Dv90, span and fraction of particles less than 
5 µm (Table 4.6). The leucine powders prepared in 20% v/v ethanol in water concentration were 
observed to have significantly larger Dv90 and larger span values (p=0.0005 and p<.0001, 
respectively; Student’s t-test) indicating poorer dispersibility at the lower pressure given that the 
Dv90 and span values at the 4.5 bar pressure were smaller compared to the powders prepared at 
5% v/v ethanol in water concentration. The fraction of particles less than 5 µm were observed to 
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be lower for powders prepared at 20% v/v ethanol in water concentration (p=0.0002; Student’s t-
test) compared to leucine powder prepared at 5% v/v ethanol in water concentration where there 
was no difference observed in the two formulations at the higher pressure.  
4.3.5.2 Effect of ethanol concentration in feed dispersion on DPI emitted mass 
The cumulative emitted mass data from the modified containment unit DPI are plotted as 
a percentage of the nominal mass in Figure 4.5 (primary y-axis, circles) for each actuation. Overall, 
the powders were shown to have good aerosolization properties with ≥ 88% of the nominal mass 
emitted after 3 actuations for both leucine powder formulations. The mass emitted on the first 
actuation (as a percentage of the nominal mass) was observed to be significantly higher for 
powders prepared with 5% v/v ethanol in water compared to powders prepared with 20% v/v 
ethanol in water (63.8 vs 53.8%, p=0.0485; Student’s t-test). However, overall performance was 
observed to be similar between the two formulations in the subsequent actuations. On the third 
actuation, the cumulative mass emitted (% nominal mass) was observed to be 90.3% and 89.5% 
for the 5% and 20% v/v ethanol in water feed dispersions, respectively, indicating that it was 
possible to efficiently empty the 10 mg surfactant formulation using only three-3 mL actuations. 
The mass emitted for each actuation as a percentage of the mass remaining in the device, 
calculated from the difference in the nominal mass and the mass emitted in the previous 
actuation(s), is plotted on the secondary y-axis in Figure 4.5 (triangle markers). For the 5% v/v 
ethanol in water feed dispersion, a lower percentage of powder was emitted with each successive 
actuation (64, 60, and 34% of the mass remaining for actuations 1, 2, and 3, respectively). 
However, more consistent and reproducible percent powder masses per actuation were observed 
with the 20% v/v ethanol in water feed dispersion (54, 56, and 47% of remaining for actuations 1, 
2, and 3, respectively).  
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Figure 4.5 Cumulative mass emitted (% nominal, circles) and mass emitted (% remaining, 
triangles) for leucine-Survanta-EEG powders with the modified containment unit DPI with 10 mg 
powder fill mass using 3 mL pulses of dispersion air. Markers represent the mean value, error bars 
represent the SD, n=3; EtOH=ethanol. 
4.3.5.3 Effect of ethanol concentration in feed dispersion on aerosol characteristics 
Table 4.7 lists the aerosol characteristics for the leucine-Survanta-EEG powders. The 
aerosol Dv50 values for the 5% v/v ethanol in water feed dispersion was observed to decrease with 
each successive actuation of 3 mL dispersion air, whereas the aerosol Dv50 values for the 20% v/v 
ethanol in water feed dispersion was observed to decrease from the first actuation to the second 
actuation and then level off on the third actuation. The particle fractions for the 5% v/v ethanol in 
water feed dispersion increased with each successive actuation, whereas the 20% v/v ethanol in 
water feed dispersion showed more consistent and reproducible particle fractions between 
actuations. Figure 4.6 shows the relationship between the mass of formulation emitted during each 
actuation (primary y-axis, square markers) and the measured aerosol Dv50 (secondary y-axis, 
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diamond markers).  Despite differences in the emitted mass, there were no significant differences 
observed between the formulations at each actuation. 
 
 
Figure 4.6 Mass emitted (mg, squares) and Dv50 (µm, diamonds) values for leucine-Survanta-
EEG powders with the modified containment unit DPI with 10 mg powder fill mass using 3 mL 
pulses of dispersion air. Markers represent the mean value, error bars represent the SD, n=3; 
EtOH=ethanol. 
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The aerosol plume durations were determined from exported Spraytec® files and defined 
as the time duration (in milliseconds, ms) in which data collection occurred (Table 4.7). The first 
actuation for both spray dried formulations had similar aerosol plume durations, 90.4 and 91.1 ms 
for the 5% v/v and 20% v/v ethanol in water concentrations, respectively. Successive actuations 
resulted in shorter plume durations; the second actuation was not significantly different between 
the two formulations, while the third actuation showed a significantly longer plume duration for 
the 20% v/v ethanol in water formulation compared to the powders prepared with 5% v/v ethanol 
in water (72.3 vs 46.0 ms, p=0.0003; Student’s t-test).  
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Table 4.7 Aerosol characteristics of leucine-Survanta-EEG spray dried powders using the modified containment unit DPI with 10 mg 
powder fill mass and 3 mL pulses of dispersion air. Values are mean (SD), n=3. 
Ethanol in spray 
vehicle, 
% v/v 
Mass 
emitted,  
mg 
Aerosol 
Dv50, 
µm 
Particle fraction, % Aerosol plume 
duration,  
ms^ 
Maximum 
obscuration, 
%^ 
Obscuration 
>20% duration,  
ms^ <1 µm <5 µm 
1st actuation        
5 6.42 (0.37) 4.5 (0.8) 19.6 (1.1) 51.7 (2.6) 90.4 (12.7) 91.6 (0.9)* 61.1 (0.5)* 
20 5.38 (0.51) 3.9 (0.4) 18.1 (1.1) 54.6 (2.2) 91.1 (6.4) 86.7 (1.0) 73.3 (3.6) 
        
2nd actuation        
5 2.18 (0.14) 3.3 (0.2) 21.6 (1.3) 56.4 (0.8)# 66.7 (9.5) 71.8 (4.2) 52.0 (4.4)# 
20 2.57 (0.30) 3.1 (0.1) 20.6 (0.2) 60.0 (0.7) 85.2 (10.6) 71.3 (5.6) 65.1 (3.1) 
        
3rd actuation        
5 0.48 (0.10) 2.6 (0.5) 25.5 (2.7) 61.7 (4.4) 46.0 (3.7)‡ 34.6 (5.7)‡ 17.5 (5.1)‡ 
20 0.96 (0.12) 3.2 (0.3) 20.6 (1.8) 57.8 (2.6) 72.3 (1.0) 45.4 (3.3) 38.7 (7.1) 
*Significant difference compared to 20% v/v ethanol in water concentration for the 1st actuation; Student’s t-test, p<0.05 
#Significant difference compared to 20% v/v ethanol in water concentration for the 2nd actuation; Student’s t-test, p<0.05 
‡Significant difference compared to 20% v/v ethanol in water concentration for the 3rd actuation; Student’s t-test, p<0.05 
^Significant correlation with mass emitted; Pearson correlation, p<0.05 
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Light obscuration values were determined by subtracting the average % transmission 
values from 100 for each measurement time point for the powder formulations evaluated. The 
obscuration values were plotted to study the time course of the aerosol plumes (Figure 4.7). 
Profiles appeared similar for the two ethanol concentrations with a distinct onset in plume 
formation, a stable phase of aerosol formation followed by a decline in the density of the aerosol 
plume. Maximum obscurations were determined by finding the peak obscuration value for each 
aerosol plume, with higher obscurations indicating denser aerosol clouds. The duration of the 
steady state period of aerosol generation was characterized by determining the duration of time 
that obscuration of the laser was greater than 20%.  
For the first actuation, the powders prepared with 5% v/v ethanol in water were found to 
reach a higher maximum obscuration of 91.6% compared to the powders prepared with 20% v/v 
ethanol in water, 86.7%, (p=0.0029; Student’s t-test). A shift is seen for the subsequent actuations; 
the maximum obscurations for the two formulations were similar in the second actuation and in 
the third actuation, the 20% v/v ethanol in water formulation had a significantly higher maximum 
obscuration than the 5% v/v ethanol in water formulation (45.4 vs 34.6%, p=0.0472; Student’s t-
test). This shift is expected since the maximum obscuration values were observed to have a strong 
positive correlation with powder mass emitted.  
Significant correlations of powder mass emitted was observed with aerosol plume duration, 
maximum obscuration and the duration of obscuration above 20% (Pearson correlation, p<0.05). 
Strong positive correlations were observed between emitted mass values and aerosol plume 
durations for the 5% v/v and 20% v/v ethanol in water formulations (r = 0.8911, p=0.0013, R2 = 
0.7940 and r = 0.7801, p=0.0131, R2 = 0.6085, respectively; Pearson correlation), indicating that 
longer plume durations were observed for increasing emitted mass values. Higher maximum 
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obscuration values (denser aerosol clouds) were observed for increasing emitted mass values as 
indicated by the strong negative correlations observed between emitted mass values and maximum 
obscuration values for the 5% v/v and 20% v/v ethanol in water formulations (r = -0.8441, 
p=0.0042, R2 = 0.7124 and r = -0.8955, p=0.0011, R2 = 0.8019, respectively; Pearson correlation).  
Observations of the duration of the steady state aerosol (obscuration values greater than 
20%, which was selected based on the lower obscuration values observed in profiles of the third 
actuation, Figure 4.7c) revealed that powders prepared with 20% v/v ethanol in water were 
significantly longer for all three actuations compared to powders prepared with 5% v/v ethanol in 
water concentration (1st: p=0.0042; 2nd: p=0.0137, 3rd: p=0.0137; Student’s t-test). Negative 
correlations were observed between emitted mass values and the duration of obscuration > 20% 
for the 5% v/v and 20% v/v ethanol in water formulations (r = -0.7531, p=0.0192, R2 = 0.5671 and 
r = -0.8289, p=0.0057, R2 = 0.6871, respectively; Pearson correlation), indicating that longer 
plume durations with obscuration values > 20% were observed for increasing emitted mass values. 
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Figure 4.7 Obscuration-time profiles for the (a) first actuation, (b) second actuation, and (c) third 
actuation replicate aerosol plumes from the modified containment unit DPI filled with 10 mg of 
leucine-Survanta-EEG powders dispersed with 3 mL volume of dispersion air, EtOH=ethanol. 
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The size distribution profiles plotted as mean volume fraction/µm are shown in Figure 4.8 
plotted on a log-linear scale. As observed with the emitted mass values, aerosol plume durations 
and obscuration parameters, the size distributions of the powders prepared with 20% v/v ethanol 
in water concentration showed less variability between the three actuations compared to powders 
prepared with 5% v/v ethanol in water. For both of the powders, a high aerosol submicrometer 
fraction was observed demonstrating the efficiency of the combination of the modified 
containment unit DPI and leucine-Survanta-EEG formulation to achieve a respirable aerosol with 
a very low dispersion air volume (3mL) suitable for both small animal administration and delivery 
to low body weight infants. 
 
 
Figure 4.8 Log-linear plots showing comparisons of mean volume fraction/µm distributions for 
each actuation of Survanta-EEG formulations prepared with 5% and 20% v/v ethanol in water 
concentrations; EtOH=ethanol. 
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Overall, the leucine powders prepared with 20% v/v ethanol in water were found to produce 
more consistent aerosols across the three actuations in regards to emitted mass values, aerosol 
plume durations, obscuration parameters and size distributions when compared to powders 
prepared with 5% v/v ethanol in water. Leucine has a higher solubility in water than in ethanol; 
the converse is true for phospholipids. Dispersions with higher ethanol concentration possibly 
allowed leucine to precipitate sooner in the drying process resulting in higher concentrations of 
the dispersion enhancer on the surface of the spray dried particles; therefore, resulting in less 
cohesive powders and consequently more consistent aerosols.  
4.3.5.4 Effect of ethanol concentration in feed dispersion on solid state powder 
characteristics 
The size and surface morphology of the spray dried powders was visualized using SEM. 
Leucine-Survanta-EEG powders prepared in the different feed dispersions are shown in Figure 
4.9. The powder morphology appeared similar and the size range was observed to be 
approximately 1 to 2 µm, as was expected according to the laser diffraction data. The samples 
were sputter coated 3 times to prevent sample degradation during analysis, which may have 
obscured the fine details on the surface of the particles. 
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Figure 4.9 SEM images of leucine-Survanta-EEG spray dried powder formulations prepared in 
(a) 5% v/v ethanol in water, and (b) 20% v/v ethanol in water feed dispersions. 
The total weight loss by heating was used to determine the moisture content in the spray 
dried powders. As expected, the spray dried powders were found to have low moisture contents of 
< 3% w/w (Figure 4.10a). Powders produced with a higher organic concentration were expected 
to have lower moisture content considering the preferential drying of organic solvents during the 
spray drying process. However, no significant differences were observed at the different ethanol 
(b)
(a)
  
 
128 
concentrations for the studied formulations with mean ± SD percent weight losses of 2.5 ± 0.7% 
and 2.2 ± 0.2%, respectively for the 5% v/v and 20% v/v ethanol in water feed dispersions.  
The Tg of the commercial Survanta® formulation was determined to be 37 °C (Figure 
4.10b). The observed transition temperature of the spray dried leucine-Survanta-EEG formulations 
of 34 to 36 °C is as expected since the formulation components mannitol and leucine tend to 
maintain their crystallized form when spray dried [95, 138], therefore would not contribute to a 
change in the Tg of the system. No recrystallization or melting transitions were observed in the 
spray dried powders over the range of 25 to 100 °C, however, a broad melting range between 50 
to 80 °C (above Tg) was observed in the commercial Survanta® formulation, which may indicate 
relaxing, or loss in chain order, of the acyl chains of the phospholipid structure.   
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Figure 4.10 Characteristic plots showing (a) thermogravimetric analyzer profiles with isothermal 
hold at 100 °C and (b) dynamic scanning calorimetry thermograms heated from 25 to 100 °C at a 
rate of 5 °C/min for spray dried leucine-Survanta-EEG formulations. 
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Tg = 37 °C
(a)
(b)
  
 
130 
4.4 Conclusions 
The objective of this study was to produce surfactant powders with leucine and trileucine 
(Specific aim 2-1) and study the effects of the dry powder dispersion enhancers on feed 
dispersions, powder characteristics, and primary particle size distributions (Specific aim 2-2). The 
aerosol performance of powders prepared with leucine using different feed dispersion alcohol 
concentrations were evaluated using a novel DPI designed to utilize 3 mL of dispersion air to 
deliver fine particle aerosols (Specific aim 2-3). Powders were engineered using the EEG 
application to produce submicrometer particles for high delivery efficiency to the lungs. Survanta® 
intratracheal suspension was the selected commercial surfactant formulation used in this study and 
mannitol was selected as the hygroscopic excipient included in addition to the sodium chloride 
present in the commercial suspension. 
Investigation of the two dispersion enhancers revealed that powders produced with leucine 
resulted in smaller primary particles, smaller spans, and higher fractions of submicrometer 
particles compared to powders prepared with trileucine at both ethanol concentrations studied. 
These findings can be attributed to the presence of other surface-active components in the 
formulation that compete for space at the air-liquid interface of droplets formed in the spray dryer 
resulting in a powder surface possibly more enriched with phospholipids rather than the dispersion 
enhancer resulting in powder dispersion characteristics that are difficult to predict. 
Aerosol performance of powders produced with leucine in the 20% v/v ethanol in water 
feed dispersion resulted in more consistent emitted mass values, size distributions, aerosol plume 
durations and obscuration parameters over three actuations that were less variable compared to 
leucine powders prepared in the 5% v/v ethanol in water feed dispersion. Leucine powders were 
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spray dried to a low moisture content of < 3% w/w with transition temperatures close to that of the 
commercial surfactant formulation.  
A potential issue with the methods employed in this research lies in the spray drying 
process. The inlet of the spray dryer was set to a temperature of 70 °C, which resulted in outlet 
temperatures of 37 to 41 °C. These outlet temperatures are approximately the same as the transition 
temperature of the produced powders, which may negatively impact powder formation and 
dispersibility of the resulting powders. Lower inlet temperatures of 40 to 60 °C (resulting outlet 
temperatures of 33 to 39 °C) were explored, but significantly lower powder yields of 30 to 40% 
were obtained. Other factors that largely influence the outlet temperature of the spray dryer are: 
(i) the spray rate intensity, increasing would decrease the outlet temperature; (ii) the drying gas 
flow rate, decreasing would decrease the outlet temperature; and (iii) the spray vehicle, higher 
water content results in lower outlet temperatures [94]. The spray rate intensity is influenced by 
the spray and pump percentage. For this research, the spray percentage was set to the highest 
manufacturer suggested rate of 80%, and the pump setting of 3% was selected to minimize 
dispersion bypass, so changing the pump setting would result in lower powder yield. With regards 
to the second factor, decreasing the drying gas flow rate would risk producing powders that are 
not fully dried.  Lastly, aqueous spray vehicles were studied in this research, with one consisting 
of 95% water, which does not offer much room for improvement. The inclusion of high transition 
temperature excipients may be worthwhile to revisit since preliminary work done in this area was 
with DPPC and not with the commercial surfactant formulation. 
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CHAPTER 5 
5 ASSESSMENT OF THE EFFECTS OF DESIGN MODIFICATIONS TO A LOW AIR 
VOLUME ACTUATED DRY POWDER INHALER ON AEROSOL 
PERFORMANCE CHARACTERISTICS 
5.1 Introduction 
The delivery of dry powder surfactant formulations during non-invasive ventilation offers 
a number of advantages over the current method of replacement surfactant delivery; in particular, 
it would avoid the need for invasive intubation and does not require the patient to be taken off 
ventilation to be treated.  
Effective powder aerosol delivery to the lungs is dependent on several factors including 
the powder formulation and device design. DPIs used to deliver powder formulations are 
categorized as either passive or active devices. Passive DPIs depend on patient inspiratory effort, 
while active DPIs provide an external energy source to aerosolize and deliver the powder, which 
reduces dependence on proper patient use. This characteristic of active DPIs make them useful in 
situations such as delivery to pediatric patients with low inhalation flow rates [144], inline during 
non-invasive ventilation [145], and for aerosol delivery to test animals [146].  
The previous chapter described the development of a novel pulmonary surfactant aerosol 
formulation as a spray dried powder using the excipient enhanced growth approach. Feasibility of 
dry powder surfactant administration must first be assessed for therapeutic efficacy and safety in 
small animal models. Efficient delivery of powder aerosols to small animals present unique 
challenges, such as how to produce efficient powder dispersion and delivery in animal models with 
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very small tidal volumes (0.2-0.3 mL for mice, 2-3 mL for rats [147-149]). Insufflation is a 
common method for the delivery of dry powder with the Dry Powder Insufflator™ DP-4 (Penn-
Century, Inc, Philadelphia, PA) being one of the most frequently used devices [150]. No longer 
commercially available, the DP-4-R was designed for use with rats in which a small amount of dry 
powder (1-5 mg) was manually filled into the device and the powder was dispersed using small 
“puffs” of air (2 mL) via an air-filled plastic syringe [151]. Initial studies using the DP-4-R device 
with spray dried surfactant formulations resulted in poor powder dispersion; therefore, it was found 
necessary to develop a novel device capable of efficiently aerosolizing and delivering powder 
surfactant-EEG formulations to animal models, as a highly challenging delivery scenario. This 
developed device should also be suitable and adaptable for use in delivering surfactant-EEG 
aerosols during non-invasive ventilation such as high flow nasal cannula therapy to very low birth 
weight infants. 
The aim of this research was to develop an optimal DPI that is capable of delivering 
surfactant-EEG formulations with high efficiency using a very low volume of dispersion air (3 
mL). High efficiency is determined by an emitted mass that is sufficient to theoretically elicit an 
effect in a rat surfactant depletion model. When delivered as an aerosol, as low as ~2 mg/kg of 
lipids has been shown to induce physiological changes in preterm lambs [83]. For the surfactant-
EEG formulation, delivery of 2-10 mg doses of spray dried powder will be required to assess 
therapeutic efficacy and safety in small animal models. This dose would ideally be delivered in 
the least number of actuations possible to minimize the amount of time the animal spends without 
assisted ventilation. 
 
 
  
 
 
134 
5.2 Materials and methods 
5.2.1 Spray dried powder formulations 
Surfactant-EEG spray dried powders were prepared as described in the previous chapter. 
Dispersions containing Survanta®, mannitol and leucine in a ratio of 45:33:22 % w/w in a 5% 
ethanol in water mixture with a solids concentration of 0.125% w/v were spray dried using the 
Büchi Nano Spray Dryer B-90 HP (Büchi Labortechnik AG, Flawil, Switzerland). Spray drying 
parameters were as follows: 70 °C inlet temperature (outlet temperatures of 37-41 °C), pump speed 
of 3%, spray intensity of 80%, and a gas inlet flow of 120 L/min (drying chamber pressure of 40-
42 mbar). Powders were collected from the electrostatic particle collector into vials and stored in 
a desiccator in a fridge (2-8 °C) when not in use. 
The primary particle size distribution of the spray dried surfactant-EEG powders was 
determined by laser diffraction using the Sympatec HELOS. A total of ten spray dried powder 
batches were used in this study. The powders were observed to be monodisperse with an overall 
mean ± SD Dv50 of 1.3 ± 0.07 µm and 1.0 ± 0.04 µm for 1.0 and 4.5 bar dispersion pressures, 
respectively. This resulted in coefficients of variation of < 6% across the ten batches, indicating 
good reproducibility of the spray drying process. The particle size distribution profiles at the 4.5 
bar dispersion pressure are shown in Figure 5.1. The span was determined to be 1.4 ± 0.1 at 4.5 
bar dispersion pressure with percent particle fractions of 50.1 ± 2.6% and 99.9 ± 0.3% for Dv<1 
µm and Dv<5 µm, respectively.  
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Figure 5.1 Particle size cumulative distribution (primary y-axis) and frequency distribution 
(secondary y-axis) of the spray dried surfactant-EEG powder batches determined using the 
Sympatec RODOS dispersion pressure of 4.5 bar. Markers represent the mean value, error bars 
represent the SD, n=10. 
5.2.2 Low dispersion air volume actuation dry powder inhalers 
A device developed to use a low dispersion  air volume to aerosolize dry powders was 
design by Farkas et al. [141]. The low air volume DPI (LV-DPI), developed to deliver powder 
aerosol with a dispersion air volume of 10 mL per actuation, consists of two halves that when 
assembled, pierces a size 0 capsule housed in the chamber of the device. The capsule is pierced by 
two hollow capillaries: 1) the inlet capillary with an internal diameter (ID) of 0.60 mm and 2) an 
outlet capillary with an ID of 0.89 mm. Dispersion air is introduced into the device using a 
disposable syringe via a standard luer lock connection to the inlet. Their single sided (SS) design 
(Figure 5.2), referring to the inlet and outlet capillaries configured on the same side of the capsule, 
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was observed to have a high emitted dose (84.8% of loaded dose) with a mass median aerodynamic 
diameter of 2.13 µm and a fine particle fraction less than 5 µm of the emitted dose of 89.3% [141].  
 
 
Figure 5.2 Axial cross-section of assembled single side device showing the inlet and outlet 
capillaries inside the capsule.  
For delivery of surfactant-EEG powder formulations using very low volume dispersion air, 
the lead LV-DPI design was initially modified with an extended length outlet delivery tube of 90 
mm when measured from the outer o-ring of the device (Figure 5.3a). The delivery tube was 
extended with the intention of developing a device for oral tracheal intubation of small animal 
models and the length was selected based on the delivery tube of the Penn Century Dry Powder 
Insufflator. A series of design modifications were then made in an effort to maximize aerosol 
performance – high emitted mass with good powder dispersion for the surfactant-EEG formulation 
with a dispersion air volume suitable for small animal administration.  
The first design modification made with the extended delivery tube device was removal of 
the capsule and replacement with an integral dose containment chamber into which the formulation 
was loaded. Initial studies investigated the effects of a reduction of the powder chamber volume 
in the dose containment unit. The volume was reduced from 0.68 mL to 0.21 mL (~30% of the 
air inlet
o-rings 0.89 mm outlet 
capillary
0.60 mm inlet
capillary
size 0
capsule
aerosol outlet
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original volume) to account for the chamber dead space that becomes a concern when decreasing 
the dispersion air volume from 10 mL to 3 mL (30% of the original volume). Incorporation of a 
dose containment unit eliminated the need of protruding inlet and outlet capillaries for capsule 
piercing, therefore the capillaries were retracted from the powder chamber as shown in Figure 
5.3b.  
The smaller powder chamber with non-protruding inlet and outlet capillaries was carried 
into the next design modification which focused on the airflow pathway in the dose containment 
unit. Instead of the near 180-degree turn in the airflow path of the SS design, a straight through 
(ST) airflow path configuration was explored. In this configuration, the airflow path travels in a 
single direction where the aerosol exits out the opposite end of the powder chamber from where 
the air enters (Figure 5.3c). Farkas et al. studied this design configuration with multiple inlet 
designs – using a size 0 capsule and 10 mL volume of dispersion air – and found that an inlet 
design with four-0.60 mm inlet capillaries (clustered together around the longitudinal axis of the 
capsule) resulted in the best aerosol performance with good dispersion (MMAD of 1.6 µm, fine 
particle fraction less than 5 µm of the emitted dose of 95.2%), but poorer emitted dose (61.9%) 
when compared to the SS design [152]. 
The next design change that was studied explored the number of air inlet holes. The 
previous designs consisted of one-0.60 mm air inlet hole; in an effort to reduce powder adherence 
on the walls of the powder chamber, an inlet with three-0.60 mm holes spaced equidistant along 
the longitudinal axis of the device was designed and tested with the reduced powder chamber 
volume device in the ST configuration (Figure 5.3d).  
Having extensively studied the delivery tube ID of 0.89 mm, delivery tube IDs smaller and 
larger (0.60 mm and 1.17 mm, respectively, Figure 5.3e) were studied to determine the effect of 
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delivery tube ID on aerosol performance of the surfactant-EEG powders. The device configuration 
resulting in the best aerosol performance was determined as that having the smallest Dv50 with 
the highest emitted mass on the first actuation.  
The final device design change explored different delivery tube lengths with the delivery 
tube internal diameter of 0.89 mm. All previous design changes were studied at the delivery tube 
length of 90 mm. The effect of delivery tube length on aerosol performance was studied for shorter 
delivery tube lengths – 55, 45, 30 and 7 mm – with the 55 mm tube length being the minimum 
length required for in vivo studies as dictated by the length of the catheter that would be used with 
the surfactant-depleted small animal models. 
All DPIs were constructed using rapid prototyping (Object24 printer, Stratasys Ltd., Eden 
Prairie, MN) with a rigid opaque photopolymer, VeroWhitePlus (RGD835). The outlet delivery 
tubes were custom cut from stainless steel (SAE 304) tubing and secured in place with water 
resistant epoxy.  
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Figure 5.3 Axial cross-section of assembled containment unit DPIs: (a) SS with 0.68 mL powder 
chamber, (b) SS with 0.21 mL powder chamber, (c) ST with 90 mm delivery tube. Open powder 
chamber view of studied air inlets (d) and delivery tube internal diameters (e); SS: single side, ST: 
straight through. 
5.2.3 Aerosol performance of modified containment unit DPIs 
The emitted mass and particle size of the aerosols exiting the modified containment unit 
DPIs were studied. As described in the previous chapter, the emitted mass was determined by 
gravimetric analysis and the particle size distribution of the aerosol exiting the device was 
determined by laser diffraction using a Malvern Spraytec® (Malvern Instruments, Ltd., 
Worcestershire, UK). Powder was weighed and manually filled into one half of the device 
containment unit (or capsule for the DPI depicted in Figure 5.3a). Once assembled, the device with 
powder was weighed to determine the pre-actuation weight. A 5 mL syringe was filled with room 
air to 3 mL and connected to the luer-lock inlet of the DPI. The device and syringe were mounted 
in a horizontal position on a fixed stand to ensure a consistent position at a distance 3 cm from the 
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laser light was maintained for replicate runs. The powders were deaggregated by manual 
compression of the syringe. The syringe was then disconnected from the device and the device 
was reweighed to determine the post-actuation weight. Particle size measurements were repeated 
for up to three actuations. The different parameters explored in this study are listed in Table 5.1. 
  
Table 5.1 Device design parameters explored for the modified containment unit DPI with 3 mL 
volume of dispersion air. 
Experiment 
Powder 
chamber 
volume, mL 
Device 
configuration 
Air 
inlet 
holes 
Delivery 
tube ID, 
mm 
Delivery 
tube length, 
mm 
Powder 
fill mass, 
mg 
1 0.68 SS 1 0.89 90 3 
2 0.21 SS 1 0.89 90 3 
3 0.21 ST 1 0.89 90 3 
4 0.21 ST 3 0.89 90 3, 5, 10 
5 0.21 ST 3 0.60 90 3 
6 0.21 ST 3 1.17 90 3 
7 0.21 ST 3 0.89 55 3, 5, 10 
8 0.21 ST 3 0.89 45 3, 5, 10 
9 0.21 ST 3 0.89 30 5 
10 0.21 ST 3 0.89 7 5 
SS = Single side, ST = Straight through, ID = internal diameter. 
 
 
5.2.4 Aerosol performance with micronized powder 
The aerosol performance of micronized albuterol sulfate with the ST device was studied to 
determine if powders prepared by a method other than spray drying could be dispersed and 
delivered with the modified containment unit DPI using 3 mL volumes of dispersion air. 
Micronized albuterol sulfate USP was purchased from Letco Medical, LLC (Decatur, AL). The 
micronized powder was first evaluated using the Sympatec HELOS with RODOS dispersion unit 
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to determine the particle size at two dispersion pressures. The particle size distribution profiles at 
the 4.5 bar dispersion pressure are shown in Figure 5.4. The micronized powder was observed to 
be larger in size, have a larger span and a smaller submicrometer particle fraction compared to the 
spray dried surfactant powders. The micronized powder had mean ± SD Dv50 of 1.7 ± 0.02 µm 
and 1.3 ± 0.05 µm for 1.0 and 4.5 bar dispersion pressures, respectively. The span was determined 
to be 1.9 ± 0.1 at the 4.5 bar dispersion pressure with percent particle fractions of 34.8 ± 1.4% and 
99.9 ± 1.0% for Dv<1 µm and Dv<5 µm, respectively. A powder fill mass of 10 mg was used 
when assessing aerosol performance. 
 
 
Figure 5.4 Particle size cumulative distribution (primary y-axis) and frequency distribution 
(secondary y-axis) of the micronized albuterol sulfate powder determined using the Sympatec 
RODOS dispersion pressure of 4.5 bar. Markers represent the mean value, error bars represent the 
SD, n=4. 
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5.2.5 Statistical analysis 
Data analysis was performed using JMP® Pro software version 12.0 (SAS Institute Inc., 
Cary, NC). Student’s t-statistic or one-way analysis of variance (ANOVA) followed by Dunnett’s 
method or Tukey’s HSD was performed to determine statistically significant differences in the 
data obtained. The Pearson correlation coefficient was determined to quantify the strength of linear 
relationships. P values less than 0.05 were considered as statistically significant. 
5.3 Results and discussion 
5.3.1 Effect of powder chamber volume, design configuration, and number of air inlet holes  
At a powder fill mass of 3 mg, the unmodified SS LV-DPI with the extended outlet 
capillary (90 mm delivery tube) was observed to have an emitted mass of 20.2 ± 3.6 % on the first 
3 mL actuation of air. After the third 3 mL actuation of air, a cumulative emitted mass of 43.6 ± 
4.4 % was observed (Table 5.2, Expt 1). In this first experiment with the delivery tube and powder 
chamber oriented horizontally, the low fill mass formed a shallow powder bed that resided below 
the outlet capillary resulting in powder losses under the outlet capillary and consequently low 
emitted mass values.  
Rotating the device so the delivery tube pointed vertically upwards showed no 
improvement in the emitted mass (18.7 ± 8.1 %) after the first 3 mL actuation of air. Changing the 
orientation of the DPI would affect the position of the formulation powder bed within the inhaler 
with the powder bed in the direct path of the inlet airflow, but in this case revealed that orientation 
had no effect on the dose emission likely due to the low volume of dispersion air into the larger 
powder chamber. 
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Reducing the powder chamber volume from 0.68 mL to 0.21 mL and removing inlet and 
outlet capillary protrusion in the powder chamber significantly doubled the percent emitted mass 
after one actuation (p=0.0048; Student’s t-test) and generated an aerosol with a mean ± SD Dv50 
of 2.5 ± 0.6 µm. Decreasing the powder chamber volume was expected to increase the emitted 
mass as the dead space in the original design was removed enabling the lower volume of dispersion 
air to empty the powder chamber more efficiently. In addition, removing the outlet capillary 
protrusion in the powder chamber eliminated the powder loss that was observed around the base 
of the capillary, therefore contributing to the higher observed emitted mass. The particle fraction 
less than 1 µm and 5 µm was 28.8 ± 3.8% and 60.1 ± 4.4%, respectively. After three 3 mL 
actuations, the cumulative emitted mass was 77.1% of the nominal fill mass (Table 5.2, Expt 2).  
The next design modification explored the design configuration in which the dispersion 
airflow path travels straight through the dose containment unit. In this case, rather than directing 
the dispersion air directly at the powder bed, the air flow is directed over the top of the powder. 
The simpler ST design significantly increased the emitted mass after the first actuation to 55.5% 
of the nominal fill mass compared to the SS design (40.4%, p=0.0109; Student’s t-test) without 
having a significant effect on the Dv50 (2.7 vs 2.5 µm, p=0.6016; Student’s t-test). Insignificant 
changes were observed in the fine particle fraction data, with a decrease in the submicrometer 
particle fraction (23.3%, p=0.0618; Student’s t-test) and an increase in the particle fraction <5 µm 
(62.5%, p=0.7163; Student’s t-test) compared to 28.8% and 60.1%, respectively for the SS design 
(Table 5.2, Expt 3 compared to Expt 2). The larger outlet diameter of 0.89 mm relative to the inlet 
diameter of 0.60 mm, caused a deceleration in the inlet airflow and an increase in secondary 
velocities in the containment unit. The secondary velocities generated from the difference in 
inlet/outlet diameters were responsible for aerosolization of the powder bed. The total mass 
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emitted following three 3 mL actuations with the ST design configuration was 83% of the nominal 
fill mass.  
The observed results imply that the inlet airflow path had a larger influence on the emitted 
mass than on powder dispersion. The SS design directed the inlet airflow path at the powder bed, 
which may have created turbulent forces that caused the aerosolized powder to impact on the walls 
of the containment unit, which resulted in a lower emitted mass. Since the ST design directed the 
inlet airflow path to travel in a single direction over the powder bed within the containment unit, 
it reduced the chance of creating turbulent forces, which resulted in more powder exiting the 
device.   
An inlet design with three-0.6 mm holes, spaced evenly apart, was also studied (Expt 4). 
The inlet was designed to have three jets of air make contact with the powder with the intention of 
reducing the amount of powder remaining in the containment unit after actuation. Incorporation of 
three air inlet holes in the ST design significantly increased the emitted mass to 70.9% from 55.5% 
of the nominal fill mass (p=0.0040; Student’s t-test) while the Dv50 remained unaffected at 2.7 
µm. The total cross-sectional area of the inlet (1.8 mm) was greater than the single outlet diameter 
of 0.89 mm, providing an inlet jet that enabled better emptying of the dose containment unit. An 
insignificant increase in the submicrometer particle fraction to 26.8% (p=0.1437; Student’s t-test) 
and insignificant decrease in the particle fraction <5 µm to 57.5% (p=0.4587; Student’s t-test) was 
observed. The total emitted mass after the third 3 mL actuation was 92% (Table 5.2, Expt 4). Given 
the significant increase in emitted mass without an observed change in the Dv50 value, the three 
air inlet hole design with ST device configuration was explored further. 
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Table 5.2 Effect of powder chamber volume, design configuration, number of air inlet holes, and delivery tube internal diameter on 
aerosol performance of surfactant-EEG spray dried powders (fill mass: 3 mg, values are mean (SD), n≥3). 
Expt 
Powder 
chamber 
volume, 
mL 
Device 
config 
Air 
inlet 
holes 
Delivery 
tube ID, 
mm† 
1st actuation Cumulative 
mass emitted on 
3rd actuation, 
% nominal 
mass 
Mass 
emitted, 
mg 
Mass 
emitted, 
% nominal 
mass 
Dv50, 
µm 
Particle fraction, % 
<1 µm <5 µm 
1 0.68 SS 1 0.89 0.62 (0.12) 20.2 (3.6) . . . 43.6 (4.4) 
2 0.21 SS 1 0.89 1.23 (0.22)* 40.4 (7.5)* 2.5 (0.6) 28.8 (3.8) 60.1 (4.4) 77.1 (13.7) 
3 0.21 ST 1 0.89 1.67 (0.16)‡ 55.5 (5.7)‡ 2.7 (0.6) 23.3 (3.4) 62.5 (10.5) 83.1 (7.9) 
4 0.21 ST 3 0.89 2.12 (0.12)# 70.9 (3.7)# 2.7 (0.2) 26.9 (2.1) 57.5 (2.6) 92.4 (1.9) 
5 0.21 ST 3 0.60 1.05 (0.03)^ 33.9 (0.3)^ 1.7 (0.1)^ 32.6 (0.2)^ 73.5 (5.7)^ 70.8 (2.6) 
6 0.21 ST 3 1.17 2.26 (0.13) 74.2 (4.7) 6.8 (0.1)^ 12.0 (1.1)^ 44.7 (0.7)^ 98.2 (3.6) 
*Significant difference compared to 0.68 mL powder chamber volume; Student’s t-test, p<0.05 
‡Significant difference compared to SS device configuration; Student’s t-test, p<0.05 
#Significant difference compared to one-0.60 mm air inlet hole; Student’s t-test, p<0.05 
†Statistically significant effect of delivery tube internal diameter comparing expts 4-6; one-way ANOVA, p<0.05 
^Significant difference compared to 0.89 mm delivery tube internal diameter; Dunnett’s method, p<0.05 
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5.3.2 Effect of outlet delivery tube internal diameter on aerosol performance 
To determine the effect of the internal diameter (ID) of the outlet delivery tube on the 
aerosol performance of the best performing containment unit DPI (Expt 4), additional devices of 
the ST design were manufactured with internal diameters of 0.60 mm and 1.17 mm. Table 5.2 
(Expt 4, 5, 6) summarizes the emitted mass data (after one actuation, cumulative mass after three 
actuations) and particle size data (aerosol Dv50, particle fractions <1 µm and <5 µm) for the 
different devices.  
The 0.89 mm ID device was shown to be a good compromise between device emptying 
and aerosol performance in regard to particle size characteristics (Expt 4). One-way ANOVA 
revealed significant differences in the emitted mass and particle size data of the different ID 
devices (p<.0001). Using Dunnett’s method for post-hoc analysis, the 0.60 mm ID device was 
observed to empty significantly less powder on the first actuation compared to the 0.89 mm ID 
device (33.9 vs 70.7% of the nominal fill mass, p<.0001). During testing, powder was noticeably 
clumped at the outlet hole of the 0.60 mm ID device partially blocking the exit resulting in the 
poor emptying. No difference was seen in the percent mass emitted for the 1.17 mm ID device 
compared to the 0.89 mm ID device.  
The aerosol Dv50 values were observed to increase with increasing ID, which 
corresponded to decreasing submicrometer particle fraction values. The mean Dv50 value for the 
0.89 mm ID device was 2.7 µm, significantly larger than the Dv50 of 1.7 µm for the 0.60 mm ID 
device (p<.0001) and significantly smaller in size than 6.8 µm for the 1.17 mm ID device 
(p=0.0032). For all three outlet delivery tube devices, the total cross-sectional area of the inlet (1.8 
mm) was greater than the diameter of the outlet (0.60, 0.89 or 1.17 mm), indicating that the 
hydrodynamic force needed to deaggregate that powder was in the form of an inlet jet. The outlet 
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diameter of 0.60 mm had the highest pressure at the outlet and consequently had more dispersed 
powders but resulted in poor emptying. The delivery tube with a larger ID of 1.17 mm had the 
lowest pressure at the outlet of the three IDs studied and therefore had the poorest dispersion. The 
submicrometer particle fraction for the 0.89 mm ID device was 26.8%, which was found to be 
significantly lower compared to the 0.60 mm ID device (p=0.0036), but significantly higher than 
that of the 1.17 mm ID device (p<.0001). 
Pearson correlation coefficients were determined to assess the relationship of outlet 
delivery tube ID with aerosol performance characteristics. The correlation statistics are listed in 
Table 5.3. All correlations studied had strong significant relationships with the delivery tube ID; 
the absolute value of correlation coefficients for all relationships were > 0.85 with p-values <0.05. 
The mass emitted in the first actuation and the cumulative mass emitted on the third actuation were 
found to have positive correlations with the outlet delivery tube ID; higher emitted fractions with 
larger outlet delivery tube internal diameters. A positive correlation was observed between the 
Dv50 values with the outlet delivery tube ID, increasing outlet delivery tube ID resulted in larger 
Dv50 values. The particle fractions <1 µm and <5 µm were found to have strong negative 
correlations with the outlet delivery tube ID, increasing outlet delivery tube ID resulted in 
decreasing particle fraction values. The design modifications investigated revealed that the ST 
device with a three air inlet hole design and a 0.89 mm ID outlet delivery tube offered the optimum 
performance in terms of delivered dose and aerosol performance and was used for further studies 
described below. 
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Table 5.3 Correlation statistics of outlet delivery tube internal diameter with aerosol performance 
characteristics. 
Characteristic 
Correlation 
coefficient, 
r 
Significance, 
p-value 
Coefficient of 
determination, 
R2 
Mass emitted on 1st actuation 0.8622 0.0028* 0.7434 
Dv50 values 0.9369 0.0002* 0.8777 
Particle fraction <1 µm -0.9576 <.0001* 0.9170 
Particle fraction <5 µm -0.9654 <.0001* 0.9320 
Cumulative mass emitted on 3rd actuation 0.9353 0.0002* 0.8747 
*Significant; Pearson correlation, p<0.05 
 
 
5.3.3 Effect of outlet delivery tube length and fill mass on powder performance 
Three outlet delivery tube lengths (90, 55 and 45 mm lengths) were studied. The volume 
of the delivery tubes were determined to be 0.056, 0.034 and 0.028 mL for the 90, 55, and 45 mm 
tube lengths, respectively. Time durations for manual compression of the syringe was determined 
using a Photron PCI R2 high-speed camera to capture images at 1000 frames per second with 
Photron FASTCAM Viewer software to analyze the images. The 90 mm delivery tube length 
device was observed to take 0.14 ± 0.00 s to deliver 3 mL of actuation air, while both the 55 mm 
and 45 mm delivery tube lengths were observed to take 0.12 ± 0.01 s to deliver 3 mL of actuation 
air. This resulted in a short burst of 1.3 L/min for the 90 mm delivery tube length device and 1.6 
L/min for the two shorter delivery tube length devices. The slower flow rate observed for the 
longest delivery tube length device was expected considering the larger internal volume of this 
device compared to the two shorter delivery tube devices (total volume for 90 mm delivery tube 
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length device 0.27 mL compared to 0.25 mL and 0.24 mL for 55 mm and 45 mm delivery tube 
length devices, respectively).  
The effect of delivery tube length on aerosol performance was studied at three powder fill 
masses: 3, 5 and 10 mg in the best performing containment unit DPI as described previously. The 
data are shown in Table 5.4. Overall, it was observed that increasing the fill mass of the surfactant-
EEG formulation increased the delivered powder mass from the modified containment unit DPI 
using each of the three delivery tube lengths on the first actuation and after 3 actuations. The 
highest percent emitted masses (expressed as % nominal mass) following the first actuation were 
observed at the lowest fill mass of 3 mg for each of the delivery tube lengths (> 66% of nominal). 
The cumulative mass emitted was ≥ 77% of the nominal fill mass after 3 actuations for all runs. 
The mean ± SD total mass emitted after 3 actuations for the 90 mm delivery tube length at 3, 5 and 
10 mg fill masses were 2.77 ± 0.05, 4.77 ± 0.13 and 8.63 ± 0.23 mg, respectively. Similar values 
for the 55 mm delivery tube were 2.76 ± 0.16, 4.39 ± 0.10 and 9.08 ± 0.22 mg and the 45 mm 
delivery tube were 2.69 ± 0.13, 3.89 ± 0.04 and 8.05 ± 0.57 mg. 
Considering the emitted mass for the 90 mm delivery tube device, one-way ANOVA 
determined that fill mass had a significant effect on the percent emitted mass on the first actuation 
(p=0.0036). Tukey’s HSD determined that at the 3 mg fill mass, the percent mass emitted after the 
first actuation was significantly higher than at the 5 mg (p=0.0120) and 10 mg fill masses 
(p=0.0038), but the two higher fill masses were not significantly different (p=0.5194). After three 
actuations, there was a significant effect of fill mass on the cumulative mass emitted (p=0.0130; 
one-way ANOVA). The total percent mass emitted at the 3 and 5 mg fill masses were significantly 
higher than the 10 mg fill mass (p=0.0457 and p=0.0125; Tukey’s HSD, respectively), but the two 
lower fill masses were not significantly different (p=0.5365; Tukey’s HSD). 
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Powder dispersion efficiency during the first actuation was independent of fill mass for the 
90 mm delivery tube when considering the volume median diameter with an aerosol Dv50 of 2.7 
µm for each of the three fill masses. There was a significant effect of fill mass on the particle 
fractions <1 µm and <5 µm (p=0.0281 and p=0.0168; one-way ANOVA, respectively) for the first 
actuation. The submicrometer particle fraction at the 5 mg fill mass was significantly higher than 
at the 10 mg fill mass (29.3% vs 24.6%, p=0.0233; Tukey’s HSD), whereas the particle fraction 
<5 µm at the 10 mg fill mass was significantly higher than at the 5 mg fill mass (61.8% vs 55.0%, 
p=0.0145; Tukey’s HSD). Correlations of powder dispersion characteristics with fill mass were 
determined for the 90 mm delivery tube after the first actuation (Table 5.5), which confirmed that 
dispersion efficiency was independent of fill mass as poor correlation coefficients were observed 
with the Dv50 and submicrometer particle fractions. The particle fraction <5 µm had a correlation 
coefficient of 0.68 with p-value of 0.042.  
For the 55 mm delivery tube device, the powder fill mass had a significant effect on the 
percent emitted mass after the first actuation, the Dv50, and the submicrometer particle fraction 
(p=0.0027, p=0.0272, and p=0.0151; one-way ANOVA, respectively). The 3 mg fill mass resulted 
in significantly higher percent emitted mass than the 5 mg and 10 mg fill masses (p=0.0022 and 
p=0.0447; Tukey’s HSD, respectively) after the first actuation. The 10 mg fill mass resulted in an 
aerosol Dv50 value of 4.5 µm, which was significantly larger than the Dv50 of 3.0 µm observed 
with the 3 mg fill mass (p=0.0331; Tukey’s HSD) after the first actuation. The submicrometer 
particle fraction at the 3 mg and 5 mg fill masses were significantly higher than that of the 10 mg 
powder fill mass (p=0.0349 and p=0.0173; Tukey’s HSD, respectively).   
Significant Pearson correlation coefficients indicated that powder dispersion on the first 
actuation was dependent on fill mass with the 55 mm delivery tube. Aerosol Dv50 values showed 
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a strong positive relationship with powder fill mass; increasing fill mass resulted in increased Dv50 
values (increasingly poor dispersion) with the first actuation. The particle fractions <1 µm and <5 
µm were observed to have strong negative correlations with powder fill mass; increasing fill mass 
resulted in decreased particle fraction values.  
With the shortest delivery tube of 45 mm, the fill mass had a significant effect on all 
parameters studied (the percent emitted mass after the first actuation, the cumulative mass emitted 
after the third actuation, and the powder dispersion characteristics). There was a significant effect 
on the percent emitted mass after the first actuation (p=0.0365; one-way ANOVA) with the 3 mg 
fill mass having a significantly higher emitted mass than the 10 mg fill mass (p=0.0403; Tukey’s 
HSD). The cumulative mass emitted after the third actuation was significantly affected by fill mass 
(p=0.0306; one-way ANOVA) with the 3 mg fill mass having a higher emitted mass than the 5 mg 
fill mass (p=0.0290; Tukey’s HSD). 
For powder dispersion characteristics, the Dv50 values for the first actuation were 
significantly affected by fill mass (p=0.0015; one-way ANOVA) with the 3 mg fill mass being 
significantly smaller than the Dv50 values at the 5 and 10 mg fill masses (p=0.0013 and p=0.0079; 
Tukey’s HSD, respectively). Fill mass had a significant effect on the submicrometer particle 
fraction for the first actuation (p=0.0214; one-way ANOVA) with the 3 mg fill mass having a 
significantly higher submicrometer fraction than the 10 mg fill mass (p=0.0218; Tukey’s HSD). 
For the particle fraction <5 µm, there was a significant effect of fill mass (p=0.0186; one-way 
ANOVA) with the 3 mg fill mass having a significantly higher particle fraction that the 5 and 10 
mg fill masses (p=0.0202 and p=0.0466; Tukey’s HSD, respectively).  
Correlation analysis of the powder characteristics at the 45 mm delivery tube length found 
significant relationships of Dv50, the particle fraction <1 µm and <5 µm with fill mass (Table 5.5) 
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for the first actuation. Dv50 was found to be positively correlated with fill mass; increased fill 
mass resulted in increased Dv50 values. As with the 55 mm delivery tube length, the particle 
fractions <1 µm and <5 µm for the 45 mm delivery tube length for the first actuation were observed 
to have strong negative correlations with fill mass; increasing fill mass resulted in decreased 
particle fraction values.   
For the three delivery tube length devices studied, particle deaggregation was expected to 
be from an inlet jet as the cross-sectional area of the inlet (1.8 mm) was greater than the diameter 
of the outlet (0.89 mm). At the low fill mass of 3 mg, the powder bed was likely outside of the 
direct inlet airflow path, which enabled good emptying for all three delivery tube lengths. 
However, at the higher fill masses of 5 mg and 10 mg, it is likely that the powder bed was in the 
direct inlet airflow path, possibly creating turbulent flows and causing powder to impact on the 
walls of the containment unit, which resulted in the observed poorer emptying compared to the 
lower fill mass of 3 mg (Table 5.4). Powder dispersion was independent of device configuration 
at the low fill mass of 3 mg; the Dv50 values for all three delivery tube length devices were 2.7 
µm. However, at the higher fill masses of 5 and 10 mg, the volume of the delivery tube likely 
played a role in dispersion of the powders, with the larger volume of the 90 mm delivery tube 
length device providing better dispersion of the powders compared to the 55 mm and 45 mm 
delivery tube length devices. The longer length and therefore larger volume of the 90 mm delivery 
tube length device allowed the particles to interact with more surfaces that may have enabled better 
deaggregation.  
When comparing the three delivery tube lengths at the 10 mg fill mass, the 55 mm delivery 
tube had the highest emitted mass (although not significantly) on the first actuation at 63.8% 
compared to that for the 90 and 45 mm delivery tube devices (52.3 and 54.7%, respectively). With 
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a lipid concentration of ~27% in the powder formulation, the 55 mm delivery tube device was able 
to deliver 1.7 mg of lipids in the first actuation, nearly 3 times the theoretical minimum of 0.60 mg 
of lipids needed to elicit a physiological change in a 300 g surfactant depleted rodent model. The 
aerosol Dv50 and submicrometer particle fraction for the first actuation were determined to be 4.5 
µm and 19.5%, respectively (Table 5.4). For the 90 mm delivery tube device, 1.4 mg of lipids was 
delivered in the first actuation, which is more than double the theoretical minimum expected to 
elicit an effect. While the shorter length device emitted more powder in the one actuation, the 
smaller aerosol Dv50 of 2.7 µm and higher submicrometer particle fraction of 24.6%, compared 
to the 55 mm delivery tube device, makes the longer delivery tube device a better candidate for 
delivery of dry powder surfactant aerosols to surfactant depleted rodent models. 
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Table 5.4 Effect of delivery tube length and fill mass on aerosol performance of surfactant-EEG spray dried powders. Values are mean 
(SD), n=3. 
Delivery 
tube length, 
mm 
Fill mass, 
mg‡ 
1st actuation Cumulative mass 
emitted after 3 
actuations,              
% nominal mass 
Mass emitted, 
mg 
Mass emitted, 
% nominal mass 
Dv50, 
µm 
Particle fraction, % 
<1 µm <5 µm 
90 3 2.12 (0.12) 70.9 (3.7)*# 2.7 (0.4) 26.9 (2.1) 57.5 (2.6) 92.4 (1.9)# 
90 5 2.83 (0.19) 56.2 (4.4) 2.7 (0.2) 29.3 (1.2)# 55.0 (0.7)# 94.8 (3.1)# 
90 10 5.28 (0.43) 52.3 (4.4) 2.7 (0.2) 24.6 (1.2) 61.8 (2.2) 85.4 (3.0) 
        
55 3 2.15 (0.09) 73.6 (3.5)*# 3.0 (0.3)# 23.7 (1.6)# 57.1 (2.2) 94.5 (6.0) 
55 5 2.73 (0.23) 54.9 (4.2) 3.2 (0.3) 24.5 (1.8)# 54.7 (1.1) 87.8 (2.7) 
55 10 6.42 (0.37) 63.8 (3.6) 4.5 (0.8) 19.6 (1.1) 51.7 (2.6) 90.3 (2.2) 
        
45 3 2.03 (0.15) 66.8 (4.4)# 2.7 (0.6)*# 21.4 (4.3)# 65.3 (13.5)*# 88.3 (3.5)* 
45 5 2.88 (0.13) 56.7 (2.5) 7.2 (1.8) 15.2 (1.3) 44.5 (3.7) 76.5 (0.8) 
45 10 5.51 (0.61) 54.7 (6.2) 9.1 (0.7) 13.4 (0.2) 39.8 (1.4) 79.8 (6.1) 
‡Statistically significant effect of fill mass; one-way ANOVA, p<0.05. 
*Significant difference compared to 5 mg fill mass for the same delivery tube device; Tukey’s HSD, p<0.05. 
#Significant difference compared to 10 mg fill mass for the same delivery tube device; Tukey’s HSD, p<0.05. 
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Table 5.5 Correlation statistics of powder fill mass with powder dispersion characteristics for the 
three delivery tube lengths during the first actuation. 
Delivery 
tube length, 
mm Characteristic 
Correlation 
coefficient, 
r 
Significance, 
p-value 
Coefficient of 
determination, 
R2 
90 Dv50 values -0.0286 0.9481 0.0008 
90 Particle fraction <1 µm -0.5701 0.1090 0.3250 
90 Particle fraction <5 µm 0.6843 0.0420* 0.4682 
     
55 Dv50 values 0.8228 0.0065* 0.6770 
55 Particle fraction <1 µm -0.7914 0.0111* 0.6263 
55 Particle fraction <5 µm -0.7784 0.0135* 0.6059 
     
45 Dv50 values 0.8371 0.0049* 0.7007 
45 Particle fraction <1 µm -0.7257 0.0269* 0.5266 
45 Particle fraction <5 µm -0.7115 0.0316* 0.5063 
*Significant; Pearson correlation, p<0.05 
 
A plot depicting the cumulative percent mass emitted after each actuation for each fill mass 
and delivery tube length is shown in Figure 5.5. Overall, the different delivery tube lengths 
demonstrated good powder emptying with >74% and ≥77% emitted after the second and third 
actuations of 3 mL of dispersion air, respectively. For all three fill masses, the cumulative mass 
emitted was lowest for the 45 mm delivery tube length. 
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Figure 5.5 Cumulative mass emitted (% nominal) for each actuation by delivery tube length and 
fill mass. Markers represent the mean value, error bars represent the SD, n=3. 
5.3.4 Aerosol plume characteristics 
The use of laser diffraction allowed for real time measurement of aerosol plumes exiting 
the modified containment unit DPIs. The aerosol plume characteristics of the first actuation were 
studied for the three delivery tube lengths at the different fill masses (Table 5.6).  
The light obscuration values were determined by subtracting the average % transmission 
values from 100 for each measurement time point for the powder lots evaluated. The obscuration 
values were plotted to study the time course of the aerosol plumes during the first spray actuation 
(Figure 5.6). All profiles appeared to have an initial increase in obscuration, a steady state with 
relatively stable obscuration values followed by a decline in the obscuration values.  
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Table 5.6 Aerosol plume characteristics of the first actuation of surfactant-EEG spray dried powders delivered with the optimized 
containment unit DPI. Values are mean (SD), n=3. 
Delivery tube 
length, 
mm 
Fill mass, 
mg 
Mass emitted, 
mg 
Aerosol plume 
duration, 
ms 
Maximum 
obscuration, 
% 
Obscuration >20% 
Duration, 
ms 
% Aerosol plume 
duration 
90 3 2.12 (0.12) 53.6 (5.8) 47.8 (4.5) 44.3 (3.9) 82.9 (5.1) 
90 5 2.83 (0.19) 63.1 (6.0) 57.4 (3.4) 47.3 (3.1) 75.4 (7.4) 
90 10 5.28 (0.43) 84.2 (11.6) 79.2 (5.2) 65.5 (4.1) 78.2 (5.9) 
       
55 3 2.15 (0.09) 53.1 (4.9) 46.2 (0.9) 42.0 (2.4) 79.4 (5.0) 
55 5 2.73 (0.23) 63.6 (3.4) 72.5 (2.2) 50.6 (3.1) 79.6 (1.7) 
55 10 6.42 (0.37) 90.4 (12.7) 91.6 (0.9) 61.1 (0.5) 68.4 (9.6) 
       
45 3 2.03 (0.15) 51.1 (5.7) 63.7 (6.6) 40.7 (7.0) 79.5 (5.5) 
45 5 2.88 (0.13) 72.0 (10.0) 86.0 (1.5) 51.1 (4.0) 71.8 (10.2) 
45 10 5.51 (0.61) 108.7 (6.6) 94.7 (1.2) 84.5 (9.5) 77.6 (4.3) 
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With increasing fill mass, the aerosol plume profiles of the first actuation were observed to 
develop more distinguishable steady state aerosols. Aerosol plume duration increased with 
increasing fill mass for each delivery tube length. Of the three delivery tube lengths, the 90 mm 
length was observed to have the least variability in aerosol plume duration across fill masses (65 
± 14 ms) compared to the 55 mm and 45 mm delivery tube lengths (69 ± 18 ms and 77 ± 26 ms, 
respectively), further indicating that powder dispersion during the first actuation is independent of 
fill mass at the longer length.  
The maximum obscuration was determined by finding the peak obscuration value for each 
aerosol plume. At each delivery tube length, it was observed that there is an increase in the percent 
maximum obscuration indicating progressively denser aerosol plumes with increased fill mass for 
the first actuation. The relative steady state portion of the profiles was studied by determining the 
duration above 20% obscuration. For each delivery tube length, an increase in the aerosol time 
with obscuration values >20% was observed with increasing fill mass during the first actuation. 
The obscuration >20% as a percent of the total aerosol plume duration for each replicate was 
determined to normalize the data for comparison across fill masses and delivery tube lengths. 
There were no significant differences observed across fill masses and delivery tube lengths, during 
the first actuation indicating that the duration of the steady state portion of the aerosol plume is a 
function of the total aerosol plume duration.  
At the 3 mg fill mass, the aerosol plume duration for the first actuation is comparable across 
the three delivery tube lengths with similar maximum obscuration values for the 90 mm and 55 
mm delivery tube devices. The 45 mm delivery tube device had a significantly denser aerosol 
plume indicated by the maximum obscuration value of 64% compared to the 55 mm and 90 mm 
delivery tube lengths (p=0.0087 and p=0.0134; Tukey’s HSD, respectively) despite having a 
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similar mass emitted on the first actuation (Table 5.4). Increasing the fill mass to 5 mg, the aerosol 
durations remained comparable for the 90 mm and 55 mm delivery tube lengths, but the 45 mm 
delivery tube length was higher at 72 ms, although not significantly. The maximum obscuration 
was significantly affected by delivery tube length (p<.0001; one-way ANOVA) with significant 
differences between all pairs (p<0.05; Tukey’s HSD). At the 10 mg fill mass, the aerosol plumes 
generated from the 45 mm delivery tube length appeared to be longer in duration and reach higher 
obscuration values, indicating denser aerosol clouds than those produced from the 55 mm and 90 
mm delivery tube lengths (Figure 5.6).   
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Figure 5.6 Replicate obscuration-time profiles for different fill masses of surfactant-EEG powder 
studied with the (a) 90 mm (b) 55 mm, and (c) 45 mm delivery tube lengths of the optimized 
containment unit DPI on the first 3 mL actuation of dispersion air, n=3. 
  
 
  
 
 
161 
The aerosol performance of the optimized containment unit DPI with delivery tube lengths 
of 30 mm and 7 mm were also tested at the 5 mg fill mass (Table 5.7). Pearson correlation 
coefficients were determined to assess the strength of the relationships between the delivery tube 
length and the powder dispersion characteristics for the aerosol plume emitted during the first 
actuation (Dv50 and the particle fractions less than 1 µm and 5 µm). A strong negative correlation 
was observed where longer delivery tube lengths resulted in smaller Dv50 values (r = -0.8777, 
p<.0001) with the following relationship,  
 
Dv50, µm = 15.48 – 0.1604*delivery tube length, mm                         Equation 5.1 
with a coefficient of determination of R2 = 0.7706. A strong positive correlation was observed 
where the particle fraction less than 1 µm was found to increase with increasing delivery tube 
length (r = 0.9290, p<.0001) with the following relationship, 
 
Particle fraction <1 µm, % = 7.861 + 0.2410*delivery tube length, mm                   Equation 5.2 
with a R2 = 0.8631. A strong positive correlation was also observed between the particle fraction 
less than 5 µm and the delivery tube length (r = 0.8868, p<.0001), 
 
Particle fraction <5 µm, % = 26.98 + 0.3547*delivery tube length, mm                   Equation 5.3 
with a R2 = 0.7863. The scatterplot correlations are shown in Figure 5.7.  
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Table 5.7 Effect of delivery tube length on aerosol performance of surfactant-EEG spray dried 
powders (fill mass: 5 mg, values are mean (SD), n=3). 
Delivery 
tube 
length, 
mm 
1st actuation Cumulative 
mass emitted 
on 3rd 
actuation, 
% nominal 
Mass 
emitted, 
mg 
Mass emitted, 
% nominal 
mass 
Dv50, 
µm 
Particle fraction, % 
<1 µm <5 µm 
30 2.73 (0.04) 54.1 (0.6) 13.5 (1.7) 14.8 (3.1) 32.1 (2.5) 72.4 (3.7) 
7 3.46 (0.30) 68.1 (6.4) 14.3 (1.0) 10.2 (0.7) 29.2 (1.0) 88.0 (5.7) 
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(a)   
(b)   
(c)   
Figure 5.7 Correlation of delivery tube length of the optimized containment unit DPI with a) Dv50, 
b) particle fraction <1 µm, and c) particle fraction <5 µm of surfactant-EEG powders on the first 
3 mL actuation of air with 5 mg powder fill mass. Markers represent individual values.
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5.3.5 Aerosol performance with micronized powder 
A fill mass of 10 mg was used to determine the aerosol performance of the micronized 
albuterol sulfate with the 90 mm and 55 mm delivery tube length devices. The data are shown in 
Table 5.8. The optimized containment unit DPI was shown to deliver > 70% of the nominal fill 
mass on the first actuation for both delivery tube lengths. This resulted in Dv50 values of 5.8 and 
5.3 µm for the 90 and 55 mm delivery tube lengths, respectively. The larger Dv50 values and lower 
submicrometer particle fraction values for the micronized powder compared to the spray dried 
powder was expected as the primary particle size distributions were larger for the micronized 
powder (Figure 5.4 vs Figure 5.1). 
 
Table 5.8 Aerosol performance of micronized albuterol sulfate powder with the optimized 
containment unit DPI (fill mass: 10 mg, values are mean (SD), n≥3). 
Delivery 
tube 
length, 
mm 
1st actuation Cumulative 
mass emitted 
on 3rd 
actuation, 
% nominal 
mass 
Mass 
emitted, 
mg 
Mass emitted, 
% nominal 
mass 
Dv50, 
µm 
Particle fraction, % 
<1 µm <5 µm 
90 7.22 (0.36) 72.8 (3.1) 5.8 (1.8) 13.2 (2.0) 48.6 (7.4) 94.4 (0.5) 
55 7.35 (0.35) 72.5 (3.0) 5.3 (1.8) 9.4 (3.0) 51.8 (9.3) 90.3 (2.2) 
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5.4 Conclusions 
The objective of this study was to develop an optimized dry powder inhaler for the delivery 
of spray dried surfactant powders by determining the influence of a series of design modifications 
and powder fill mass on aerosol performance (Specific aims 3-1 and 3-2). The inhaler was required 
to disperse relatively high powder masses (3-10 mg) with very low volumes of dispersion air for 
applications of delivering drugs as aerosols to small rodent animal models and being suitable for 
delivery of aerosols to low birth weight infants. Challenges to the design optimization included (i) 
being restricted to a low dispersion air volume (~3 mL), and (ii) a preference of delivering the dose 
in one actuation. The low volume of dispersion air was restricted by the low tidal volume of the 
selected animal model. Delivering the dose in one actuation was preferred to minimize the time 
that the animal spent off the ventilator following lung lavage and surfactant administration. The 
aim was to develop a device that was capable of delivering ≥ 2 mg/kg of lipids in one 3 mL 
actuation of air. For the surfactant-EEG formulation, this translates to approximately 2.2 mg of 
spray dried powder for a 300 g rodent. Design modifications made to an active DPI prototype 
enabled delivery of > 2 mg of spray dried powder using one 3 mL actuation of dispersion air with 
3-10 mg powder fill masses.  
Studying the effects of delivery tube length and fill mass on aerosol performance revealed 
an optimal device with powder dispersion characteristics independent of fill mass (3-10 mg) with 
good powder emptying in one actuation. With a powder fill mass of 10 mg, the lead design was 
able to deliver 5.3 mg of surfactant powder with an aerosol Dv50 of 2.7 µm in a single 3 mL 
actuation of dispersion air.  
The device developed in this research can be adapted for use in the treatment of infants on 
non-invasive ventilation. A low volume of air, as is used to disperse the powder formulations in 
  
 
 
166 
the optimized containment unit DPI, is vital when dealing with preterm infants with tidal volumes 
as low as 4 mL/kg [81]. The optimized containment unit DPI was also shown to perform well with 
micronized drug (7.2 mg emitted from 10 mg fill mass with aerosol Dv50 of 5.8 µm), indicating 
that the device has potential for use in other applications. 
A possible issue with the optimized containment unit DPI is the difficulty in controlling 
the density of the aerosol plume exiting the device. Too dense of a cloud has the potential of 
impacting along the trachea and bronchi of the rodent airways (or delivery tubing in the case of 
treatment to infants on non-invasive ventilation) decreasing the amount of aerosol available to 
reach the alveoli of the lung. The aerosol cloud was noticeably less dense at lower fill masses as 
indicated by the obscuration profiles presented in Figure 5.7, which could be a method to explore 
in order to control the aerosol cloud exiting the device. 
  
 
 
167 
CHAPTER 6  
6 EVALUATION OF THE IN VITRO AEROSOL DELIVERY EFFICIENCY OF 
SURFACTANT-EEG FORMULATIONS USING NOVEL LOW-VOLUME MIXER-
HEATERS 
6.1 Introduction 
Viral bronchiolitis, a common cause of lower respiratory tract infection in infants, is 
characterized by wheezing and mucus plugging, often leading to airway obstruction [45, 153]. 
Conventional treatments include supplemental oxygen and respiratory support. The administration 
of bronchodilators have been studied, but have not shown effectiveness in symptomatic 
management of the disease [154] and are not recommended for use [49]. The use of high flow 
nasal cannula (HFNC) therapy has been indicated to be feasible and well tolerated in infants with 
bronchiolitis [53] and delivery of a surfactant aerosol during HFNC therapy could possibly hasten 
the resolution of symptoms. Heated and humidified inspiration gas delivered during HFNC therapy 
enables delivery of higher inspired gas flow rates (up to 12 L/min in infants and 30 L/min in older 
children) than those typically seen with dry gas delivery (maximum of 2 L/min) [53]. 
Efficient delivery of inhaled drugs via the nasal route is important for the infant population 
as they are preferential nasal breathers. Lung deposition of < 4% has been reported in 
spontaneously breathing infants using a jet nebulizer with a face mask interface [103, 155]. An in 
vitro study found that the most efficient interface for aerosol delivery to a realistic seven-month-
old model was nebulization via a front-loaded mask, which produced delivered doses of 1.52% 
and 0.71% of the nominal dose, using jet and vibrating mesh nebulizers, respectively [156]. The 
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low delivery efficiencies of inhaled aerosols to infants using this standard of care system suggests 
the need for the development of more efficient methods for the delivery of high dose medications 
and to avoid drug waste.  
An aerosol mixer system, developed at Virginia Commonwealth University (VCU), was 
designed for use with vibrating mesh nebulizers to generate submicrometer excipient enhanced 
growth (EEG) aerosols [157]. The unit consisted of a large mixing region (aerosol reservoir) where 
aerosol generated from the commercial vibrating mesh nebulizer was mixed with recirculating 
heated air then entrained to pass a narrow heat-transfer region. The entrained drug aerosol would 
be delivered to the patient via connective tubing and a nasal cannula interface. The mixer-heater 
system was shown to achieve in vitro lung delivery efficiencies > 70% of the nebulized dose at 
conventional high flows (~30 L/min) when using adult breathing conditions and a deep tidal 
volume of 930 mL [158]. The first-generation mixer-heater system has been modified to provide 
HFNC therapy together with aerosol drug delivery. The newly modified mixer-heater system has 
a reduced chamber volume and can be operated at lower flows, which enables its use with the 
infant population.  
The aim of this study was to determine the in vitro particle size and delivery efficiency of 
a dispersion of commercial surfactant containing EEG excipients, sodium chloride and mannitol, 
using a commercial vibrating mesh nebulizer and newly modified VCU low-volume mixer-heater 
systems with a streamlined nasal cannula (VCU Department of Engineering). Performance of the 
novel delivery system was compared to the performance of a front-loaded infant face mask 
standard of care system. Also tested was a high flow therapy system that utilized a commercial 
infant high flow nasal cannula interface. 
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6.2 Materials and methods 
6.2.1 VCU mixer-heater systems 
6.2.1.1 Low-volume mixer-heater design 
The low-volume mixer heater system has been described by Spence et al. [159]. As with 
the original mixer-heater design [157], the reservoir-based system is designed to produce 
submicrometer pharmaceutical aerosols from vibrating mesh nebulizers. The new design enables 
use of the mixer-heater during high flow nasal cannula (HFNC) therapy (Figure 6.1). The VCU 
low-volume mixer heater has a volume of 61.6 mL, from the midplane of the nebulizer to the outlet 
plane, which is reduced from the first-generation mixer-heater that had a volume of 576 mL just 
in the mixing region. The VCU low-volume mixer-heater was designed to utilize two nebulizers – 
one for the drug formulation and one for saline – but only one nebulizer was used for this study 
with a stopper placed in the second nebulizer opening. Standard infant ventilator tubing with an 
internal diameter of 10 mm was used to connect the mixer-heater device to a novel streamlined 
nasal cannula. Room temperature ventilation gas at a rate of 6 L/min was introduced into the VCU 
low-volume mixer-heater with the heating element set to 60 °C, which resulted in an exit aerosol 
temperature of 35 °C at the exit of the nasal cannula. The device was produced using rapid 
prototyping (Object 24 printer, Stratasys Inc., Eden Prairie, MN) with VeroWhitePlus™ 
(RGD835, Stratasys Inc., Eden Prairie, MN) material.  
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Figure 6.1 Computer aided design rendered image of the VCU low-volume mixer-heater. 
6.2.1.2 Very low-volume mixer-heater design 
Design changes were made to the VCU low-volume mixer-heater to further reduce the 
volume of the system to improve its efficiency and minimize respiration losses [160]. The main 
design change was removal of the heating element and incorporation of an external heat source to 
provide warm ventilation gas (43 °C) into the system at a rate of 6 L/min to mix with the 
aerosolized drug (Figure 6.2). This resulted in an exit aerosol temperature of 25 °C from the 23 
cm length of tubing (Tygon® B-44-4X with 5 mm ID, Saint-Gobain, Courbevoie, France) that was 
used to connect the streamlined cannula. The optimized device had a reduced volume of 2.66 mL 
(from the centerline of the nebulizer inlet plane to the outlet plane) in comparison to the previous 
low-volume mixer-heater configuration (61.6 mL), resulting in a greater than 20-fold reduction in 
volume. The VCU very low-volume mixer-heater was designed for use with a modified Aerogen® 
Solo (Aerogen, Galway, Republic of Ireland), which eliminated the dead space at the outlet of the 
inlet air flow 
of 6 L/min
outlet to 
streamlined 
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inlet
mixing section
heating section
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nebulizer to further reduce the total volume of the delivery system (Figure 6.2). As with the 
previous design, the device was produced using rapid prototyping. 
 
 
 
Figure 6.2 Computer aided design rendered image of VCU very low-volume mixer-heater and 
modified Aerogen® Solo. 
6.2.2 Realistic infant nose-throat model 
In vitro aerosol deposition experiments were performed with a realistic nose-throat model 
based on computed tomography (CT) scans of a 20-week-old male infant weighing 7.7 kg. The 
realistic model was constructed using Mimics® (Materialize, Ann Arbor, MI) image segmentation 
software and constructed using rapid prototyping (Object 24 printer, Stratasys Inc., Eden Prairie, 
MN) with a rigid opaque photopolymer (VeroWhitePlus™, RGD835, Stratasys Inc., Eden Prairie, 
MN). The model anatomy includes nostrils, turbinates, nasopharynx, larynx and a portion of the 
trachea and is segmented into three portions: (i) the anterior nose, (ii) the middle passage, and (iii) 
the nasopharynx, larynx and trachea (Figure 6.3).  
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Figure 6.3 Infant nose-throat model, based on the computed tomography scans of a 20-week-old 
male infant weighing 7.7 kg, with streamlined infant nasal cannula. 
6.2.3 In vitro nasal delivery experimental set up 
Initial studies were performed with albuterol sulfate as the drug in the nebulization studies, 
due to the challenges of routinely assaying the surfactant-EEG formulation via quantification of 
DPPC using LC-MS. These studies were focused on mixer-heater optimization, which would be 
applicable for all nebulizer formulations. Optimization experiments were performed with 0.5% 
w/v albuterol sulfate in water solution prepared by dissolving albuterol sulfate USP (Letco 
Medical, LLC, Decatur, AL) in water. For all initial testing, an Aerogen® Pro nebulizer (Aerogen, 
Galway, Republic of Ireland) was used; the nebulizer was filled with 3.5 mL of the nebulizer 
formulation and weighed prior to and following nebulization for each run to determine the nominal 
dose by mass – the amount of drug emitted by nebulizer. A solution density of 1 g/mL was assumed 
and the mass difference before and after nebulization was multiplied by the albuterol sulfate (AS) 
concentration (Equation 6.1) to determine the nominal dose (Equation 6.2) of albuterol sulfate 
nebulized. 
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6.2.3.1 VCU low-volume mixer-heater with streamlined infant nasal cannula 
Reducing the volume of the mixer-heater and using the low ventilation gas flow rates 
required for infant delivery presented a significant challenge for efficient drying of the nebulizer 
aerosol output to produce the required submicrometer aerosol. To ensure adequate drying of the 
aerosol, a modified nebulizer controller was used to reduce the nebulizer output following 
procedures developed by Holbrook et al. [161]. The modified controller was set to operate the 
nebulizer at the same frequency as the commercial controller (128 kHz), while the amplitude of 
the applied sinusoidal operating voltage was reduced to produce approximately one-fourth of the 
aerosol output by mass from the vibrating mesh nebulizer, from 50 Vrms to 14.1 Vrms. A function 
waveform generator (Agilent Technologies model 33120A, Santa Clara, CA) was used to generate 
the desired signal, which was amplified using a modulated power supply (TS200 Option 5B, Accel 
Instruments, Irvine, CA).  
The modified reduced output controller was used to operate the vibrating mesh nebulizer 
in the experimental setup with the low-volume mixer-heater delivery system as shown in Figure 
6.4. Ventilation gas (air) was delivered through the system at a constant flow rate of 6 L/min (100 
mL/s). The VCU low-volume mixer-heater operating temperature was set to a nominal value of 
60 °C, which resulted in an exit aerosol temperature from the streamlined cannula of 35 °C.  
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Figure 6.4 Experimental setup for the VCU low-volume mixer-heater system with streamlined 
infant nasal cannula. 
6.2.3.2 Face mask standard of care system 
The face mask standard of care system experimental test setup is depicted in Figure 6.5. A 
front-loading face mask based on Bubbles the Fish II® pediatric mask (Pari Respiratory Equipment 
Inc., Midlothian, VA) was tightly fitted to the infant model. The Aerogen® Pro nebulizer was 
connected to the infant mask using an adapter designed to connect the mask and nebulizer; the 
nebulizer was operated using the commercial Aerogen® controller in continuous mode. 
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Figure 6.5 Face mask standard of care system experimental setup 
6.2.3.3 High flow nasal cannula standard of care system 
A high flow therapy device, Vapotherm model 2000i, (Vapotherm, Exeter, NH) was set to 
37 °C and used to provide high flow heated and humidified air at a rate of 6 L/min (100 mL/s) to 
the experimental setup as shown in Figure 6.6. The mesh nebulizer was positioned in a porous 
walled T-piece (Aeroneb® Aerosol Adapter, Vapotherm®, Stevensville, MD), which was attached 
to the Vapotherm® infant nasal cannula and infant model. The commercial Aerogen® controller 
was used to operate the mesh nebulizer in continuous mode. 
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Figure 6.6 High flow nasal cannula standard of care system experimental setup. 
6.2.4 Breathing conditions 
Experiments were performed under two breathing conditions: (i) steady state inhalation 
flow conditions (without an exhalation cycle) and (ii) realistic breathing cycle (with both inhalation 
and exhalation cycles). The steady state inhalation flow utilized a vacuum pump to draw air 
through the experimental setups at a constant flow of 7 L/min (117 mL/s). The realistic breathing 
cycle was generated by a breath simulator (ASL 5000, IngMar Medical, Pittsburgh, PA) based on 
the breathing profile of an 8 kg infant [81]. The breathing profile (Figure 6.7) is a sinusoidal 
waveform with a peak inspiratory flow rate of 10.5 L/min (175 mL/s), a tidal volume of 56 mL, 
40 breaths per minute and an inspiratory-expiratory ratio of 1:2. The inhalation and exhalation 
durations were 0.5 s and 1.0 s, respectively. 
 
Infant
nose-throat model Respiratory 
filter
Vacuum pump 
or 
Breath simulator
Aerogen®
Pro Ventilation gas 
6 L/minVapotherm infant 
cannula
Heated delivery 
tube
Va
po
the
rm
sy
ste
mCommercial 
controller
  
 
 
177 
 
Figure 6.7 Two cycles of a realistic breathing profile based on an 8 kg infant. The ventilation gas 
flow rate is 100 mL/s (6 L/min) delivered continuously. Ideally, drug aerosol is delivered to the 
patient in the ventilation gas flow only during inhalation and the delivery time should be 
synchronized such that delivery occurs when the inhalation flow rate is greater than the ventilation 
gas flow as shown by the nebulization duration. To achieve this delivery through the low-volume 
mixer heater, nebulization must be triggered during the exhalation cycle, as shown by the 
nebulization trigger time. In this example, the nebulization trigger time was 0.8 s before the next 
breath and the nebulization duration was 0.3 s. 
6.2.4.1 Optimization of breath synchronized aerosol drug delivery  
To reduce drug losses, the use of breath-actuated nebulization was studied. A relay timer 
(Time Delay Relay TD-88122, Macromatic Industrial Controls, Inc., Menomonee Falls, WI) was 
used to trigger the modified reduced output controller to actuate the nebulizer for a set time 
duration. The optimal setting for two parameters were determined: (i) nebulization trigger time – 
the time at which the nebulizer was triggered during the exhalation cycle relative to the start of the 
next inhalation phase of the breathing cycle, and (ii) the nebulization duration – the amount of time 
the nebulizer was set to operate during the cycle. 
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Based on the volume of the VCU low-volume mixer-heater device (from the centerline of 
the nebulizer inlet plane to the outlet plane, 61.6 mL), the volume of the ventilator tubing 
connecting the mixer-heater to the streamlined cannula (9.4 mL), and the ventilation gas air flow 
entrained through the system (100 mL/s), the theoretical delivery time for the aerosol generated 
by the nebulizer to reach the infant cannula was calculated to be 0.71 s. From the realistic breathing 
profile, the time in which the inspiratory flow was greater than the ventilation gas air flow of 6 
L/min (100 mL/s in Figure 6.7) was determined to be 0.3 s out of a total inhalation time of 0.5 s.  
Starting conditions for the nebulization trigger time and the nebulization time were selected 
as 0.8 s prior to the start of inhalation and 0.3 s, respectively. For all experiments, the nebulizer 
was filled with 3.5 mL of 0.5% w/v AS in water solution and allowed to run for 20 minutes. The 
filter component, the estimated % lung dose, was analyzed in the optimization experiments.  
6.2.5 Droplet sizing experiments with the Andersen Cascade Impactor 
Sizing experiments were performed using the Andersen Cascade Impactor (ACI, Copley 
Scientific, Nottingham, UK) placed in an environmental chamber (Espec, Hudsonville, MI) set to 
99% relative humidity (RH) to minimize effects of evaporative size changes during sizing 
measurements. A vacuum pump was used to draw air through the impactor at a flow rate of 28.3 
L/min as monitored with a mass flow meter (TopTrak® 822, Sierra Instruments, Monterey, CA) 
placed between the impactor and vacuum pump. Aerosol delivery experiments were performed 
with 0.5% w/v AS in water solution. The Aerogen® Pro nebulizer was filled with 3.5 mL of 
nebulizer formulation and weighed prior to and following nebulization for each run to determine 
the nominal dose by mass (Equation 6.1). A solution density of 1 g/mL was assumed and the mass 
difference before and after nebulization was multiplied by the albuterol sulfate concentration to 
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determine the nominal dose of albuterol sulfate nebulized. In order to obtain similar emitted 
masses, the nebulizer was allowed to run for 5 minutes and 20 minutes for experiments performed 
with the commercial controller and the modified reduced output controller, respectively.  
Drug was extracted from the impactor stages and filter to determine the emitted dose, the 
mass median aerodynamic diameter (MMAD), the geometric standard deviation (GSD) and 
particle mass fraction less than 1 µm and less than 5 µm. MMAD, GSD, and particle fractions 
were determined by linear interpolation. MMAD values were directly calculated as the size 
associated with a cumulative count of 50% based on mass percentages calculated relative to the 
impactor dose. GSD values were calculated following Equation 6.3. Particle mass fractions were 
calculated as the cumulative mass fraction frequency associated with sizes of 1 µm and 5 µm, 
respectively. Each measurement was performed a minimum of three times.  
 
Q"R =	S0<T2	/8	U646?/8<@2	U5678	59	VW.YZ%0<T2	/8	U646?/8<@2	U5678	59	Y\.V]%                                                                      Equation 6.3 
6.2.6 High performance liquid chromatography assay 
Drug was recovered from the components using known volumes of water and analyzed 
using an isocratic high-performance liquid chromatography (HPLC) assay method. The mobile 
phase consisted of 30% ammonium formate buffer (20 mM, pH 3.4) and 70% methanol. A 
Restek™ Allure™ pentafluorophenyl column (150 mm x 3.0 mm, particle diameter 5 µm) was 
used to separate AS at 0.75 mL/min with an injection volume of 100 µL on a Waters 2695 
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Separations Module and detection performed at 276 nm using a Waters 2475 fluorescence detector 
(Waters Corporation, Milford, MA). 
6.2.7 Statistical analysis 
Data analysis was performed using JMP® Pro software version 12.0 (SAS Institute Inc., 
Cary, NC). Student’s t-statistic or one-way analysis of variance (ANOVA) followed by Dunnett’s 
method or Tukey’s HSD was performed to determine statistically significant differences in the 
data obtained. The Pearson correlation coefficient was determined to quantify the strength of linear 
relationships. P values less than 0.05 were considered as statistically significant. 
6.3 Results and discussion 
6.3.1 Droplet aerosol sizing experiments with the ACI 
6.3.1.1 Effect of modified controller on nebulizer initial aerosol droplet size 
The effect of the nebulizer controller amplitude on initial droplet size was determined by 
comparing the size of the aerosol at the exit of the mesh nebulizer generated from the commercial 
Aerogen® controller with the aerosol size generated using the modified controller (driving 
amplitude of one-fourth of the commercial controller, 14.1 Vrms vs 50 Vrms). Experiments were 
performed at 25 °C and 99% RH in the environmental chamber. Bimodal size distributions were 
observed for both controller configurations (Figure 6.8, top). The droplets generated with the 
commercial controller were determined to have a mean ± SD MMAD of 5.0 ± 0.1 µm and GSD 
of 1.8 ± 0.04. The droplets generated with the modified controller were determined to be 
significantly smaller with a mean ± SD MMAD of 3.8 ± 0.6 µm compared to the commercial 
controller (p=0.0087; Student’s t-test). The controller amplitude was found to have a significant 
effect on the particle fraction less than 5 µm, with higher particle fractions observed with the 
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modified controller compared to the commercial controller (69.8 % vs 50.8 %, p=0.0011; Student’s 
t-test). No differences were observed in the GSD values of the particle size distributions and the 
submicrometer particle fractions between the two controllers. Results are shown in Table 6.1.  
Reducing the driving amplitude to one-fourth that of the commercial controller resulted in 
a proportional decrease in output from the nebulizer, from 300 µL/min for the commercial 
controller to 72 µL/min for the modified controller (Table 6.1). The significantly smaller MMAD 
values observed with the modified controller were due to the decreased output from the nebulizer; 
since less droplets were exiting the nebulizer at a given time (lower aerosol concentration at the 
exit of the nebulizer), this resulted in less interactions between droplets and therefore reduced 
droplet coagulation. MMAD values from the nebulizer were observed to have a positive 
correlation with the output rate from the nebulizer (r = 0.7805, p=0.0046, R2 = 0.6092; Pearson 
correlation), where an increase in output rates resulted in larger median droplet diameters. 
6.3.1.2 Effect of mixer-heater on nebulizer aerosol droplet size 
The size of the aerosol at the exit of the streamlined infant nasal cannula was also 
determined following generation and drying in the VCU low-volume mixer-heater operating at 60 
°C. Studies were similarly performed in a controlled temperature and humidity environment. 
Experiments were performed at 35 °C, the temperature of the exit aerosol from the streamlined 
cannula, and 99% RH in the environmental chamber. The modified controller was used to power 
the vibrating mesh nebulizer to produce aerosol that mixed with ventilation gas introduced into the 
VCU low-volume mixer-heater at 6 L/min. The size of the aerosol exiting the nasal cannula was 
compared to the size determined at the exit of the nebulizer. The aerosol exiting the streamlined 
cannula of the VCU low-volume mixer-heater delivery system was determined to have a mean ± 
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SD MMAD of 1.4 ± 0.1 µm and a GSD of 1.4 ± 0.0. This resulted in a significantly smaller MMAD 
and GSD compared to the aerosol exiting the nebulizer (p<.0001 and p=0.0306, respectively; 
Student’s t-test). The particle fractions were significantly affected by the use of the VCU low-
volume mixer-heater with a higher percent of particles less than 1 µm and less than 5 µm compared 
to the aerosol exiting the nebulizer (p=0.0052 and p<.0001, respectively; Student’s t-test).  
The use of the VCU low-volume mixer-heater enabled drying of the droplets exiting the 
nebulizer; the aerosol was mixed with dry ventilation gas and then further dried as the nebulizer 
aerosol-ventilation gas mixture was heated. This resulted in particles that were more monodisperse 
(top plot of Figure 6.8, square vs diamond markers) and less variable (smaller standard deviation 
values obtained for MMAD calculations, Table 6.1). 
Considering the solids concentration of the nebulizer formulation, the initial droplet size 
of 3.8 µm, and the density of albuterol sulfate of 1.34 g/cm3, the predicted dry particle size of a 
0.5% w/v solution of AS is estimated to be 0.68 µm, which indicates that the particles exiting the 
streamlined cannula are likely not completely dry. The larger than predicted particle size suggests 
that the VCU low volume mixer-heater system can still be optimized as ensuring complete drying 
of the droplets from the mixer-heater would possibly allow for improved delivery efficiency of 
aerosols to the infant lungs.
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Figure 6.8 Droplet size distributions of mass fraction/µm (top) and cumulative percent mass 
undersize (bottom) of 0.5% w/v albuterol sulfate in water from the Aeroneb® Pro nebulizer 
determined by cascade impaction with the ACI in an environmental chamber set to 99% RH. 
Aerosol size was determined at the nebulizer exit using the (i) commercial controller and (ii) 
modified controller, together with (iii) the aerosol size at the streamlined cannula exit following 
aerosol generation into the VCU low-volume mixer-heater. Markers represent the mean value, 
error bars represent the SD, n≥3. 
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Table 6.1 Droplet size characteristics of 0.5% w/v albuterol sulfate in water from the Aeroneb® Pro nebulizer determined by cascade 
impaction with the ACI. Aerosol size was determined at the nebulizer exit using the (i) commercial controller and (ii) modified 
controller, together with (iii) the aerosol size at the streamlined cannula exit following aerosol generation into the VCU low-volume 
mixer-heater. Values are mean (SD), n≥3. 
Controller 
(amplitude voltage) 
Droplet size measurement 
position 
Output rate, 
µL/min 
MMAD,  
µm GSD 
Particle fraction, % 
<1 µm <5 µm 
Commercial (50 Vrms) nebulizer exit 300 (10) 5.0 (0.1) 1.8 (0.0) 2.5 (0.1) 50.8 (1.9) 
Modified (14.1 Vrms) nebulizer exit 72 (10) 3.8 (0.6)* 1.7 (0.2) 10.1 (6.8)* 69.8 (6.7)* 
Modified (14.1 Vrms) streamlined cannula exit 101 (3) 1.4 (0.1)# 1.4 (0.0)# 25.5 (3.5)# 99.5 (0.0)# 
*Significant difference compared to commercial controller; Student’s t-test, p<0.05 
#Significant difference compared to exit of nebulizer with modified controller; Student’s t-test, p<0.05 
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6.3.2 In vitro aerosol deposition with a realistic infant nose-throat model 
6.3.2.1 Effect of aerosol delivery system on in vitro drug deposition 
The drug deposition results comparing the face mask standard of care delivery system with 
the VCU low-volume mixer-heater system using steady state inhalation flow conditions (7 L/min) 
and continuous nebulization are shown in Figure 6.9. The mean ± SD emitted dose from the patient 
interface (amount of drug available to enter the nose-throat model) was significantly higher in the 
VCU low-volume mixer-heater system, 97.5 ± 0.5%, compared to the face mask standard of care 
system, 78.6 ± 0.9% (p<.0001; Student’s t-test). For the face mask standard of care system, a 
majority of the drug deposition was on the nose-throat model, 73.9 ± 8.5% of the nominal dose, 
compared to 3.9 ± 1.0% that was observed with the VCU low-volume mixer-heater system 
(p=0.0001; Student’s t-test). For the VCU low-volume mixer-heater system, a majority of the drug 
deposition was observed on the filter (the estimated % lung dose), 76.2 ± 2.9%, which was 
significantly higher than that observed for the face mask standard of care system (p<.0001; 
Student’s t-test).  
The smaller droplets introduced to the in vitro infant nose-throat airway using the VCU 
low-volume mixer-heater system compared to the face mask standard of care system, 1.4 µm vs 
the 5.0 µm, resulted in improved aerosol drug delivery efficiency through the realistic airway; the 
smaller droplets were able to traverse the narrow airways of the model more efficiently than the 
larger droplets. Aerosol drug deposition on the delivery device (nebulizer outlet) was higher for 
the face mask standard of care system compared to the VCU low-volume mixer-heater system. 
Similarly, deposition on the patient interface (face mask) was also higher for the standard of care 
aerosol delivery method compared to the VCU low-volume mixer-heater system (Figure 6.9). 
Table 6.2 shows the total and regional (italicized) deposition for the different components. These 
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results clearly indicate the advantages of the smaller aerosol droplet size generated using the VCU 
low-volume mixer-heater which produced minimal drug deposition losses in the delivery device 
and cannula and maximizes the amount of drug aerosol able to penetrate the nasal passages of the 
infant and be delivered to the patient airways, as shown by the estimated % lung dose of 76 %.   
 
 
 
Figure 6.9 Aerosol drug deposition comparison for the face mask standard of care system and the 
VCU low-volume mixer-heater system using steady state inhalation conditions. Delivery device: 
face mask system = nebulizer outlet; mixer-heater system = nebulizer outlet, mixer-heater, tubing. 
Bars represent the mean value, error bars represent SD, n=3. *Significant difference; Student’s t-
test, p<0.05. 
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Table 6.2 Total and regional aerosol drug deposition comparison for the standard of care systems 
with the VCU mixer-heater delivery system using steady state inhalation conditions. Values are 
mean (SD), n=3. 
Component 
Face mask standard 
of care system 
VCU low-volume 
mixer-heater system 
HFNC standard of 
care system 
Delivery device    
Nebulizer outlet 10.3 (1.6) 0.2 (0.1) 4.0 (1.8) 
Mixer-heater n/a 2.1 (0.6) n/a 
Tubing n/a 1.0 (0.1) n/a 
T-piece n/a n/a 57.0 (2.4) 
Total 10.3 (1.6) 3.3 (0.6)# 61.0 (4.1) 
    
Interface* 11.0 (0.9) 0.8 (0.2)# 2.3 (0.3) 
    
Nose-throat model    
Anterior nose . 0.9 (0.2) 2.5 (0.4) 
Middle passage . 1.2 (0.3) 10.7 (2.5) 
Nasopharynx . 1.8 (0.9) 20.0 (1.5) 
Total 73.9 (8.5) 3.9 (1.0)# 33.1 (4.2) 
    
Estimated lung dose 13.9 (1.0) 76.2 (2.9)# 1.3 (0.2) 
*Face mask system: face mask; mixer-heater system: streamlined nasal cannula; HFNC system: 
commercial infant nasal cannula 
#Significant difference compared to face mask standard of care system; Student’s t-test, p<0.05 
 
 
The high flow therapy system with HFNC was also tested to determine the drug deposition 
in the realistic infant nose-throat model with a commercial system while humidity is incorporated. 
In this system, the delivery device, which consisted of the nebulizer outlet and the T-piece, had 
the highest drug deposition at 61% of the nominal dose with a mean ± SD emitted dose from the 
interface of 36.7 ± 4.1% of the nominal dose. This resulted in 33% deposition in the nose-throat 
model and only 1.3% of the nominal dose reaching the filter. The high deposition in the T-piece is 
likely due to two related factors: 1) the high rate of aerosol exiting the nebulizer, and 2) the larger 
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sized aerosols generated from the nebulizer with the commercial controller. With entrained air at 
a flow rate of 6 L/min, deposition in the T-piece is due to impaction losses from both the high rate 
of aerosol at the exit of the nebulizer and to impaction of the particles entrained in the turbulent 
flow. The presence of humidity in the system prevented aerosol evaporation and drying which 
maintained the size of the aerosol droplets as they exited the nebulizer. There was significant 
deposition of the 5 µm aerosol in the passageways of the delivery system and nose-throat model 
due to inertial impaction and sedimentation resulting in the observed poor estimated % lung dose 
of 1.3% of nominal dose. 
6.3.2.2 Effect of a realistic breath cycle on in vitro aerosol deposition  
The effect of incorporating realistic breathing conditions on drug deposition was studied 
using continuous aerosol generation from the nebulizer. For the VCU low-volume mixer-heater 
system the estimated % lung dose was decreased significantly when an exhalation cycle was 
incorporated into the breathing cycle, from 76.3 ± 2.9% to 12.0 ± 0.8% of the nominal dose 
(p<.0001; Student’s t-test). No significant differences in drug deposition were observed in the other 
device components (delivery device or patient interface) or the nose-throat model. Similarly, 
incorporating the exhalation cycle found significant decreases in the estimated % lung dose with 
the face mask standard of care delivery system, from 13.9 ± 1.0% to 5.2 ± 0.30% of the nominal 
dose (p<.0001; Student’s t-test). There were significant differences seen in aerosol drug deposition 
on the other components of the standard of care delivery system; increases in drug deposition were 
observed for the delivery device and interface components (p=0.0168 and p=0.0482, respectively; 
Student’s t-test), while a decrease in deposition was observed in the nose-throat model (p=0.0017; 
Student’s t-test).  
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For the VCU low-volume mixer-heater system, the mean ± SD emitted dose from the 
interface of 95.2 ± 0.6% was not different from steady state inhalation flow conditions (95.7 ±0.5% 
of the nominal dose), but significantly higher than the emitted dose from the interface for the face 
mask standard of care system (63.3 ± 1.8%, p<.0001; Student’s t-test). A comparison of the 
estimated % lung dose in the two delivery systems when realistic breathing conditions were 
employed found that the VCU low-volume mixer-heater system had a significantly higher 
estimated % lung dose compared to the face mask standard of care system (p<.0001; Student’s t-
test). Deposition in the delivery device, interface, and nose-throat model were all significantly 
lower in the mixer-heater system compared to the face mask standard of care system (Table 6.3, 
p<0.05; Student’s t-test). The decrease in estimated % lung dose observed in both systems was 
attributed to exhalation losses due to constant nebulization throughout the breath cycle. 
 
Table 6.3 Deposition comparison of standard of care systems with the VCU low-volume mixer-
heater delivery system with realistic breathing conditions and constant nebulization. Values are 
mean (SD), n=4. 
Component 
Face mask standard of care 
system 
VCU low-volume mixer-
heater system 
Delivery device 17.8 (3.4) 3.7 (0.5)# 
Interface* 18.9 (5.0) 1.0 (0.2)# 
Nose-throat model 46.5 (4.1) 2.6 (0.7)# 
Estimated lung dose 5.2 (0.3) 12.0 (0.8)# 
*Face mask system: face mask; mixer-heater system: streamlined nasal cannula 
#Significant difference compared face mask standard of care system; Student’s t-test, p<0.05 
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6.3.3 Optimization of aerosol delivery synchronization with realistic breathing cycle  
In order to minimize drug losses and increase the estimated % lung dose, the use of aerosol 
delivery synchronization with the breathing cycle was explored to ensure that aerosol was 
delivered to the airways only during inhalation. Experiments were performed with realistic 
breathing conditions in which nebulization was synchronized with the patients simulated breathing 
pattern in this highly controlled laboratory environment to investigate the critical variables 
controlling efficient aerosol delivery. The effect of the nebulizer aerosol output rate, the 
nebulization trigger time within the breathing cycle and the nebulization duration on the estimated 
% lung dose were each studied independently. 
6.3.3.1 Effect of nebulizer aerosol output rate on in vitro aerosol deposition 
In order to determine the effect of the output rate of the nebulizer with the VCU low-
volume mixer-heater system on the estimated % lung dose, the modified controller driving 
amplitude was varied to produce lower nebulizer output rates as shown in Table 6.4. The nebulizer 
was triggered 0.3 s prior to the start of inhalation and the nebulization duration was 0.2 s for these 
studies to determine the effect of output rate on the estimated % lung dose. Data are shown in 
Table 6.4. 
Due to the use of breath-synchronized nebulization, lower output rates (5-10 µL/min) were 
observed since the nebulizer was only triggered for 0.3 s of each 1.5 s breath cycle compared to 
the values observed during continuous nebulization (70-100 µL/min, Table 6.1). The output rate 
of the nebulizer was observed to have a strong positive correlation with the driving amplitude (r = 
0.8877, p<.0001, R2 = 0.7881; Pearson correlation); the output rate increased with increasing 
driving amplitude. This outcome was expected as the same trend was observed when comparing 
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output rates of the commercial controller with the modulated controller in earlier studies using 
continuous nebulization (Table 6.1).  
The estimated % lung dose was observed to have a negative correlation with the output 
rate of the nebulizer (r = -0.7253, p=0.0050, R2 = 0.5260; Pearson correlation); the estimated % 
lung dose as a percent of the nominal dose decreased with increasing output rate. From the droplet 
sizing experiments, it was observed that reducing the aerosol output from the nebulizer resulted in 
smaller droplet sizes, therefore, the negative correlation of estimated % lung dose with the aerosol 
output rate is likely due to higher deposition of the larger aerosol droplet in the other components 
in the system (delivery device, interface, and nose-throat model) at the higher output rates, 
resulting in the lower estimated % lung dose.  
A strong positive correlation was observed with the mass of drug recovered from the filter 
component with the output rate of the nebulizer (r = 0.8831, p<.0001, R2 = 0.7798; Pearson 
correlation); higher masses of drug were recovered with increasing aerosol output rate. Although 
the 5.1 µL/min output rate provided more efficient delivery (higher estimated % lung dose as a 
percent of the nominal dose), the higher output rates of 9.4 and 11.1 µL/min were able to deliver 
a higher mass of drug to the filter in the same delivery time of 20 minutes, with the output rate of 
11.1 µL/min delivering nearly twice as much drug compared to the output rate of 5.1 µL/min. 
Thus, future studies were performed with a driving amplitude of 4 Vpp and an output rate of ~11 
µL/min. 
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Table 6.4 Comparison of nebulizer output rate of the modified controller on estimated % lung 
dose and total delivered lung dose. Values are mean (SD), n≥3. 
Driving amplitude 
Output rate,  
µL/min* 
Estimated lung dose, 
% nominal* 
Total lung dose,  
µg* 
4 Vpp 11.1 (1.5) 29.2 (4.0) 329 (42) 
3 Vpp 9.4 (1.0) 31.9 (1.2) 308 (40) 
2 Vpp 5.1 (0.4) 36.0 (4.5) 188 (9.5) 
*Significant correlation with driving amplitude; Pearson correlation, p<0.05 
 
 
6.3.3.2 Effect of nebulizer synchronization on in vitro aerosol deposition 
To ensure maximal delivery of aerosol to the lungs, the aerosol should be delivered in the 
ventilation gas during inhalation when the inhalation flow rate is greater than the ventilation gas 
flow. For the realistic breathing profile, the time interval during which the inhalation flow is greater 
than the ventilation gas flow was determined to be 0.3 s (Figure 6.7). To study the synchronization 
of the nebulizer actuation to achieve the highest estimated % lung dose, the nebulization duration 
was held constant at 0.3 s. For these highly controlled in vitro studies, it was possible to investigate 
the time (trigger time) in the breathing cycle when the nebulizer should be actuated in order to 
maximize aerosol delivery. The results plotted in Figure 6.10 show the estimated % lung dose 
values as a function of the nebulization trigger time relative to the start of inhalation (top) and also 
when shown on the time axis of the breathing cycle (bottom). For these studies the output rates 
from the nebulizer ranged from 8 to 20 µL/min.  
The nebulization trigger time with the highest estimated % lung dose (mean ± SD of 32.0 
± 2.7% of the nominal dose) was determined to be 0.4 s prior to the start of inhalation phase of the 
breathing cycle. The nebulization trigger time of 0.4 s was also found to have the highest drug 
recovery for the different trigger times studied (492 ± 84 µg, Table 6.5), indicating that the aerosol 
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from the nebulizer took approximately 0.4 s to travel to the exit of the streamlined cannula with 
entrained air flow of 6 L/min. The plot of estimated % lung doses at different trigger times when 
plotted on the same scale as the breathing profile had a similar profile to that of the inhalation flow 
(bottom plot of Figure 6.10), indicating that delivery of the nebulized aerosol is synchronized with 
the inhalation profile when offset by 0.4 s prior to the start of inhalation and that this was the 
optimal nebulization trigger time. 
The lowest estimated % lung dose as a percent of the nominal dose and the lowest 
recovered drug dose (4.1 ± 0.9% and 79 ± 20 µg, respectively) was observed when the nebulization 
trigger time was set to 1.0 s prior to the next inhalation. Since it has been determined that the 
aerosol takes 0.4 s to travel from the nebulizer to the exit of the streamlined cannula, then the 
aerosol generated at a trigger time of 1.0 s prior to the next inhalation would reach the nose-throat 
model near the peak of the exhalation cycle (bottom plot of Figure 6.10), consistent with the low 
lung and recovered drug doses observed at this trigger time.  
The delivery time for the aerosolized drug to travel from the nebulizer to the nose-throat 
model was therefore determined as 0.4 s, future studies were performed with a fixed nebulization 
trigger time of 0.4 s prior to the next inhalation.  
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Figure 6.10 Estimated in vitro lung dose at different nebulization trigger times relative to the start 
of inhalation (top) and relative to the realistic breathing profile (bottom) with nebulization duration 
of 0.3 s. Markers represent the mean value, error bars represent the SD, n=3. 
-5
0
5
10
15
20
25
30
35
0.0 0.3 0.6 0.9 1.2 1.5
Es
tim
at
ed
 lu
ng
 d
os
e 
(%
 n
om
in
al
)
Nebulization trigger time relative to start of inhalation cycle (s)
-150
-100
-50
0
50
100
150
200
-5
0
5
10
15
20
25
30
35
0.0 0.5 1.0 1.5 2.0 2.5 3.0
Fl
ow
 ra
te
 (m
L/
s)
Es
tim
at
ed
 lu
ng
 d
os
e 
(%
 n
om
in
al
)
Time (s)
Estimated lung dose
Breathing flow rate
0.4s prior to 
next inhalation
0.4s 
  
 
 
195 
Table 6.5 Comparison of in vitro aerosol deposition for nebulization trigger times relative to the 
start of inhalation with a nebulization duration of 0.3 s and realistic breathing conditions. Values 
are mean (SD), n=3. 
Nebulization trigger 
time relative to start 
of inhalation 
Output rate,  
µL/min 
Estimated lung dose,  
% nominal 
Total recovered drug,  
µg 
0.2 s 7.9 (1.0) 14.9 (2.2) 114 (14) 
0.3 s 14.2 (3.7) 25.5 (2.3) 347 (59) 
0.4 s 15.7 (1.7) 32.0 (2.8) 492 (84) 
0.5 s 17.3 (3.6) 28.1 (1.5) 477 (120) 
0.6 s 16.9 (5.8) 20.4 (1.5) 332 (84) 
0.8 s 17.4 (3.9) 7.1 (0.4) 121 (30) 
1.0 s 20.3 (5.6) 4.1 (0.9) 79 (20) 
 
 
6.3.3.3 Effect of nebulization duration on in vitro aerosol deposition 
Once the optimal point in the breathing cycle to synchronize delivery of the nebulized 
aerosol with the peak of the inhalation cycle was determined (0.4 s prior to the start of inhalation), 
the optimal nebulization duration was then studied. The nebulization durations of 0.1 s and 0.2 s 
were tested and compared to results obtained for the 0.3 s nebulization duration. At nebulization 
durations of 0.1 s and 0.2 s, the estimated % lung doses were determined to be 30.0 ± 2.0% and 
35.0 ± 1.5% of the nominal dose, respectively. One-way ANOVA revealed a significant effect of 
nebulization duration on the estimated % lung dose, p=0.0445. A significant difference was 
revealed between 0.1 s and 0.2 s nebulization durations (p=0.0397; Tukey’s HSD), both of which 
were not shown to be significantly different from the 0.3 s nebulization time (p>0.05; Tukey’s 
HSD). In terms of total delivered dose of drug, the highest dose of AS was recovered when the 
nebulization duration was set to 0.3 s compared to the 0.2 s or 0.1 s nebulization time (492 vs 420 
vs 154 µg), respectively. While the percentage drug delivery is important in terms estimating the 
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efficiency of the aerosol delivery process, the total delivered lung dose is also critical for 
applications where relatively large doses of drug are required for therapeutic efficacy. 
The output rate and recovered drug dose were both found to have significant correlations 
with the nebulization duration at the 0.4 s nebulization trigger time. A positive correlation was 
observed between output rate and nebulization duration (r = 0.8774, p=0.0009, R2 = 0.7698; 
Pearson correlation); longer nebulization durations resulted in higher output rates. The recovered 
drug dose was positively correlated with nebulization duration (r = 0.8756, p=0.0009, R2 = 0.7667; 
Pearson correlation); increased nebulization durations resulted in higher recovered drug doses. 
These correlations were expected as longer nebulization durations allow for more drug to be 
nebulized, resulting in increased output rates and higher drug recovery.  
 
Table 6.6 Comparison of in vitro aerosol deposition when varying the nebulization duration for 
nebulization trigger time of 0.4 s prior to the next inhalation with realistic breathing conditions. 
Values are mean (SD), n≥3. 
Nebulization duration 
Output rate,  
µL/min* 
Estimated lung dose, 
% nominal 
Total recovered drug,  
µg* 
0.1 s 5.0 (0.2) 30.0 (2.0) 154 (8) 
0.2 s 12.1 (2.7) 35.0 (1.5) 420 (71) 
0.3 s 15.7 (1.7) 32.0 (2.8) 492 (84) 
*Significant correlation with nebulization duration; Pearson correlation, p<0.05 
 
 
6.3.4 Optimized in vitro deposition with a realistic infant nose-throat airway model 
The optimized breath-actuation conditions for maximizing in vitro aerosol delivery in a 
realistic infant nose-throat airway model were determined. The optimized conditions were as 
follows: driving amplitude of 4 Vpp, nebulization trigger time of 0.4 s prior to the start of 
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inhalation and nebulization duration of 0.2 s. The nebulizer was filled with 3.5 mL of 0.5% w/v 
AS and set to run for 20 minutes. Table 6.7 shows the full characterization of the regional aerosol 
deposition when tested using these conditions. As expected, the estimated % lung dose was 35% 
of the nominal dose. The mean ± SD emitted dose from the interface was 84.1 ± 0.6%, which was 
significantly lower than what was observed with continuous nebulization with realistic breathing 
conditions (95.3 ± 0.6%, p<.0001; Student’s t-test). Significantly higher deposition was observed 
in the delivery device and nose-throat model when compared to continuous nebulization with 
realistic breathing conditions (Figure 6.11, p<.0001 and p=0.0032, respectively).  
It was assumed that any drug not recovered in the assay was due to respiration loss – drug 
loss due to aerosol generation during the exhalation portion of the breathing cycle and exhaled 
drug losses. Respiration losses were estimated by calculating the difference between the nominal 
dose and the recovered dose. A recovered dose of 61.5 ± 3.2% of the nominal dose was obtained 
for the optimized settings, resulting in an estimated respiration loss of 38.5 ± 3.2% of the nominal 
dose. To study the respiration loss in the system, the regional deposition experiment with the nose-
throat model was repeated at the nebulization duration setting of 0.1 s as it was expected to have 
the lowest respiration loss since nebulization trigger time is less critical at lower nebulization 
duration times, thus increasing the chances of capturing the entire aerosol dose generated during 
each breath. Table 6.7 shows the deposition results for the components of the system.  
The total mean ± SD recovered dose was 76.3 ± 7.0%, resulting in an estimated respiration 
loss of 23.7 ± 7.0% of the nominal dose. However, decreasing the respiration loss using the 0.1 s 
nebulization duration resulted in increased deposition in the delivery device. When compared with 
the 0.2 s nebulization duration and continuous nebulization, it was observed that increasing 
deposition was seen in the delivery device with decreasing nebulization duration (Figure 6.11, r = 
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-0.8706, p=0.0005, R2 = 0.7579; Pearson correlation). It was observed that the shorter nebulization 
duration of 0.1 s resulted in inconsistent aerosol generation during the run, which may be have 
caused the observed increased deposition in the delivery device.  
The higher deposition in the delivery device resulted in an emitted dose from the interface 
for the 0.1 s nebulization duration that was significantly lower than what was observed with 0.2 s 
nebulization duration and with continuous nebulization with realistic breathing conditions (69.2 ± 
4.1%, p=0.0017 and p=0.0001, respectively; Student’s t-test). However, the estimated % lung dose 
with the 0.1 s nebulization duration was comparable to that of the 0.2 s nebulization duration when 
values were calculated as percent of the nominal dose (37% vs 35% of the nominal dose). When 
aerosol delivery was considered relative to the fraction of the aerosol that was emitted from the 
cannula (to normalize for losses within the delivery device), the estimated % lung dose for 0.1 s 
nebulization duration was significantly higher compared to that of the 0.2 s nebulization (53.9 ± 
7.8% vs 41.9 ± 0.6% of the interface dose, p=0.0485; Student’s t-test) with similar nose-throat 
model deposition (12.6 ± 2.5% vs 12.3 ± 3.5% of the interface dose, respectively). More of the 
aerosol from the shorter nebulization duration was captured on the filter as indicated by the higher 
estimated % lung dose when compared to the 0.2 s nebulization duration, which was the expected 
outcome with decreased nebulization duration. 
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Table 6.7 Comparison of in vitro aerosol deposition when varying the nebulization duration with 
breath-actuated nebulization with 0.4 s nebulization trigger time prior to the start of inhalation and 
realistic breathing conditions. Values are mean (SD) percent of nominal dose, n≥3. 
Component 
Nebulization duration 
0.2 s 0.1 s 
Delivery device 14.1 (1.6) 26.4 (4.0) 
Streamlined cannula 1.9 (1.1) 4.4 (1.1) 
Nose-throat model 10.3 (2.9) 8.4 (2.0) 
Estimated % lung dose 35.2 (0.6) 37.1 (3.7) 
Estimated respiratory loss 38.5 (3.2) 23.7 (7.0) 
 
 
  
 
Figure 6.11 Comparison of in vitro aerosol deposition when varying the nebulization duration 
using the VCU low-volume mixer-heater. Bars represent the mean value, error bars represent the 
SD, n≥3. *Significant difference; Student’s t-test, p<0.05. 
Although the lower nebulization duration of 0.1 s provided more efficient delivery, 
significantly less drug was delivered in 20 minutes at this nebulization duration when compared 
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to the 0.2 s nebulization duration setting (162 ± 27 µg vs 310 ± 14 µg of AS, p=0.0004; Student’s 
t-test). The estimated % lung dose achieved with the VCU low-volume mixer-heater at 0.2 s 
nebulization duration during realistic breathing conditions was 35% of the nominal dose, a 
significant improvement over the current methods of aerosol delivery to the lungs of infants which 
deliver < 4% of the nominal dose [156] using similar highly controlled in vitro testing conditions.  
The in vitro testing conditions with a breathing simulator allowed for determination of the 
highest potential estimated % lung dose by utilizing a nebulization trigger time. Realistically, the 
use of a nebulization trigger time is not practical in a clinical environment as the breathing profile 
of infants with respiratory issues is erratic and nonuniform. The in vitro experiments demonstrated 
that a nebulization trigger time of 0.4 s resulted in the highest estimated lung dose, indicating the 
importance that timing of aerosol delivery has on ensuring inhalation of the drug aerosol in 
maximizing the dose that reaches the infant lung.  
6.3.5 In vitro aerosol deposition with a realistic infant nose-throat airway model from the 
VCU very low-volume mixer-heater 
Initial experiments were performed with the VCU very low-volume mixer-heater system 
and modified controller to aerosolize 0.5% w/v AS solution [160]. These studies showed that due 
to the very low volume of the mixer-heater, it was now possible to synchronize nebulization with 
the start of the inhalation cycle and eliminate the need of the nebulization trigger time prior to the 
start of inhalation while maintaining a high estimated % lung dose. In this section, studies were 
performed to investigate the aerosolization of a surfactant-EEG formulation using the optimized 
settings determined with AS solution. 
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6.3.5.1 Surfactant-EEG dispersion for nebulization 
Surfactant-EEG nebulization formulations were produced by combining mannitol with 
Survanta® and water to produce a solids concentration of 0.5% w/v. The formulation was dispersed 
by sonication as described for preparation of feed dispersions for spray drying in Chapter 4 – 
indirect sonication for 40 minutes in a heated water bath sonicator set to 60 °C. The formulation 
had a final concentration of 54% phospholipids, 10% mannitol, and 20% sodium chloride, with 
the remaining 16% consisting of other components present in the commercial Survanta® 
suspension (triglycerides, fatty acids, and proteins). The solids concentration was verified by 
determining the weight of 2 mL of the surfactant-EEG dispersion allowed to dry overnight in an 
oven set to 80 °C; three replicates were performed with a mean ± SD percent solids of 0.47 ± 0.2% 
w/v. Dispersion stability was determined by measuring the zeta potential (Zetasizer Nano S, 
Malvern Instruments, Ltd., Worcestershire, UK) and the DPPC content of the formulations was 
determined by LC-MS as described in Chapter 3. Zeta potential and percent DPPC content data 
are shown in Table 6.8. 
The dispersions were observed to be stable for at least 20 days following preparation as 
indicated by the zeta potential absolute values greater than 30 mV. DPPC content was determined 
to be approximately 1.2 mg/mL for 7 days after preparation, which theoretically equates to 2.3 mg 
of phospholipids per mL according to the Survanta® label claim [30]. The dispersions could be 
reliably used for up to 7 days following preparation if stored in the refrigerator (2-8 °C) when not 
in use.  
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Table 6.8 Surfactant-EEG nebulizer formulation dispersion stability and DPPC content over time. 
Values are mean (SD), n≥3. 
Measurement parameter Day 1 Day 3 Day 7 Day 20 
Zeta potential, mV -32.4 (0.3) -33.2 (1.2) - -42.4 (3.5) 
DPPC content, mg/mL 1.23 (0.01) 1.18 (0.03) 1.19 (0.03) - 
 
 
6.3.5.2 Effect of nebulizer formulation composition on aerosol concentration  
The effect of nebulizer formulation composition on the aerosol particle concentration was 
determined using a condensation particle counter comparing the AS nebulizer formulation with 
the surfactant-EEG formulation. For each formulation, aerosols were continuously generated from 
the modified Aerogen® Solo nebulizer using the modified controller into a T-piece that was 
connected to a condensation particle counter (CPC model 3022A, TSI Inc., Shoreview, MN).  
Dilution airflow was introduced into the T-piece to deliver aerosol to the CPC that was configured 
in high flow operation (1.5 L/min).  The dilution gas flow rate was varied to produce flows of 3, 
6, and 8 L/min. Measurements were performed for 300 s per run. There were differences in the 
aerosol particle concentration at the 3 L/min dilution gas flow, in which the AS solution had a 
higher aerosol particle concentration, but this difference was not observed at the higher gas flow 
rates, Figure 6.12. With similar particle concentration at both 6 and 8 L/min dilution flows (similar 
to the flows used in the mixer-heater system), the aerosols generated from the two formulations 
were deemed similar. 
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Figure 6.12 Aerosol particle concentration of albuterol sulfate and surfactant-EEG nebulizer 
formulation aerosols generated as a function of dilution gas flow rate measured using the 
condensation particle counter from aerosols generated by the modified Aerogen® Solo powered by 
the modified controller. Markers represent the mean value, error bars represent the SD, n=4. 
6.3.5.3 VCU very low-volume mixer-heater with the modified controller 
6.3.5.3.1 Effect of the VCU very low-volume mixer-heater on the aerosol droplet size  
Sizing experiments with the ACI were performed with the modified controller to determine 
the particle size distribution of the surfactant-EEG formulation with the VCU very low-volume 
mixer-heater. The aerosol size distribution was measured at the exit of the nebulizer to evaluate 
the initial aerosol size.  The droplet size distribution was then determined at the exit of the delivery 
tubing from the very low-volume mixer-heater system during continuous nebulization. The droplet 
size distributions are shown in Figure 6.13. Studies were performed in the environmental chamber 
which was set to 25 °C, the temperature of the aerosol exiting the nebulizer and VCU very low-
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volume mixer-heater. Relative humidity in the chamber was maintained at 99% RH to minimize 
droplet evaporation during sizing measurements.  
A bimodal droplet size distribution was observed for the aerosol exiting the nebulizer, 
which was less apparent when the aerosol was passed through the VCU very low-volume mixer-
heater. The initial particle size of the droplets at the exit of the nebulizer was determined to have 
a mean ± SD MMAD of 2.2 ± 0.8 µm, which was significantly reduced by the VCU very low-
volume mixer-heater to droplets with an MMAD of 1.0 ± 0.0 µm (p=0.0356; Student’s t-test). The 
incorporation of the VCU very low-volume mixer-heater was found to have a significant effect on 
the particle fractions less than 1 µm and 5 µm, with higher particle fractions observed with the 
VCU very low-volume mixer-heater compared to the nebulizer alone (p=0.0006 and p=0.0003, 
respectively; Student’s t-test). No differences were observed in the GSD values of the particle size 
distributions with and without incorporation of the VCU very low-volume mixer-heater. Results 
are listed in Table 6.9.  
As observed with the previous generation mixer-heater and AS nebulizer formulation, the 
use of the VCU very low-volume mixer-heater enabled efficient drying of the surfactant-EEG 
droplets that exited the nebulizer by mixing the aerosol with warmed ventilation gas. Replacing 
the heating zone of the mixer-heater with heated ventilation gas to reduce the volume of the 
delivery system was successfully implemented for this surfactant-EEG formulation. This resulted 
in aerosol particles that were smaller than the aerosols generated using the VCU low-volume 
mixer-heater (1.0 vs 1.4 µm) with a higher fraction of particles less than 1 µm (51 vs 26 %).  
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Figure 6.13 Aerosol droplet size distributions of the modified Aeroneb® Solo nebulizer output 
(nebulizer exit) and following delivery from the very low-volume mixer-heater (delivery tubing 
exit) of 0.5% w/v surfactant-EEG formulation generated by the Aerogen® Solo with the modified 
controller. Markers represent the mean value, error bars represent the SD, n≥3. 
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Table 6.9 Aerosol droplet size characteristics of the modified Aeroneb® Solo nebulizer output and following delivery from the very 
low-volume mixer-heater (delivery tubing exit) of 0.5% w/v surfactant-EEG formulation determined by cascade impaction with the 
ACI. Aerosols were generated using the modified and commercial Aerogen® controllers. Values are mean (SD), n≥3. 
Controller  
(amplitude voltage) Droplet size measurement position 
MMAD, 
µm GSD 
Particle fraction, % 
<1 µm <5 µm 
Modified (14.1 Vrms) Initial size at nebulizer exit  2.5 (0.9) 2.6 (1.0) 20.8 (6.6) 77.2 (3.0) 
Modified (14.1 Vrms) Final size at delivery tubing exit  1.0 (0.0)* 2.1 (0.1) 51.3 (0.6)* 96.7 (0.6)* 
Commercial (50 Vrms) Initial size at nebulizer exit 4.2 (0.3)‡ 1.8 (0.1) 7.2 (2.8)‡ 63.7 (5.7)‡ 
Commercial (50 Vrms) Final size at delivery tubing exit 2.0 (0.4)#^ 2.3 (0.3)# 22.1 (7.0)#^ 88.5 (1.9)#^ 
*Significant difference compared to initial size at nebulizer exit with the modified controller; Student’s t-test, p<0.05 
#Significant difference compared to initial size at nebulizer exit with the commercial controller; Student’s t-test, p<0.05 
‡Significant difference compared to the modified controller at the nebulizer exit; Student’s t-test, p<0.05 
^Significant difference compared to the modified controller at the delivery tubing exit; Student’s t-test, p<0.05 
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6.3.5.3.2 Effect of the VCU very low-volume mixer-heater on in vitro regional aerosol 
deposition 
The VCU very low-volume mixer-heater was evaluated using the in vitro aerosol 
deposition set up described previously with a realistic infant breathing profile and nose-throat 
infant airway model. Due to the reduced volume of the system, offset of the start of nebulization 
with the start of inhalation was no longer required to synchronize aerosol delivery with inhalation 
to the model. Therefore, nebulization was triggered at the start of each inhalation. Initial 
development studies with this device revealed that the VCU very low-volume mixer-heater using 
a nebulization duration of 0.3 s and the modified controller delivered 100 µL of 0.5% w/v AS 
solution in a total time of 14 minutes, with an estimated % lung dose of 48.1 ± 2.3% of the nominal 
dose [160]. This was shown to offer a significant improvement over the delivery of around 35% 
of the nominal dose observed with the VCU low-volume mixer heater.  
The initial realistic deposition studies with albuterol sulfate were then performed using the 
0.5% w/v surfactant-EEG nebulizer formulation. To ensure that an adequate amount of DPPC 
could be detected from the system components, a volume of 620 µL of the surfactant-EEG 
nebulizer formulation was used for the deposition studies. Complete nebulization (run to dryness) 
took approximately 40 minutes. An estimated % lung dose of 30.4 ± 2.8% of the nominal dose 
was observed. Minimal deposition was observed on the other components of the system, a total of 
7.7 ± 0.8% of the nominal dose, indicating high respiration loss (61.9 ± 2.0% of the nominal dose). 
Table 6.10 lists the deposition recovered on the different components in the system. 
The deposition with a nebulization duration of 0.1 s was studied to determine if the 
respiration loss in the system could be decreased. A volume of 750 µL of surfactant-EEG 
formulation was filled into the nebulizer, which was allowed to run for 130 minutes. The estimated 
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% lung dose was found to be 52.1 ± 1.7% of the nominal dose, significantly higher than that 
observed with the nebulization duration of 0.3 s (p=0.0003; Student’s t-test). The deposition in the 
other components were similar to that determined with 0.3 s nebulization duration, except for the 
cannula component, which was significantly higher with the shorter nebulization duration of 0.1 s 
(p=0.0248; Student’s t-test), Figure 6.14. The respiration loss was estimated as 36.1 ± 2.9% of the 
nominal dose, an improvement over the longer nebulization duration, but higher than expected for 
the short nebulization duration used in this study; a respiration loss of 18.3 ± 4.3% of the nominal 
dose was observed for AS studies. An estimated % lung dose of 52.1% of the nominal dose equates 
to 430.7 ± 16.5 µg of DPPC (or an estimated 813 µg of total phospholipids), which took over 2 
hours to deliver. An increase in the output rate of the aerosol from the VCU low-volume mixer-
heater was further studied to determine if delivery time of surfactants could be minimized while 
still maintaining the high delivery efficiency.  
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Table 6.10 Comparison of in vitro aerosol DPPC deposition when varying the nebulization duration using the VCU very low-volume 
mixer-heater with surfactant-EEG. The modified controller and commercial controller was used to initiate nebulization at the start of a 
realistic inhalation breathing cycle. Values are mean (SD) percent of nominal dose, n=3. 
Controller Component 
Nebulization duration 
0.3 s 0.1 s 
Modified     
 Delivery device 2.7 (0.3) 3.1 (0.6) 
 Streamlined cannula 3.8 (0.3) 7.2 (1.7)* 
 Nose-throat model 1.2 (0.2) 1.5 (0.7) 
 Estimated lung dose 30.4 (2.8) 52.1 (1.7)* 
 Estimated respiratory loss 61.9 (2.0) 36.1 (2.9) 
    
Commercial     
 Delivery device 7.5 (3.2) 6.1 (0.9)^ 
 Streamlined cannula 8.1 (1.8)‡ 5.3 (1.4) 
 Nose-throat model 5.2 (1.7)‡ 0.8 (0.3)# 
 Estimated lung dose 14.7 (0.3)‡ 31.2 (0.4)#^ 
 Estimated respiratory loss 64.6 (3.1) 56.7 (0.4) 
*Significant difference compared to nebulization duration of 0.3 s with modified controller; Student’s t-test, p<0.05 
#Significant difference compared to nebulization duration of 0.3 s with commercial controller; Student’s t-test, p<0.05 
‡Significant difference compared to modified controller at nebulization duration of 0.3 s; Student’s t-test, p<0.05 
^Significant difference compared to modified controller at nebulization duration of 0.1 s; Student’s t-test, p<0.05 
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Figure 6.14 Comparison of in vitro aerosol DPPC deposition when varying the nebulization 
duration using the VCU very low-volume mixer-heater with surfactant-EEG and the modified 
controller initiating nebulization at the start of a realistic inhalation breathing cycle. Bars represent 
the mean value, error bars represent the SD, n=3. *Significant difference; Student’s t-test, p<0.05. 
 
6.3.5.4 VCU very low-volume mixer-heater with the commercial controller 
Using the modified controller, it was not possible to further increase the driving amplitude 
as it was operated at the maximum setting in previous studies. Therefore, in an attempt to increase 
the aerosol output from the VCU very low-volume mixer-heater, the commercial controller was 
used in a series of studies to operate the Aerogen® Solo. Aerosol deposition in the realistic infant 
airway model and delivery time with the surfactant-EEG formulation was studied to determine the 
delivery efficiency compared to the modified controller.  
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6.3.5.4.1 Effect of the commercial controller on the aerosol droplet size from the VCU very 
low-volume mixer-heater 
The initial droplet aerosol size distribution of the surfactant-EEG aerosols exiting the 
nebulizer outlet and following passage through the VCU very low-volume mixer-heater at the 
tubing exit were determined following aerosol generation using the commercial controller. Size 
distribution measurements were performed in an environmental chamber set to 25 °C and 99% RH 
as previously described.  
The initial size of the nebulized aerosol revealed large aerosol droplets exiting the 
nebulizer, with a mean ± SD MMAD of 4.2 ± 0.3 µm and GSD 1.8 ± 0.1, compared to those 
generated with the modified controller (MMAD of 2.5 µm). The aerosol produced following 
passage through the VCU very low-volume mixer-heater and exiting the delivery tubing was 
observed to have a significantly reduced MMAD of 2.0 ± 0.4 µm (p<.0001; Student’s t-test) 
compared to the droplets measured at the exit of the nebulizer. A bimodal distribution was 
observed for the aerosol exiting the VCU very low-volume mixer-heater, which was determined 
to be significantly more polydisperse than the initial aerosol generated by the nebulizer (p=0.0088; 
Student’s t-test). The bimodal distribution suggests that partial or incomplete drying may have 
occurred in the mixer-heater which had a final size of 2.0 µm compared to the MMAD of 1.0 µm 
observed with the modified controller. As observed with the modified controller, the use of the 
VCU very low-volume mixer-heater to generate an aerosol was found to have a significant effect 
on the particle fractions less than 1 µm and 5 µm, with higher particle fractions observed with the 
VCU very low-volume mixer-heater compared to the nebulizer alone (p=0.0022 and p<.0001, 
respectively; Student’s t-test). Data are shown in Table 6.9 and plotted in Figure 6.15.  
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As expected, the droplets produced with the commercial controller were significantly 
larger when compared to those produced with the modified controller, both at the exit of the 
nebulizer and at the exit of the delivery tubing connected to the mixer-heater (p=0.0039 and 
p=0.0027, respectively; Student’s t-test). The higher output from the nebulizer (281 ± 67 µL/min), 
when operated by the commercial controller, resulted in less evaporation of the droplets as they 
exited the nebulizer due to the higher local concentration and therefore the larger observed droplet 
size compared to the modified controller which produced a lower output. The VCU very low-
volume mixer-heater was not able to completely dry the higher output of larger droplets. The 
aerosol output with the commercial controller was observed to be significantly larger than the 
aerosol droplets exiting the VCU very low-volume mixer-heater that were produced using the 
modified controller. Aligned with the significantly larger aerosol size observed, there were 
significant differences in the particle fractions less than 1 µm and 5 µm, with higher particle 
fractions observed with the modified controller compared to the commercial controller (nebulizer 
exit: p=0.0040 and p=0.0038, delivery tubing exit: p=0.0004 and p=0.0018, respectively; Student’s 
t-test).  
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Figure 6.15 Aerosol droplet size distributions of the Aeroneb® Solo nebulizer output (nebulizer 
exit) and following delivery from the very low-volume mixer-heater (delivery tubing exit) of 0.5% 
w/v surfactant-EEG formulation generated by the Aerogen® Solo with the commercial controller. 
Markers represent the mean value, error bars represent the SD, n=5. 
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6.3.5.4.2 Effect of the commercial controller on the in vitro regional aerosol deposition from 
the VCU very low-volume mixer-heater 
Deposition testing with the commercial controller was performed with the VCU very low-
volume mixer-heater using nebulization durations of 0.3 s and 0.1 s. A volume of 750 µL of 
surfactant-EEG formulation was filled into the nebulizer and allowed to run to dryness, which took 
8.4 ± 0.3 minutes and 25.7 ± 0.4 minutes for the 0.3 s and 0.1 s nebulization durations, respectively, 
and delivered 123.7 ± 3.1 and 263.8 ± 3.5 µg of DPPC (or an estimated 233 and 498 µg of total 
phospholipids). Table 6.10 shows the DPPC deposition of the emitted aerosol on the different 
components in for each nebulization duration.  
Similar emitted doses from the nasal cannula were observed for the nebulization durations 
of 0.3 s and 0.1 s with the commercial controller (84.5 ± 4.6% and 88.6 ± 0.6% of nominal dose, 
respectively). Figure 6.16 compares the DPPC deposition for two nebulization durations with the 
commercial controller. Significant differences were observed with deposition in the nose-throat 
model and the estimated % lung dose. The nebulization duration of 0.3 s was observed to have 
significantly higher deposition in the infant model compared to the nebulization duration of 0.1 s 
(p=0.0123; Student’s t-test), which may be due to less deposition during exhalation with the shorter 
nebulization duration.  
The shorter nebulization duration of 0.1 s resulted in a significantly higher estimated % 
lung dose of DPPC compared to the nebulization duration of 0.3 s (p<.0001; Student’s t-test), 
however, the rate of drug delivery should also be considered. The nebulization of 750 µL of 
surfactant-EEG at the nebulization duration of 0.1 s took 26 minutes to deliver, which was more 
than 3 times longer than with the nebulization duration of 0.3 s. An estimated 715 µg of 
phospholipids would be delivered in 26 minutes if a nebulization duration of 0.3 s were to be used, 
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nearly 1.5x more phospholipids than with the 0.1 s nebulization duration (498 µg of total 
phospholipids). The delivery time of surfactants would be minimized at the higher nebulization 
duration but at the expense of delivery efficiency, which holds true when the results are compared 
with the modified controller.  
 
 
 
Figure 6.16 Comparison of in vitro aerosol DPPC deposition when varying the nebulization 
duration using the VCU very low-volume mixer-heater with surfactant-EEG and the commercial 
controller initiating nebulization at the start of a realistic inhalation breathing cycle. Bars represent 
the mean value, error bars represent the SD, n=3. *Significant difference; Student’s t-test, p<0.05. 
Use of the commercial controller resulted in a significantly lower estimated % lung dose 
of DPPC for both nebulization durations compared to those measured with the modified controller 
(0.3 s nebulization duration: p=0.0006, 0.1 s nebulization duration: p<.0001; Student’s t-test). For 
the 0.3 s nebulization duration, higher DPPC deposition was observed on all components using the 
commercial controller system compared to the modified controller system, with the cannula and 
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nose-throat model having significantly higher DPPC deposition (p=0.0152 and p=0.0171, 
respectively; Student’s t-test). With the 0.1 s nebulization duration, the DPPC deposition in the 
delivery device was significantly higher using the commercial controller system compared to the 
modified controller system (p=0.0086; Student’s t-test).  
The drug delivery rate was compared for the different combinations of controller type and 
nebulization durations. The estimated % lung dose was used to determine the estimated amount of 
phospholipids delivered (based on recovered DPPC lung dose and the Survanta® label claim) and 
then used to determine the estimated delivery rate of phospholipids to normalize the results for 
delivery time. The results are shown in Table 6.11. 
The modified controller with 0.1 s nebulization duration was shown to have the highest 
estimated % lung dose but the slowest estimated delivery rate for phospholipids. The commercial 
controller with 0.3 s nebulization duration was observed to have the highest delivery rate for 
phospholipids but the lowest estimated % lung dose. The other two controller-nebulization 
duration combinations (modified controller with 0.3 s nebulization duration, commercial controller 
with 0.1 s nebulization duration) had results that were somewhere in between. It appears that a 
balance between drug delivery rate and delivery efficiency needs to be determined for optimal 
delivery of surfactants using the VCU very low-volume mixer-heater. 
The use of surfactant therapy as supplemental treatment for infants with bronchiolitis has 
only been proposed and the dose that would be needed to elicit an effect (hasten the resolution of 
symptoms) is not known. Dose estimates based on current treatment protocols for neonatal RDS 
with commercial replacement surfactant would likely result in an overestimate as delivery of a 
liquid bolus is known to be much less efficient than delivery in an aerosolized form when the target 
site is the peripheral region of the lungs. Aerosolized delivery of surfactants on animal models 
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have shown that as little as 2 mg of phospholipids per kg of body weight has been observed to 
show improved outcomes [83]. For an 8 kg infant, this would be delivery of 16 mg of 
phospholipids, which would take between 9.6 h to administer by the fastest, but least efficient 
method (commercial controller with 0.3 s nebulization duration) to 42.3 h (1.8 days) with the 
slowest, but most efficient method (modified controller with 0.1 s nebulization time). With the 
commercial controller and 0.1 s nebulization duration, 16 mg of phospholipids could be 
theoretically delivered in 13.7 hours, which is reasonable considering that treatment would be 
administered concomitantly with supplemental oxygen support, possibly alleviating symptoms in 
a shorter time than the typical 2 to 3 days that most children spend in the hospital when admitted 
for treatment for bronchiolitis [46].    
 
Table 6.11 Comparison of estimated delivered doses and respiratory losses for the nebulization 
durations of 0.3 s and 0.1 s with the modified and commercial controllers using the VCU very low-
volume mixer-heater. Values are mean (SD), n=3. 
Controller,  
nebulization duration 
Estimated lung 
dose,  
% nominal 
Estimated PL 
delivery,  
µg 
Estimated PL 
delivery, 
µg/min 
Respiratory 
loss,  
% nominal 
Modified, 0.3 s 30.4 (2.8) 397.8 (37.9) 9.9 (1.0) 61.9 (2.0) 
Modified, 0.1 s 52.1 (1.7) 812.6 (31.2) 6.3 (0.2) 36.1 (2.9) 
Commercial, 0.3 s 14.7 (0.2) 233.4 (5.8) 27.9 (0.4) 64.6 (3.1) 
Commercial, 0.1 s 31.2 (0.4) 497.7 (6.5) 19.4 (0.2) 56.7 (0.4) 
PL=phospholipids 
 
 
Aerosolization with the commercial controller resulted in increased respiration loss for 
both nebulization durations, 64.6 ± 3.1% of nominal dose for nebulization duration of 0.3 s and 
56.7 ± 0.4% of nominal dose for nebulization duration of 0.1 s, compared to the estimated losses 
with the modified controller. To study the unexpectedly high estimated respiration loss in the 
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system, the commercial controller with nebulization duration of 0.1 s was selected as it was shown 
to have the second highest estimated % lung dose, second lowest respiratory loss and second 
highest phospholipid delivery rate (Table 6.11).  
6.3.5.4.3 Assessment of DPPC recovered dose using steady state inhalation flow with the 
very low-volume mixer-heater and the commercial controller 
With the commercial controller and nebulization duration of 0.1 s, aerosol deposition 
studies were repeated with a total capture aerosol filter (replacing the infant airway model) placed 
at the exit of the nasal cannula in an attempt to determine the fate of the delivered aerosol. Steady 
state inhalation flow of 30 L/min was drawn through the filter to capture the aerosol exiting the 
cannula. Surfactant-EEG nebulizer formulation volumes of 750 µL were filled into the nebulizer 
and allowed to run to dryness.  
Table 6.12 and Figure 6.17 shows a comparison of the DPPC deposition and recovery for 
the steady state inhalation experiments compared with the previously described deposition and 
recovery observed using similar conditions and sampled with a realistic breathing cycle. The 
output rate measured during the steady state inhalation experiments was similar to previous 
experiments with the breathing cycle. Significantly higher deposition was observed in the delivery 
device and cannula components when compared to those observed with delivery using a realistic 
breathing profile (p=0.0004 and p=0.0090, respectively; Student’s t-test). The mean ± SD total 
recovered dose using a steady state inhalation flow of 30 L/min was 74.8 ± 0.8% of the nominal 
dose which was significantly higher than the recovery observed during realistic breathing (43.3%), 
due to the capture of the respiration losses. However, it was expected that the use of a steady state 
inhalation flow would allow capture of all of the emitted aerosol exiting the cannula and mass 
balance of DPPC would be observed compared to the nominal dose. However, approximately 25% 
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of the nominal dose was not accounted for during the steady state study. One hypothesis was that 
the DPPC stability was affected by the heating process during the aerosol drying. Small changes 
in the chemical structure would affect its molecular weight and therefore its quantitative analysis 
using the LC-MS method.   
 
Table 6.12 Comparison of DPPC aerosol deposition and recovery from the very low-volume mixer 
heater captured using a realistic breathing cycle and a steady state inhalation flow of 30 L/ min. 
Steady state inhalation deposition experiments were performed using heated and room temperature 
ventilation gas flowing through the very low-volume mixer heater with the commercial controller 
with 0.1 s nebulization duration. Values are mean (SD), n=3. 
Parameter 
Realistic breathing 
cycle with nose-
throat model 
Steady state 
inhalation, 
heated gas 
Steady state 
inhalation, 
 room temp gas 
Output rate, µL/min 28.6 (0.4) 27.3 (0.5) 22.1 (0.5) 
Recovered dose, % nominal 43.3 (0.4) 74.8 (0.8) 79.3 (0.4) 
Delivery device, % nominal 6.1 (0.9) 13.9 (0.8)* 7.8 (1.3)# 
Cannula, % nominal 5.3 (1.4) 9.3 (0.4)* 22.1 (3.1)*# 
Filter, % nominal 31.9 (0.2) 52.8 (1.7) 49.4 (1.5) 
Statistical analysis only performed on delivery device and cannula components: 
*Significant difference compared to experiments with exhalation; Student’s t-test, p<0.05 
#Significant difference compared to constant inspiratory with heat; Student’s t-test, p<0.05 
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Figure 6.17 Comparison of DPPC aerosol deposition from the VCU very low-volume mixer heater 
captured using a realistic breathing cycle and a steady state inhalation flow of 30 L/ min. Steady 
state inhalation deposition experiments were performed using heated and room temperature 
ventilation gas flowing through the VCU very low-volume mixer heater with the commercial 
controller with 0.1 s nebulization duration. Bars represent the mean value, error bars represent the 
SD, n=3. *Significant difference; Student’s t-test, p<0.05. RT=room temperature 
6.3.5.4.4 Assessment of DPPC recovered dose using room temperature ventilation gas with 
using the very low-volume-mixer-heater and the commercial controller with steady 
state inhalation flow 
The DPPC recovered dose was assessed using an aerosol generated from the VCU very 
low-volume mixer-heater using room temperature ventilation gas. Surfactant-EEG nebulizer 
formulation volumes of 750 µL were filled into the nebulizer and allowed to run to dryness.  
The mean ± SD total recovered dose for constant inspiratory flow was 79.3 ± 0.4% of the 
nominal dose using the room temperature ventilation gas which was not significantly different 
from the studies performed with the heated ventilation gas (74.8%) as shown in Table 6.12. There 
was also no significant difference observed in the filter deposition (Table 6.12 and Figure 6.17). 
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This suggests that heating the DPPC aerosol likely did not affect its stability with its observed total 
recovery remaining unchanged despite changes in its regional deposition due to its likely larger 
size when delivered using room temperature ventilation gas. Significantly higher deposition was 
observed in the cannula component using room temperature ventilation gas when compared to 
heated ventilation gas experiments with breathing or using state-steady inhalation flow (p=0.0010 
and p=0.0021, respectively; Student’s t-test). This was expected as the absence of heat resulted in 
aerosol that was incompletely dried when exiting the VCU very low-volume mixer-heater resulting 
in larger sized aerosol that deposited by impaction onto the cannula interface. 
6.4 Conclusions 
The objective of this study was to determine the delivery efficiency of novel low-volume 
mixer-heater systems in use with an EEG dispersion of commercial surfactant with sodium 
chloride and mannitol using a commercial vibrating mesh nebulizer. Albuterol sulfate solutions 
were used to perform studies to determine the efficiency of a novel delivery system, which was 
compared to the performance of a front-loaded infant face mask standard of care system (Specific 
aim 4-1). The optimal nebulization trigger time and nebulization duration settings were determined 
for the novel delivery system (Specific aim 4-2) using realistic breathing conditions and a realistic 
in vitro infant model. Following modifications to the novel low-volume mixer-heater system, the 
aerosol performance with a surfactant-EEG formulation was determined (Specific aim 4-3). An 
albuterol sulfate solution of 0.5% w/v was selected for use in optimization studies due to its 
established assay method and ease of extraction from sample components given its high solubility 
in water.  
Comparison of steady state experiments with the novel low-volume mixer-heater and the 
face mask standard of care system revealed significant differences in deposition; highest 
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deposition with the low-volume mixer-heater system was an estimated % lung dose of 76% of 
nominal dose, whereas the face mask delivery system had the highest deposition on the nose-throat 
model of 74% of nominal dose. This is due to the size of the aerosol droplets entering the model 
for each of the systems, 1.4 µm and 5.0 µm for the mixer-heater and face mask systems, 
respectively. The low-volume mixer-heater was able to dry the aerosol droplets exiting the 
nebulizer sufficiently enough to navigate through the passageways of the nose-throat model to 
reach the filter for a high estimated % lung dose.  
Incorporation of a realistic breathing profile significantly reduced the estimated % lung 
dose for both the low-volume mixer-heater and face mask standard of care systems, 12% and 5.2% 
of nominal dose, respectively. The significant difference observed in the estimated % lung dose is 
due to the rapid and shallow breathing pattern characteristic to infants; the profile consisted of a 
0.5 s inhalation and 1 s exhalation with a tidal volume of 56 mL. The controller and delay timer 
settings were studied to maximize the estimated % lung dose for the low-volume mixer-heater 
system. With a driving amplitude of 4 Vpp, a nebulization trigger time of 0.4 s prior to the next 
inhalation and a nebulization duration of 0.2 s, the estimated % lung dose was increased to 35% 
of nominal dose, a significant improvement over the <4% of nominal dose using standard of care 
methods as reported in literature [103, 155]. However, sizing experiments showed that there was 
still room for improvement of the mixer-heater system.  
Design changes to the low-volume mixer-heater were made to improve efficiency over the 
current design. The very low-volume mixer-heater was developed with an external heat source 
which allowed the mixer-heater volume to be reduced from 61.6 mL to 2.7 mL. Performance of 
the very low-volume mixer-heater system was determined with a surfactant-EEG formulation 
prepared with the Survanta® commercial formulation and mannitol. With the modulated controller 
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and nebulization duration of 0.3 s, the estimated % lung dose was determined to be 30% of nominal 
dose with a phospholipid delivery rate of 10 µg/min. Increased efficiency was observed with a 
lower nebulization duration of 0.1 s, estimated % lung dose of 52% of nominal, but a sacrifice in 
the phospholipid delivery rate to 6 µg/min. Use of the commercial controller was explored to 
increase the phospholipid delivery rate. At a nebulization duration of 0.1 s with the commercial 
controller, the estimated % lung dose was determined to be 31% of nominal dose with a 
phospholipid delivery rate of 19 µg/min, an improvement over that of the modulated controller. 
A potential issue with this study is the low recovered doses seen with experiments 
performed both with and without exhalation incorporated. Due to the low solubility of DPPC in 
water, <5 µg/mL, the use of methanol was employed whenever possible. However, the nebulizer, 
mixer-heater, cannula, and nose-throat model are susceptible to breakdown when in contact with 
organic solvents, thus water was used to wash the components and then methanol was combined 
with the water wash to dissolve the drug. This procedure likely led to the low observed recoveries. 
Exploration of other washing techniques could possibly be explored in order to improve the 
percent of drug recovered.   
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CHAPTER 7 
7 ASSESSMENT OF THE EFFECT OF SPRAY DRYING PROCESSES ON 
SURFACTANT PROTEIN CONCENTRATION 
7.1 Introduction 
The fundamental role that surfactant proteins play in proper pulmonary surfactant function 
necessitates the need to ensure their presence and activity in the final surfactant-EEG formulation. 
After processing for human use, commercially available natural surfactant formulations contain 
only the two hydrophobic proteins, SP-B and SP-C. The two proteins are subject to various stresses 
at multiple points throughout formulation processing such as: (i) thermal stress from sonication at 
elevated temperatures, (ii) shear stress due to cavitation during sonication, (iii) sheer stress, 
dehydration stress and stress due to adsorption of the proteins to the air-liquid interface during the 
atomization process of spray drying. The multiple stressors can lead to physicochemical 
degradation and possible loss of activity.  
The most common physical deaggregation that proteins undergo is denaturation, or protein 
unfolding, which may occur during the atomization process in spray drying. During droplet 
formation, large air-liquid interfaces are produced causing the proteins to adsorb to the surface and 
unfold, which results in partial or total loss of the tertiary and possibly secondary structures of the 
proteins leading to loss of activity [110]. Covalent aggregation is a common chemical degradation 
mechanism of proteins. Since SP-B contains disulfide bonds, the hydrophobic protein may 
undergo degradation by covalent aggregation in which a free thiol of one protein carries out a 
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nucleophilic attack on the disulfide linkage of another protein molecule creating a new 
intermolecular disulfide bond [162]. Further propagation of this would lead to insoluble high 
molecular weight aggregates and loss of activity. 
Another common chemical degradation mechanism that can significantly alter protein 
structure and function is deamidation – hydrolysis of the side chain amide on glutamine or 
asparagine residues to yield a carboxylic acid [110]. SP-B has four glutamine residues and SP-C 
has one asparagine residue, indicating that both proteins may undergo deamidation. Oxidation of 
proteins results in formation of sulfoxide derivatives, with methionine as the most susceptible 
amino acid; SP-B has two methionine residues and SP-C has one. As described, the hydrophobic 
surfactant proteins are expected to undergo protein conformation changes following processing, 
which further stresses the need to assess their presence and activity in the final surfactant-EEG 
formulation. 
Analysis of the surfactant proteins pose a particularly difficult challenge as: (i) their 
hydrophobic nature makes them difficult to separate from the mixture of lipids, and (ii) there are 
low and variable quantities of protein present in the commercial formulations used to prepare the 
final EEG formulations. The concentration of the combined proteins (both SP-B and SP-C) in 
Survanta® is <1 mg/mL [30], which may differ from batch-to-batch since the surfactant is derived 
from bovine sources that naturally vary in components, approximately 0.10-0.13% w/w SP-B and 
0.5% w/w SP-C compared to endogenous bovine surfactant [11, 163]. Survanta® is prepared by 
lavage of minced whole bovine lung that undergoes different levels of centrifugation followed by 
extraction with organic solvent and then supplementation with DPPC, palmitic acid, and 
tripalmitin. The last processing steps include organic solvent evaporation and resuspension in 
saline by sonication [164]. The surfactant formulation endures sonication for preparation of the 
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commercial product, which indicates that the hydrophobic proteins are able to withstand the energy 
input of sonication and should therefore be present following sonication employed during EEG 
formulation preparation.  
Minocchieri et al. have studied the effect of nebulization on surfactant [165]. Using 
transmission electron microscopy and the Langmuir-Wilhelmy balance, the authors suggested that 
similarities in characteristics found between non-nebulized and nebulized surfactant would result 
in similar clinical effect and therefore concluded that vibrating mesh nebulizers are suitable for 
surfactant nebulization. Since spray drying employs similar methods of nebulization to atomize 
feed solutions and suspensions, the presence of surfactant proteins should be detected following 
the spray drying process.  
The aim of this study was to establish a method for determining protein presence in the 
commercial Survanta® suspension and then apply the technique to samples from each step involved 
in preparation of surfactant-EEG formulations prepared with the commercial suspension. 
7.2 Materials and methods 
7.2.1 Protein purification by precipitation 
Protein precipitation enables concentration and purification of the protein sample from 
interfering substances, such as salts and detergents (surfactants), for downstream applications. In 
the commercial Survanta® formulation, the proteins need to be separated from a complex mixture 
of salt and lipids. Lipids are insoluble in polar solvents like water, but highly soluble in non-polar 
or weakly polar organic solvents (e.g. chloroform, acetone, ether, benzene), while amino acids, the 
subunits of protein, are largely insoluble in the lipid solvents.  
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Pérez-Gil et al. [18] determined the solubilities of the hydrophobic surfactant proteins, SP-
B and SP-C, isolated from minced porcine lungs. At the protein concentration of 7.5 µg/mL, the 
authors observed that only minimal amounts of SP-B were soluble in 100% acetonitrile, whereas 
pure trifluoroethanol or methanol dissolved SP-B almost completely (90-95%); in addition, neither 
methanol nor methanol/water mixtures dissolved an estimable amount of SP-C (Figure 7.1).  
The use of different solvents was investigated for protein purification from Survanta®, 
which included hexane/isopropanol, acetone, methanol/chloroform and trichloroacetic acid in 
acetone. Samples were then directly infused into the mass spectrometer (see section 7.2.2). 
 
 
Figure 7.1 Solubility of SP-B (top) and SP-C (bottom) in different organic solvent/water mixtures 
at protein concentrations of 7.5 µg/mL; TFE = trifluoroethanol (circles), MeOH = methanol 
(triangles), ACN = acetonitrile (squares) [18]. 
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7.2.1.1 Hexane/isopropanol 
Methods described by Rodriguez-Vico et al. [113] for a protein precipitation procedure 
using a hexane-isopropanol mixture was applied to Survanta®. A 100 µL aliquot of the commercial 
suspension was mixed with 5 mL of hexane/isopropanol (3:2, v/v). The mixture was then 
centrifuged for 15 min at 4000×g (Sorvall™ ST 16R, ThermoFisher Scientific Inc., Waltham, 
MA). The supernatant, containing lipids, was discarded and the pellet, containing protein, was 
dried off with a stream of nitrogen gas.  
7.2.1.2 Methanol/chloroform 
A methanol/chloroform procedure for protein purification was adapted from Wessel et al. 
[166]. In a microcentrifuge tube, methanol was combined with Survanta® in a ratio of 4:1 (0.40 
mL methanol, 0.10 mL Survanta®) and vortexed. Chloroform was added in the same volume as 
the starting Survanta® sample volume, 0.10 mL, then vortexed. Deionized water was next added 
in a ratio of 3:1 of the starting Survanta® sample volume, 0.30 mL, then vortexed. The mixture 
was centrifuged for 5 min at 14000×g, which resulted in 3 layers: 1) large aqueous top layer, 2) 
protein interphase, and 3) smaller chloroform bottom layer. The top layer was carefully removed 
and discarded. An additional 0.40 mL of methanol was added to the interphase/chloroform 
mixture, then vortexed. The mixture was centrifuged for 5 min at 14000×g to cause the precipitate 
to adhere to the tube walls. The supernatant was removed and the protein pellet was dried under a 
stream of air. 
7.2.1.3 Acetone  
The use of acetone for protein precipitation is a common method for precipitation and 
concentration of proteins. A straight forward method described by Pierce Biotechnology was 
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employed for acetone precipitation of proteins in Survanta® [167]. In an acetone-compatible 
polypropylene microcentrifuge tube (Fisherbrand™, ThermoFisher Scientific Inc., Waltham, MA) 
cold acetone (-20 °C) was combined with Survanta® in a ratio of 4:1 (1.2 mL aliquot of acetone, 
0.30 mL aliquot of Survanta®) and vortexed. The sample mixture was incubated for 60 min at -20 
°C acetone, then centrifuged for 10 min at 14000×g. The supernatant was separated from the pellet 
and the acetone wash/incubation/centrifuge process was repeated two additional times with the 
collected pellet. After the third wash procedure, the acetone was dried, uncapped, at room 
temperature for 30 min. 
7.2.1.4 Trichloroacetic acid in acetone 
A method using trichloroacetic acid (TCA) in acetone was adapted from Nejadi et al [168]. 
A 15% w/v solution of TCA in acetone was prepared and cooled to -20 °C. The TCA solution was 
combined with Survanta® in a ratio of 4:1 (1.2 mL TCA in acetone, 0.30 mL Survanta®) and 
equilibrated at -20 °C for 60 min. After 60 min, the sample was centrifuged at 15000×g at 4 °C 
for 20 min. The supernatant was carefully removed and discarded and the pellet was dried at room 
temperature for 60 min. 
7.2.2 Analysis by direct infusion into mass spectrometer 
Pelleted samples prepared from protein precipitation methods were reconstituted in 
methanol and directly infused into a triple quadrupole mass spectrometer (Micromass® Quattro, 
Waters Corporation, Milford, MA) using positive electrospray ionization mode. A programmable 
syringe pump (Harvard Apparatus 55-1144 model 44, Harvard Apparatus, Holliston, MA) and a 
500 µL glass syringe (GASTIGHT® 1750, Hamilton Co., Reno, NV) were used to infuse samples 
at a rate of 10 µL/min. The mass spectrometer (MS) was set to collect ≥ 60 scans from different 
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m/z ranges within 200-2000 (e.g. scans were collected every 2 s for m/z 1200-2000, therefore the 
MS was set to scan for a total time of 2 min). The initial mass spectrometer settings were set per 
manufacturer suggestions and from preliminary tuning studies with rabbit SP-B standards from an 
ELISA kit for detection of bovine SP-B (MyBioSource, San Diego, CA); parameter settings for 
the electrospray ionization are shown in Table 7.1.  
 
Table 7.1 Starting electrospray mass spectrometer settings for analysis of surfactant samples 
MS Parameter Setting 
Capillary voltage, kV 3.5 
Cone voltage, V 35 
Extractor voltage, V 3 
RF lens voltage, V 0.3 
Source temperature, °C 120 
Desolvation temperature, °C 300 
Desolvation flow, L/h 250 
Cone flow, L/h 50 
Multiplier 400 
 
 
7.2.3 Protein purification by analytical chromatographic separation 
Characteristics for the bovine surfactant proteins are listed in Table 7.2. Based on their 
amino acid sequence, the isoelectric point (pI) for SP-B and SP-C were predicted from an online 
computing tool, ExPASy Compute pI/Mw [169-171].  
Amino acids are classified as hydrophilic or hydrophobic depending on their side chains 
and the side chain interaction with water is used to determine its hydropathy index [172] – the 
larger the number, the more hydrophobic. The hydropathy index values were estimated using an 
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online GRAVY calculator [173]. GRAVY is the grand average of hydropathy, the value of which 
is the sum of hydropathy values of all amino acids divided by the protein length. 
Separation based on hydrophobicity was performed with a protein column (XBridge® 
protein Bridged Ethyl Hybrid (BEH) C4 column, 300Å, 3.5 µm, 2.1 mm x 100 mm, 0.35 mL 
column volume, Waters Corporation, Milford, MA). The use of different mobile phase solvents 
were explored following published methods [174, 175]. The electrospray mass spectrometry 
conditions were the same as those used in the direct infusion experiments (Table 7.1). 
 
Table 7.2 Comparison of bovine SP-B and SP-C characteristics [169-173]. 
Characteristic SP-B SP-C 
Isoelectric point 9.03 8.96 
Hydropathy index 1.09 2.58 
Protein chain length 79 34 
Monoisotopic mass (Da) 8699.78 3565.24 
Cationic residues 8 2 
 
 
7.2.4 Non-specific assay of proteins 
Fluorescamine, sodium phosphate (Na2HPO4), and sodium phosphate monobasic 
(NaH2PO4•H2O) were purchased from Fisher Scientific Co. (Hanover Park, IL). Survanta® 
(beractant) intratracheal suspension was purchased from Cardinal Health, Inc. (Greensboro, NC) 
and stored at 2-8 °C. Pearlitol® PF-mannitol was donated from Roquette Pharma (Lestrem, 
France). 
For non-specific analysis of proteins, the reagent fluorescamine is commonly used for 
detection of primary amino acid groups [176]. The Survanta-EEG formulation was prepared and 
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spray dried as described in Chapter 4, but without leucine since it is an amino acid and its presence 
would be detected in the fluorescamine assay. Samples prepared for analysis and theoretical 
protein content based on the Survanta® label claim [30] are listed in Table 7.3. The theoretical 
protein concentration was first determined for the feed dispersion samples, then used to calculate 
the amount of Survanta® and Survanta-EEG powder needed to target the same concentration in the 
samples. 
 
Table 7.3 Prepared protein samples and theoretical protein content for fluorescamine assay. 
Protein sample 
Sample 
aliquot 
MeOH 
diluent,  
mL 
Theoretical total 
protein concentration,  
mg/mL 
Survanta® 0.35 mL 20 0.0175 
Feed dispersion post-sonication 0.25 mL n/a 0.0173 
Bypass feed dispersion  0.25 mL n/a 0.0173 
Survanta-EEG powder (without leucine) 12.5 mg 10 0.0172 
 
  
An aliquot (0.25 mL) of each prepared protein sample was combined with 1.25 mL of 0.05 
M sodium phosphate buffer, pH 8, in a test tube. During vigorous shaking using a vortex mixer, 
0.50 mL of fluorescamine in acetone (0.30 mg/mL) was rapidly added using a syringe. Aliquots 
of 100 µL were transferred in triplicate to a 96-well plate and fluorescence measurements were 
made with excitation and emission wavelengths set to 390 nm and 475 nm, respectively, using a 
Synergy™ H1 Hybrid Multi-Mode Reader (BioTek Instruments, Inc., Winooski, VT).  
7.2.5 Enzymatic assay of proteins 
Enzyme-linked immunosorbent assay (ELISA) kits (Bovine Pulmonary Surfactant-
Associated Protein B (SP-B) ELISA kit MBS703513 and Bovine Pulmonary Surfactant-
  
 
233 
Associated Protein C (SP-C) ELISA kit MBS700517, MyBiosource.com, San Diego, CA) were 
used to determine the presence of proteins at the different processing steps during formulation 
preparation. The assay used a sandwich enzyme technique specific for SP-B or SP-C. 
 Standards were prepared following manufacturer instructions. Samples were prepared by 
diluting Survanta®, feed dispersions post-sonication, feed dispersions bypassed on the spray dryer, 
and leucine-Survanta-EEG powders in 60/40% v/v acetonitrile/water with theoretical protein 
concentrations of 100-500 µg/mL. Solvent selection was based on the work of Pérez-Gil et al. [18]  
(Figure 7.1). Standards were analyzed in duplicate, while samples were analyzed in triplicate. 
Repeat washing was performed with an automated microplate washer (Wellwash 4 Mk2, 
Labsystems, ThermoFisher Scientific Inc., Waltham, MA). Absorbance readings were measured 
at 450 nm using a microplate reader (Synergy™ H1 Hybrid Multi-Mode Reader, BioTek 
Instruments, Inc., Winooski, VT). 
7.3 Results and discussion 
7.3.1 Protein precipitation 
The precipitation of proteins from Survanta® was performed using hexane/isopropanol, 
methanol/chloroform, acetone, and TCA in acetone. The collected pellets were solubilized with 
methanol prior to direct infusion into the MS. A comparison of the scans collected from 200-2000 
m/z is shown in Figure 7.2. The acetone (Figure 7.2c) and TCA in acetone (Figure 7.2d) 
precipitation samples were observed to provide spectrums with a lower number of individual 
molecular ions, compared to the other solvents, perhaps indicating greater extraction specificity. 
The highest intensity molecular ions for the four precipitation methods was observed at m/z of 
734.7 and 757, indicating that DPPC was still present in the samples (DPPC+H+ of 734.6 m/z and 
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DPPC+Na+ of 756.6 m/z). The methanol/chloroform (Figure 7.2b) and TCA in acetone (Figure 
7.2d) precipitation methods appeared to be better at removing salt from the commercial 
formulation as the DPPC sodium adducts were observed to be lower when compared to the 
hexane/isopropanol and acetone precipitation methods, with the methanol/chloroform 
precipitation method showing the lowest ratio of DPPC+Na+ to DPPC+H+. This is likely due to 
sodium chloride having the higher solubility in methanol compared to the other solvents (NaCl 
solubility at 25 °C per 100 g solvent: 1.4 g in methanol; 0.003 g in isopropanol, but insoluble in 
hexane; 0.000042 g in acetone).  In addition, the methanol/chloroform procedure was the only 
method to use water as one of the wash solvents (NaCl solubility at 25 °C: 36 g /100 g water). 
The presence of DPPC as the highest observed ion in the precipitation samples indicates 
that the procedures used were not effective in purifying the hydrophobic proteins from the 
commercial surfactant formulation. However, it was still of interest to determine if the multiply 
charged molecular ions of the intact hydrophobic proteins could be detected. 
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Figure 7.2 Mass spectrum comparison of protein precipitation methods on Survanta® with (a) 
hexane/isopropanol, (b) methanol/chloroform, (c) acetone, and (d) TCA in acetone. 
(a)
(b)
(c)
(d)
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Using Q-TOF nano-ESI, the primary structure of SP-B was determined by Liu et al. [26] 
as follows: FPIPI PYCWL CRTLI KRIQA VIPKG VLAMT VAQVC HVVPL LVGGI CQCLV 
ERYSV ILLDT LLGRM LPQLV CGLVL RCSS. There are 8 basic amino acid residues in the 
sequence of the SP-B monomer – lysine (K), arginine (R) and histidine (H) – indicating eight 
possible ionization sites. Each monomer has four amphipathic a-helices and the cysteines (C) are 
all oxidized to form disulfide bonds, three intra-molecular disulfide bonds and one inter-molecular 
disulfide bond that links two SP-B monomers to create a homodimer [26, 177]. The ExPASy 
Compute pI/Mw tool determined the theoretical monoisotopic mass of the SP-B monomer as 
8699.78 Da. The mass of the dimer, with 7 disulfide bonds (2.016 Da decrease per disulfide bond 
[178]), was calculated to be 17395.53 Da. 
The sequence of SP-C was determined by Q-TOF nano-ESI as LIPCC PVNIK RLLIV 
VVVVV LVVVV IVGAL LMGL [26]. Rich in valine (V) and leucine (L), SP-C is the most 
hydrophobic of the surfactant proteins [179]. A single a-helix monomer with 34 amino acid 
residues, SP-C has a theoretical monoisotopic mass of 3565.24 Da. The two cysteines of the protein 
are palmitoylated [26, 174], which enables SP-C to improve the lipid monolayer stability and re-
spreading during expansion that occurs during inhalation [15]. Palmitoylation increases the 
monoisotopic mass of SP-C to 4041.70 Da (238.23 Da increase per palmitoylation [178]). 
Two techniques were used to process the electrospray data, Transform and Maximum 
Entropy (MaxEnt). The Transform algorithm developed by Micromass® (Wilmslow, United 
Kingdom) was used to convert the m/z electrospray data from direct infusion of the precipitation 
samples onto a molecular mass spectrum. The protein molecular weights of 17395.5, 8699.8, and 
4041.7 Da were assigned for the dimer of SP-B, the monomer of SP-B and the palmitoylated SP-
C, respectively. The Transform spectrums for each sample is shown in Figure 7.3. Since the 
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Transform algorithm requires that component mass values are assigned and also that the entered 
mass values are accurate, the resulting spectrum does not definitively indicate the presence of 
proteins. The Transform spectra for each of the samples from the different precipitation methods 
show a peak at each of the mass values entered. For the hexane/isopropanol, methanol/chloroform 
and acetone samples (Figure 7.3a, Figure 7.3b and Figure 7.3c, respectively), the peak at the mass 
of the homodimer was shown to have the highest intensity, whereas the highest intensity peak was 
observed at the mass value of the SP-B monomer in the TCA in acetone sample (Figure 7.3d).  
The MaxEnt tool, which uses the method of maximum entropy for deconvolution of 
electrospray data without the need to identify the proteins present, was also applied to the protein 
precipitation electrospray data to determine if the presence of proteins could be detected. The 
analysis was done over a broad mass range (3500 to 18500 Da) with a resolution of 1 Da/channel, 
to ensure that the entire mass range of the proteins was captured. Figure 7.4 shows the results from 
MaxEnt analysis for each precipitation method sample. As expected, many peaks were observed 
for all samples given their complex mixture. The precipitation sample prepared from acetone was 
observed to have a relatively distinct peak around 4400 Da. MaxEnt analysis was performed on 
this sample over a narrower output mass range (4000 to 5000 Da) using a finer resolution (0.5 
Da/channel) to obtain a more accurate mass value; the resulting MaxEnt spectrum shown in Figure 
7.5. The mass value was determined to be 4464.5 Da, which would be closest to that of 
palmitoylated SP-C (4041.7 Da), but a difference of 423 Da suggests that the hydrophobic protein 
could be associated with something else in the mixture or that this may be a fragment of the larger 
protein. Results were similar when the protein precipitation method with acetone was repeated 
(Figure 7.6). 
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Given the uncertainty with the precipitation methods explored when performed on the 
Survanta® formulation pre-processing, alternative methods were explored to separate the complex 
mixture of components in the commercial surfactant.  
 
 
Figure 7.3 Transform spectrum comparison of protein precipitation methods on Survanta® with 
(a) hexane/isopropanol, (b) methanol/chloroform, (c) acetone, and (d) TCA in acetone with output 
mass range set from 3500 to 18500 Da.
(a)
(b)
(c)
(d)
Hexane/isopropanol
Methanol/chloroform
Acetone
TCA in acetone
4063.6
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Figure 7.4 MaxEnt spectrum comparison of protein precipitation methods on Survanta® with (a) 
hexane/isopropanol, (b) methanol/chloroform, (c) acetone, and (d) TCA in acetone for output mass 
range set from 3500 to 18500 Da.  
(a)
(b)
(c)
(d)
Hexane/isopropanol
Methanol/chloroform
Acetone
TCA in acetone
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Figure 7.5 MaxEnt spectrum for acetone precipitate sample on Survanta® with output mass 
range of 4000 to 5000 Da with a resolution of 0.5 Da/channel. 
 
Figure 7.6 Repeat acetone protein precipitation sample (a) electrospray spectrum (b) Transform 
spectrum and (c) MaxEnt spectrum of Survanta®. 
(a)
(b)
(c)
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7.3.2 Analytical separation of Survanta® components 
Precipitation experiments to separate proteins from other hydrophobic components proved 
unsuccessful as a high concentration of lipids were still present in the samples, therefore, 
separation of the components using column chromatography was explored. A 300Å BEH C4 
column was used for separation and coupled to an ESI-MS for detection. Samples were prepared 
by diluting Survanta® in methanol and dissolving the Survanta-EEG powder formulation in 
methanol prior to LC-MS analysis.  
Following procedures adapted from Harayama et al. [174], initial experiments explored 
varying concentrations of methanol/water with 0.1% formic acid using both isocratic and gradient 
elution procedures. The MS parameters were as follows: capillary, 3.5 kV; cone, 35V; source 
temperature, 120 °C; desolvation temperature, 300 °C. Ion chromatograms showing the total ion 
count (TIC) were used as fingerprint patterns for evaluation of the separation of the constituent 
components of these complex formulations prior to analysis of their mass spectral profiles.   
The mobile phase composition that resulted in the best separation of components was 
determined to be 80/20% v/v methanol/water with 0.1% formic acid at a flow rate of 0.2 mL/min 
with an injection volume of 5 µL and a run time of 22 min (Figure 7.7, top).  The largest peak was 
observed at a retention time (Tr) of 9.07 min, which was identified as DPPC from the mass 
spectrum showing a m/z of 734.7 (Figure 7.8a). Figure 7.8b shows the mass spectrum for the peak 
at Tr of 6.97 min, which was observed to consist of a mixture of two phospholipids, palmitoyl-
oleoyl phosphatidylcholine (PC 16:0/14:0, exact mass of 705.5 Da) and palmitoylpalmitol-eoyl 
phosphatidylcholine (PC 16:0/16:1, exact mass of 731.6 Da), which are the two major fluidizing 
components in pulmonary surfactant [180]. At the retention time of 2.13 min, the mass spectrum 
reveals a peak at 496 m/z, indicating the fragment after an acyl chain loss from DPPC, [DPPC+H]-
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sn1 and [DPPC+H]-sn2 [181] (PC 16:0/0:0, exact mass of 495.3 Da, Figure 7.8c). The peak at Tr 
of 1.21 min could possibly be that of the proteins since the mass spectrum shows multiple peaks 
spaced apart, a pattern typically observed with multiply charged species.  
Although a good separation of the Survanta® components was observed with a mobile 
phase of 80/20% v/v methanol/water with 0.1% formic acid, a different separation profile was 
observed when a Survanta-EEG sample was run under the same conditions (Figure 7.7, bottom), 
which would make comparison of the two formulations problematic. 
 
 
 
Figure 7.7 Comparison of total ion count chromatograms obtained for commercial Survanta® 
formulation (top) and Survanta-EEG spray dried powder (bottom) separation in mobile phase of 
80/20% v/v methanol/water with 0.1% formic acid with injection volume of 5 µL, 0.2 mL/min 
flow rate and 22 min run time. 
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Figure 7.8 Mass spectra of Survanta® components separated using with 80/20% v/v 
methanol/water with 0.1% formic acid with injection volume of 5 µL, 0.2 mL/min flow rate and 
22 min run time. MS settings: capillary=3.5 kV, cone=35 V, source temperature=120 °C, 
desolvation temperature=300 °C.
(a)
(b)
(c)
(d)
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The use of acetonitrile as the eluting solvent instead of methanol was explored. Using a 
mobile phase composition of 80/20% v/v acetonitrile/water, acetonitrile was shown to elute the 
components earlier in the chromatographic profile compared to methanol (Figure 7.9b compared 
to Figure 7.9a), which was expected as acetonitrile generally has a higher elution strength when 
compared to methanol. Different concentrations of acetonitrile in the mobile phase were explored 
while the flow rate was maintained at 0.2 mL/min. An improved separation was achieved by 
decreasing the concentration of acetonitrile to 60% (Figure 7.9c). A shorter run time of 15 min 
was used with the improved solvent mobile phase composition. Analysis of the spray dried powder 
formulation showed a similar finger print separation of the components compared to the Survanta® 
formulation using these chromatographic separation conditions. A blank injection of methanol was 
run and subtracted from both samples; a comparison of the Survanta® and Survanta-EEG total ion 
chromatograms are shown in Figure 7.10. 
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Figure 7.9 Comparison of mobile phase solvents (a) 80/20% v/v MeOH/H2O with 0.1% formic 
acid, (b) 80/20% v/v ACN/H2O with 0.1% formic acid, and (c) 60/40% v/v ACN/H2O with 0.1% 
formic acid on separation of Survanta® components with 5 µL injection volume and 0.2 mL/min 
flow rate. MeOH=methanol, H2O=water, ACN=acetonitrile. 
 
 
 
(a)
(b)
(c)
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Figure 7.10 Comparison of commercial Survanta® formulation (top) with Survanta-EEG spray 
dried powder (bottom) separation in mobile phase of 60/40% v/v acetonitrile/water with 0.1% 
formic acid with 5 µL injection volume, 0.2 mL/min flow rate and a 15 min run time. 
Each of the separated chromatographic peaks in the Survanta® total ion mass 
chromatogram was assessed to determine its mass spectral profile, in an attempt to identify the 
surfactant proteins; mass spectrum results for each significant peak are shown in Figure 7.11. 
Given the highly hydrophobic nature of the proteins, it was expected that the proteins were to elute 
early in the run. The largest peak observed was at a Tr of 10.81 min, which was determined to be 
DPPC (m/z 734). Although the identification of some peaks was possible, the complexity of the 
commercial formulation made it difficult to assign a component to each peak without further 
fractional isolation and analysis, which was beyond the scope of this study; the peak components 
that were identified are shown in Table 7.4.  
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A similar mass spectral identification was performed for the Survanta-EEG formulation 
and is shown in Figure 7.12. In both total ion chromatograms, the peak at Tr of 1.21 min was 
identified as possibly that of the proteins since the mass spectrum showed multiple peaks spaced 
apart in a pattern, indicating the possibility of multiply charged species. The isotopic distributions 
in the spectrum could not be discerned since the triple quadrupole MS has low resolution that 
cannot fully distinguish a change in the m/z of less than 0.5 in a mass spectrum – a drawback to 
using a triple quadrupole mass spectrometer.  
The Survanta® spectrum for the Tr peak at 1.21 min from 700-2000 m/z is shown in Figure 
7.13 (top) with a comparison to the peak at the same retention time in the Survanta-EEG spray 
dried powder sample (Figure 7.13, bottom).  The spectra show peaks with similar m/z values, with 
Survanta-EEG sample having a few additional peaks, suggesting that the samples have a similar 
composition.  
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Figure 7.11 Mass spectra of Survanta® components separated using with 60/40% v/v acetonitrile/water with 0.1% formic acid with 
injection volume of 5 µL, 0.2 mL/min flow rate and 15 min run time. MS settings: capillary=3.5 kV, cone=35 V, source temperature=120 
°C, desolvation temperature=300 °C. 
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Figure 7.12 Mass spectra of Survanta-EEG components separated using with 60/40% v/v acetonitrile/water with 0.1% formic acid with 
injection volume of 5 µL, 0.2 mL/min flow rate and 15 min run time. MS settings: capillary=3.5 kV, cone=35 V, source temperature=120 
°C, desolvation temperature=300 °C. 
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Table 7.4 Identified peaks from mass spectra of Survanta® separated using with 60/40% v/v 
acetonitrile/water with 0.1% formic acid with injection volume of 5 µL, 0.2 mL/min flow rate and 
15 min run time. MS settings: capillary=3.5 kV, cone=35 V, source temperature=120 °C, 
desolvation temperature=300 °C. Exact mass values from [182]. 
Retention time, 
min m/z Component 
Exact mass, 
Da 
1.90 496.2 DPPC-sn1 and DPPC-sn2 495.3* 
7.74 706.6 PC 16:0/14:0 (PMPC) 705.5 
8.58 732.6 PC 16:0/16:1 731.6 
10.81 734.7 PC 16:0/16:0 (DPPC) 733.5 
11.89 760.7 PC 16:0/18:1 (POPC) 759.6 
*Calculated using LipidMaps MS Tools [183]. 
PMPC=palmitoyl-myristoyl phosphatidylcholine, DPPC=dipalmitoylphosphatidylcholine, 
POPC=palmitoyl-oleoyl phosphatidylcholine 
 
 
 
 
Figure 7.13 Mass spectra comparison of the peak at retention time of 1.21 min for the commercial 
Survanta® formulation (top) with Survanta-EEG spray dried powder (bottom). MS settings: 
capillary=3.5 kV, cone=35 V, source temperature=120 °C, desolvation temperature=300 °C. 
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The expected m/z values for the surfactant proteins were calculated from the exact mass 
values. The protonated (increase in 1.0073 Da) and sodium adduct (increase in 22.989 Da) m/z 
values for the ionized surfactant proteins are shown in Table 7.5. During sample preparation, 
methylation of proteins commonly occurs, especially when samples are prepared in methanol [26, 
184]. Methylation is most commonly observed on arginine and lysine residues [184, 185]; SP-B 
has a total of seven arginine and lysine residues while SP-C has two. The expected m/z values for 
a single methylation are included in Table 7.5, although it is understood that as many as seven 
residues in SP-B or two residues in SP-C could be methylated. These modifications add to the 
difficulty of interpreting the peaks in the mass spectra. SP-C has been observed in its triple, 
quadruple and quintuple charge states [26, 174], and is therefore also included in Table 7.5.  
A comparison of the peak table with the peaks observed in Figure 7.13 revealed random 
matching peaks (indicated with # symbol), however there were not enough matches to conclude 
that the peak at the retention time of 1.21 min was that of the proteins. The m/z range of 700 to 
2000 was studied, in which a pattern with a consistent m/z increase of 68 was observed. This could 
represent cluster ions of sodium formate (formed from the sodium chloride present in the sample 
and the formic acid present in the mobile phase), which is often observed to have mass peaks 68 
Da apart [186]. 
Both proteins may possibly have eluted at the same time from the column given that the 
mass spectra from the other peaks do not reveal patterns to be expected when analyzing proteins. 
Interpretation of the spectrum may be more difficult if both proteins eluted in the same peak, which 
contributes to the inconclusive results. Further studies could examine improving the 
chromatography to separate and identify the proteins. 
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Table 7.5 Predicted mass charges of SP-B dimer (17395.5 Da), SP-B monomer (8699.8 Da) and 
SP-C monomer (4041.7 Da), including sodium adducts and single methylation, within the range 
of the triple quadrupole MS (200-2000 m/z). H=hydrogen, Na=sodium, Me=methyl. 
Protein Charge 
[M+H]+, 
m/z 
[M+Na]+, 
m/z 
[M+Me]+ 
m/z 
SP-B dimer 16 1088.2 1111.2# 1088.1 
 15 1160.7 1183.7 1160.6 
 14 1243.6 1266.5 1243.5 
 13 1339.1 1362.1 1339.2 
 12 1450.6 1473.6 1450.8# 
 11 1582.4 1605.4 1582.7 
 10 1740.6 1763.5 1741.0 
 9 1933.8 1956.8 1934.4 
     
SP-B monomer 8 1088.5 1111.5# 1089.2 
 7 1243.8 1266.8 1244.8 
 6 1451.0# 1474.0 1452.3 
 5 1741.0 1764.0 1742.8 
     
SP-C monomer 5 809.3 832.3 811.1# 
 4 1011.4 1034.4 1013.9 
 3 1348.2 1371.2 1351.9 
#Peaks identified within 0.5 m/z in Survanta® and Survanta-EEG formulations (Figure 7.13) 
  
 
7.3.3 Non-specific assay of surfactant proteins 
With inconclusive results from the previous experiments, a simple assay for the 
determination of primary amino groups (found in terminal amino acids of proteins) was performed. 
Fluorescamine was used for the non-specific determination of proteins in the commercial 
formulation, the feed dispersion samples, and the spray dried powders. Three batches of spray 
dried Survanta-EEG without leucine were prepared fresh and analyzed the following day with 
storage overnight in a desiccator in a fridge (2-8 °C). For comparison, the fluorescence results for 
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the processed samples were reported as a percentage of the fluorescence detected for the 
commercial formulation. The results are shown in Table 7.6.  
For each of the three batches of feed dispersions that were prepared and spray dried, similar 
results were observed for the feed dispersion samples, both post-sonication and the bypass 
dispersion, with approximately 100% of the fluorescence detected compared to the unprocessed 
commercial Survanta® formulation.  
A significant decrease in the fluorescence was observed for the Survanta-EEG spray dried 
powder sample compared to the commercial formulation; 42% of the fluorescence measured in the 
commercial Survanta® formulation was measured in the spray dried samples. Since the feed 
dispersion post-sonication and bypass feed dispersions were shown to maintain total primary 
amino acid values relative to Survanta®, the observed decrease in relative absorbance is attributed 
to the spray drying process. In the spray dryer, the feed dispersions are nebulized to form micron-
sized droplets, which is often associated with protein adsorption, partial unfolding and aggregation 
[187]. Protein adsorption to the air-liquid interface leads to increased occurrence of aggregation as 
interaction with hydrophobic residues is increased. Aggregation can lead to a change in the 
secondary structure of the proteins possibly resulting in decreased primary amino acids.   
The fluorescamine assay provided a quick qualitative method for the determination of 
surfactant proteins following processes involved to produce spray dried powder. The use of bovine 
serum albumin (BSA) as a standard to generate a calibration curve with this assay would provide 
quantitative results for the total protein content. The use of BSA as a standard with fluorescamine 
has been described by Held [188]. It should also be noted that the spray dried Survanta-EEG 
powders did not contain leucine (as this would interfere with the fluorescence assay), and its 
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absence may have affected the spray drying process and offered less protection to the surfactant 
proteins present in the formulation.   
 
Table 7.6 Fluorescence results for primary amino groups for three batches of spray dried Survanta-
EEG formulations and feed dispersions, presented as percentages of the initial values obtained for 
the unprocessed Survanta® formulation. Values are mean (SD), n=3. 
Batch 
Survanta® 
absorbance 
Fluorescence relative to Survanta®, % 
Feed dispersion 
post-sonication 
Bypass feed 
dispersion 
Survanta-EEG 
(without leucine) 
1 24385 (1574) 109.8 (6.8) 108.3 (5.8) 40.6 (2.2) 
2 25194 (69) 100.2 (0.0) 102.2 (1.6) 43.9 (0.3) 
3 24560 (247) 100.8 (1.1) 102.6 (6.4) 42.4 (1.4) 
Overall mean           24713 (425) 103.6 (5.8) 104.4 (5.3) 42.3 (1.9) 
 
 
7.3.4 Enzyme linked assay of surfactant proteins 
For protein specific analysis of SP-B and SP-C, ELISA kits for bovine SP-B and SP-C 
were used for qualitative determination of the surfactant proteins in the spray drying feed 
dispersions and in the Survanta-EEG powder formulations. Samples were prepared in 60/40% v/v 
acetonitrile/water, then assayed per manufacturer protocol. The absorbance results were 
determined for all samples and the relative absorbance were calculated for the spray drying 
samples compared to the unprocessed commercial Survanta® formulation. The calculated relative 
absorbance values are shown in Table 7.7. Each of the samples (dispersion feed and powders) were 
found to quantitatively maintain the amount of surfactant proteins (SP-B and SP-C) throughout 
the spray drying process relative to the unprocessed commercial Survanta® formulation, with 
values in the range of 89-94% observed for SP-B and 82-91% for SP-C. The spray dried Survanta-
EEG formulations had relative absorbance values for SP-B and SP-C of 92% and 91%, 
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respectively compared to the unprocessed commercial Survanta® formulation. This data together 
with the surface activity data presented in Chapter 3, supports the hypothesis that the Survanta-
EEG formulations produced using a spray drying process retain their surfactant proteins during 
processing which helps maintain their surface activity and could offer a potential method of 
delivering lung surfactant replacement therapy as a powder formulation.  
The quantitative results obtained for both SP-B and SP-C differ from the observations made 
with the non-specific assay for proteins, in which a decrease in total relative protein content was 
observed in the spray dried powder sample. The difference may possibly be due to sample 
preparation; spray dried powder samples for the fluorescamine assay were prepared in methanol, 
whereas spray dried powder samples for the ELISA assay were prepared in 60/40% v/v 
acetonitrile/water. Pérez-Gil et al. [18] determined that neither methanol nor methanol/water 
mixtures dissolved an estimable amount of SP-C (Figure 7.1). The poor solubility of SP-C in 
methanol would explain the less than 50% relative fluorescence observed as SP-C is present in the 
commercial Survanta® formulation at a higher concentration than SP-B [35, 163].  
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Table 7.7 Absorbance results of the spray dried Survanta-EEG formulation and feed dispersions 
relative to the commercial Survanta® formulation using ELISA kits for bovine SP-B and SP-C. 
 Replicate 
Absorbance relative to Survanta®, % 
Feed dispersion 
post-sonication 
Bypass feed 
dispersion Survanta-EEG 
SP-B 1 101.0 89.3 83.0 
 2 91.2 92.1 96.7 
 3 90.2 86.8 96.4 
Overall mean (SD) 94.1 (6.0) 89.4 (2.7) 92.0 (7.8) 
     
SP-C 1 86.1 90.0 95.6 
 2 80.1 84.2 87.9 
 3 80.6 84.2 89.1 
Overall mean (SD) 82.2 (3.3) 86.1 (3.4) 90.9 (4.1) 
 
 
7.4 Conclusion 
This study explored different methods of protein separation and identification to determine 
the presence of the hydrophobic surfactant proteins in the commercial Survanta® formulation 
(Specific aim 2.4). The methods evaluated included protein precipitation using various solvents, 
column chromatography coupled to mass spectrometry, non-specific protein analysis using 
fluorescence and an enzyme-linked assay specific for the hydrophobic proteins. Protein 
precipitation methods followed by direct infusion into a mass spectrometer yielded inconclusive 
results. Column chromatography was successful in separating the components of the commercial 
Survanta® formulation, but identification of the protein proved difficult. However, the non-specific 
fluorescamine assay and the enzyme-linked assay were both able to determine the presence of the 
surfactant proteins in the commercial formulation. The determined methods were then applied to 
samples collected at different processing steps of Survanta-EEG preparation. 
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The fluorescamine assay and the enzyme-linked assay were both able to show the presence 
of the surfactant proteins following the processing methods involved in preparing Survanta-EEG 
formulations. Samples were prepared from the feed dispersions post-sonication, the bypass feed 
dispersion and the spray dried Survanta-EEG powder. The fluorescamine assay showed 
approximately 100% fluorescence for the dispersion samples relative to the commercial 
formulation, but lower fluorescence results for the spray dried powder sample relative to the 
commercial formulation, which is likely due to the solvent used during sample preparation. The 
enzyme-linked assay showed that the presence of both proteins was maintained above 80% for all 
Survanta-EEG formulation processing steps relative to the commercial formulation.  
This study demonstrated that the presence of the hydrophobic surfactant proteins, SP-B 
and SP-C, are maintained following processing methods for Survanta-EEG formulation 
preparation suggesting that the EEG formulations remain active when administered to the lungs of 
infants.  
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CHAPTER 8 
8         SUMMARY AND CONCLUSIONS…………. 
Immaturity-related respiratory distress results from pulmonary surfactant deficiency in 
underdeveloped lungs of preterm infants. Surfactant replacement therapy is approved for the 
prevention and treatment of neonatal respiratory distress syndrome (RDS) but employs invasive 
delivery techniques – instillation of a liquid bolus, resulting in non-uniform distribution of 
surfactant within the airways. The use of aerosolized surfactant coupled with non-invasive 
ventilation is a promising delivery technique for treating infants with RDS, but aerosolized 
surfactant has been met with challenges of poor delivery efficiency and long delivery times. The 
development of a dry powder surfactant formulation, using the excipient enhanced growth (EEG) 
application, administered via novel delivery devices and ventilation components, designed for 
minimal depositional losses, is hypothesized to provide improved lung delivery that will overcome 
the challenges of aerosolized surfactant therapy.  
The first part of this project focused on developing methods to reproducibly produce 
micrometer sized spray dried powder surfactant formulations using the EEG technique which are 
highly dispersible and suitable for delivery using a dry powder inhaler with low device and capsule 
deposition loses. Given the high cost of commercially available naturally derived replacement 
surfactant formulations in the United States ($400-800 per vial), the initial spray drying method 
development studies were performed with the dominant phospholipid present in pulmonary 
surfactant, dipalmitoylphosphatidylcholine (DPPC), as the model drug. A full factorial design of 
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experiments was performed to investigate the influence of spray drying process and formulation 
variables on the primary particle size, aerosol performance, and surface activity of a range of spray 
dried DPPC-EEG powders. The formulation factors included the percent solids concentration, the 
percentage of hygroscopic excipients, and the percent ethanol concentration in the feed dispersion. 
The spray drying process parameters studied were spray mesh size and inlet drying temperature. 
Preliminary experiments revealed that sodium chloride was a necessary component in the 
formulation as it enabled particle formation; and that stable feed dispersions for spray drying were 
required for homogenous powder production. The DOE revealed that DPPC-EEG powders were 
most influenced by the percent solids concentration in the feed dispersion, with the lower solids 
concentration (0.125 vs 0.250% w/v) resulting in smaller primary particle size, a higher primary 
particle fraction less than 1 µm, and improved aerosol performance with a smaller MMAD than 
powders produced at the higher solids concentration. The optimized formulation of the DPPC-
EEG dry powders was characterized as having mean primary particle size of 1.03 µm with 48 % 
of particles less than 1 µm. Aerosol performance of this formulation was characterized by a mean 
MMAD of 1.6 µm which indicated good dispersion of the micrometer-sized primary particles for 
the DPPC-EEG formulation. 
The optimal processing parameters determined with DPPC-EEG powders were applied to 
produce EEG formulations with commercial surfactants. The surfactants selected to study were 
naturally derived replacement surfactant formulations available in the United States: beractant 
(Survanta®), calfactant (Infasurf®), and poractant (Curosurf®). The formulations differ in the 
composition of proteins and lipids and consequently in their solids concentration, which was 
accounted for when preparing the EEG formulations. Overall, the commercial surfactant EEG 
formulations, which have a complex combination of lipids and proteins, were found to have a 
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larger primary particle size (1.2-1.8 µm), lower primary particle fraction less than 1 µm (24-39%), 
a larger span, and poorer aerosol performance (larger MMAD of 1.9-3.3 µm, lower particle 
fractions less than 1 µm of 0.5-7%) compared to that of the DPPC-EEG formulation. The 
commercial surfactant EEG formulations were, however, shown to maintain surfactant activity 
following feed dispersion preparation and spray drying, which indicated that the spray drying 
process did not appear to have a negative effect on the main therapeutic activity of the 
formulations. Optimization of a commercial surfactant-EEG formulation was then addressed in 
further studies. 
The Survanta-EEG formulation was observed to be the most comparable to the DPPC-EEG 
formulation with respect to powder characteristics and aerosol performance and was therefore 
selected for further optimization. This study explored the effect of dispersion enhancers on the 
feed dispersion, powder characteristics and primary particle size distribution at different dispersion 
pressures. This study also investigated the influence of alcohol concentration in the feed dispersion 
on the aerosol performance of the spray dried powders using a novel dry powder inhaler in an 
attempt to improve the aerosol dispersion characteristics of the surfactant-EEG formulations.  
Dispersions for spray drying were prepared by sonication of lipids in ethanol/water 
mixtures. This method is generally successful for small volumes of liposomes, but sonication 
conditions are difficult to reproduce resulting in size variations between batches produced at 
different times. Liposomes produced by sonication are also inherently unstable due to the high 
degree of curvature of the membranes that often spontaneously fuse to form larger vesicles when 
stored below their transition temperature. Therefore, it would be advantageous to explore the use 
of extrusion methods to produce liposomes with a more monodisperse size distribution in the final 
suspension prior to spray drying. 
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Of the two dry powder dispersion enhancers studied, leucine and trileucine, the powders 
prepared with leucine, at both 1.0 and 4.5 bar dispersion pressures, resulted in smaller primary 
particles, smaller spans, and higher fractions of submicrometer particles compared to powders 
prepared with trileucine at both ethanol concentrations studied (5 and 20% v/v ethanol in water). 
Aerosol performance of the EEG formulations prepared with leucine were evaluated at both 
ethanol concentrations with a novel low-volume dose containment unit dry powder inhaler. The 
powders prepared with 20% v/v ethanol in water were observed to produce more consistent emitted 
dose masses, size distributions, aerosol plume durations and obscuration parameters over three 
actuations that were less variable when compared to leucine powders prepared in 5% v/v ethanol 
in water. Effective powder delivery as an aerosol depends on a combination of both the drug 
formulation and the delivery device. The optimization of a novel dry powder inhaler (DPI) to 
deliver the surfactant-EEG formulations was investigated.  
For applications of delivering drugs as aerosols to small rodent animal models and being 
suitable for delivery of aerosols to low birth weight infants, the inhaler design needs to disperse 
relatively high powder masses (3-10 mg) with very low volumes of dispersion air. Challenges to 
this design included 1) being restricted to a low dispersion air volume (~3 mL), and 2) a preference 
of delivering the dose in one actuation. The aim was to develop a device that was capable of 
delivering ≥ 2 mg/kg of lipids in one 3 mL actuation of air as this was the dose observed in small 
animal models that was required to elicit an effect [83]. For the surfactant-EEG formulation, this 
translates to approximately 2.2 mg of spray dried powder for a 300 g rodent.  
The novel containment unit DPI developed in this study was based on design modifications 
to an active DPI prototype developed for use with 10 mL volumes of actuation air [141]. The 
design modification that was observed to have the largest impact on the emitted mass was reducing 
  
 
262 
the powder chamber volume from a size 0 capsule (0.68 mL) to a dose containment unit with a 
volume of 0.21 mL. With a 3 mg fill mass, the reduction in chamber volume resulted in a 100% 
increase in the emitted mass based on the nominal mass. Subsequent design modifications were 
then investigated to improve the aerosol dispersion, which included altering the entrainment air 
flow path through the device, increasing the number of air inlet holes (from one to three), and 
investigating the effects of the outlet delivery tube internal diameter on aerosol performance. 
Incremental increases in the % emitted mass were observed with changes to the entrainment air 
flow path and increasing the number of air inlet holes. Correlations were revealed when studying 
the effect of the delivery tube internal diameter – increasing internal diameter resulted in increasing 
% emitted mass and increasing Dv50 values.    
The effect of delivery tube length and fill mass on the emitted mass and Dv50 values 
revealed an optimal device that was found to have powder dispersion characteristics independent 
of fill mass (3-10 mg) with good powder emptying in one actuation. At a 10 mg fill mass this lead 
design was able to deliver 5.3 mg of surfactant powder with an aerosol Dv50 of 2.7 µm in a single 
3 mL actuation of dispersion air. The novel DPI developed in this study could be adapted for use 
in the treatment of infants on non-invasive ventilation. A low volume of air, as is used to disperse 
the powder formulations in the optimized containment unit DPI, is vital when dealing with preterm 
infants with tidal volumes as low as 4 mL/kg [81]. 
The dose containment unit dry powder inhaler developed in this research successfully 
dispersed spray dried surfactant-EEG formulations using a low volume of air. At the higher fill 
mass of 10 mg, however, a dense aerosol plume exited the DPI on the first actuation using 3 mL 
of dispersion air, which may cause unwanted deposition in small airways or narrow delivery 
tubing. The use of secondary flows, established by an inlet orifice smaller than the outlet orifice, 
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should be explored to decelerate the inlet airflow to improve deaggregation of the spray dried 
powders and possibly control the momentum cloud effect. 
Surfactant therapy in infants has been observed to improve mucus hydration [189], 
suggesting its potential use in the treatment of lung diseases with airway mucus obstruction, such 
as viral bronchiolitis. With no cure, bronchiolitis treatment focuses on supportive care which 
includes delivery of supplemental oxygen via high flow nasal cannula therapy (HFNC). Ancillary 
delivery of nebulized surfactant during HFNC could potentially hasten resolution of symptoms.  
A novel low-volume aerosol mixer-heater system designed to generate submicrometer 
EEG aerosols has the potential for use during HFNC administration [159]. Aerosol is generated 
by a commercial vibrating mesh nebulizer into the mixer-heater device, where it is mixed with 
room temperature ventilation gas and then heated to dry the aerosol to produce micrometer sized 
particles for inhalation with minimal deposition losses. The low-volume mixer-heater system was 
tested to determine the in vitro delivery efficiency with a realistic infant nose-throat model. Initial 
experiments were performed under steady state inhalation flow of 7 L/min to compare aerosol 
deposition and delivery efficiency with standard of care methods using an albuterol sulfate 
nebulizer formulation. The low-volume mixer-heater system was operated with a modified 
controller, which reduced the output of the nebulizer to approximately 25% of that observed with 
the commercial controller. 
The estimated lung dose with the low-volume mixer-heater system was observed to be 
significantly higher than the face mask standard of care system (76 vs 14% of the nominal dose). 
The smaller droplets entering the in vitro model using the low-volume mixer-heater system 
compared to the face mask standard of care system, 1.4 µm vs the 5.0 µm, resulted in improved 
aerosol drug delivery efficiency through the realistic airway. When a realistic breathing profile 
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was incorporated, the estimated % lung dose for both systems decreased significantly (to 12% and 
5.2% of the nominal dose for the mixer-heater and standard of care methods, respectively). In order 
to minimize drug losses and increase the estimated % lung dose, the use of aerosol synchronization 
with the low-volume mixer-heater system was explored to ensure that drug was only delivered to 
the airways during inhalation.  
When optimized breath synchronization was used with the low-volume mixer heater, 
aerosol generated 0.4 s prior to inhalation with a nebulization duration of 0.2 s resulted in an 
estimated % lung dose of 35% of the nominal dose. Implementation of nebulization 0.4 s prior to 
inhalation is possible in the controlled laboratory environment with a breathing simulator, however 
it is not practical in a clinical environment as the breathing profile of infants with respiratory issues 
is erratic and nonuniform. These in vitro experiments however did clearly demonstrate that for this 
low-volume mixer heater, triggering the nebulizer 0.4 s prior to inhalation resulted in the highest 
estimated lung dose. These studies indicated that due to the residual volume of the low-volume 
mixer-heater, the timing of aerosol delivery relative to the inhalation cycle is of critical importance 
to ensure that the maximum dose of aerosol reaches the infant lung. Design modifications to the 
low volume mixer-heater were made to eliminate the need of breath synchronization.  
The very low-volume mixer-heater was developed with an external heat source which 
allowed the mixer-heater volume to be reduced from 61.6 mL to 2.7 mL. The in vitro delivery of 
a nebulized surfactant-EEG formulation was studied with the modified device which now allowed 
aerosol delivery to be initiated at the start of each inhalation. Combinations of controller type 
(commercial, 50 Vrms; modified, 14 Vrms) and nebulization duration (0.1 s, 0.3 s) were explored to 
determine the best settings to achieve an acceptable balance of phospholipid delivery rate and 
estimated % lung dose. The modified controller with 0.1 s nebulization duration was shown to 
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have the highest estimated % lung dose (52% of the nominal dose), but the slowest estimated 
delivery rate for phospholipids (6.3 µg/min). The commercial controller with 0.3 s nebulization 
duration was observed to have the highest delivery rate for phospholipids (28 µg/min), but the 
lowest estimated % lung dose (15% of the nominal dose). An acceptable compromise was the 
commercial controller with 0.1 s nebulization duration which had an estimated % lung dose of 
31% of the nominal and an estimated phospholipid delivery rate of 19 µg/min, a significant 
improvement over the < 4% of the nominal dose using standard of care methods as reported in 
literature [103, 155]. Assuming 2 mg of phospholipids per kg of body weight elicits an effect, for 
an 8 kg infant, it would take 14 hours to deliver 16 mg of phospholipids which could be 
administered simultaneously with HFNC non-invasive ventilation. Considering that most children 
are hospitalized for 2 to 3 days when admitted for bronchiolitis, 14 hours to possibly hasten relief 
of symptoms may be an appropriate treatment option.  
Finally, of importance for surfactant activity, the presence of the surfactant proteins (SP-B 
and SP-C) following formulation processing (which applies to feed dispersions for spray drying 
and nebulized formulations) and spray drying were determined using two methods: non-specific 
assay for primary amino acids and an enzyme-linked assay specific to SP-B and SP-C. Both assays 
were able to show the presence of proteins following processing methods involved with preparing 
Survanta-EEG formulations.  
These studies using the Survanta-EEG powder formulations and nebulized formulations 
delivered using the newly developed aerosol generation devices indicate their viability as 
alternative non-invasive methods of surfactant delivery using the inhalation route to infants. 
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